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ABSTRACT 
Since the re-emergence of avian influenza A H5Nl virus in 2003 among poultry, the virus has 
reached endemic levels in Vietnam and continues to cause human infections [4]. At present (9 
February 2011), 119 infections have been reported, 59 of which were fatal [5]. The cases in 
2004 and 2005 accounted for 76% (90/119) of the total number of reported cases from 
Vietnam [5]. This thesis retrospectively studied the clinical course of 16 cases (14%). The 
clinical features in most cases were typical for the human disease caused by the H5N 1 virus. 
The prominent clinical signs and symptoms were those of a severe influenza syndrome with 
fever, cough, and shortness of breath. However, this thesis also shows that human H5Nl 
influenza may be associated with extrapulmonary disease, including gastrointestinal and eNS 
symptoms and multi-organ failure. The abnonnalities on chest radiographs included extensive 
bilateral infiltration, lobar collapse, focal consolidation, and air bronchograms. The prominent 
laboratory factors were thrombocytopenia, neutropenia, lymphopenia, and increased levels of 
serum transaminases. 
Most patients (15/16) were treated with standard doses of the neuraminidase inhibitor 
oseltamivir. This drug has antiviral efficacy against H5Nl viruses and observational studies 
suggest that treatment with oseltamivir reduces mortality. Drug resistance may emerge during 
treatment and seems associated with antiviral and clinical failure. When testing for genotypic 
and phenotypic resistance, we detected 2 oseltamivir resistant H5N 1 variants in two patients 
who failed to clear the virus and died from the infection. In contrast, four other patients who 
showed effective suppression of viral replication during treatment all survived. 
Molecular analysis of 13 H5Nl virus strains isolated from 13/16 patients showed that all 
viruses belonged to clade 1, genotype Z H5Nl viruses. The viruses retained the molecular 
characteristics of avian viruses. Some virus strains had mutations in the HA 1 gene that 
xiv 
potentially affect receptor specificity, i.e. reduce recognition of 'avian-type' receptors, 
increase recognition of 'human-type' receptors, or both. A Glu-627-Lys substitution in the 
viral polymerase PB2, associated with adaptation and virulence of H5N 1 viruses in mammals, 
was observed in 5 of 8 isolates from fatal cases and in 3 of 4 isolates from patients who 
survived. However, no association between the presence of Lys-627 and clinical outcome was 
observed. However, in all except one of the isolates without the Glu-627-Lys substitution, an 
alternative change at position 701 (Asp to Asn) was observed which has also been associated 
with adaptation of avian viruses to replication in mammals. Data from this study also 
provided evidence for the selection of mutations in HA gene during infection, supporting the 
notion that continuing transmission of H5Nl virus from poultry to humans may provide a 
greater opportunity for the virus to adapt to humans. 
In addition, to support the diagnostic programme, I developed a molecular diagnostic assay 
that can detect both clade 1 (South-Vietnam, Cambodia, Thailand) and clade 2 (North-
Vietnam, Indonesia, Egypt) H5Nl virus variants. This molecular assay may be useful for 
diagnosis ofH5 virus infections in regions where different genetic clades co-circulate. 
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Chapter 1 
INTRODUCTION 
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ChapTer I 
1.1 Influenza 
Influenza in humans is a highly contagious respiratory disease caused by influenza viruses. It 
is transmitted from person-to-person via virus laden respiratory droplets secreted by infected 
person during symptoms of coughing and sneezing [6]. Transmission occurs through the 
respiratory route (up to 1-2 metres) or direct surface or skin-to-mucosa contact with 
respiratory secretions [7]. Influenza viruses cause a broad range of illness, from asymptomatic 
infection to various, mostly mild respiratory illnesses and, infrequently, fulminant viral 
pneumonia and/or secondary bacterial pneumonia [6]. It is estimated that annually influenza 
viruses cause 1 billion infections, 3-5 million cases of severe illness leading to 3-5 hundred 
thousands deaths worldwide [8]. Birds and mammals can also be infected by influenza viruses, 
and occasionally transmission to humans of these animal viruses occur, causing health 
problems [6, 9]. 
1.2 Influenza A viruses 
1.2.1 Biological properties 
Influenza viruses are pleomorphic, enveloped, negative single stranded RNA viruses 
belonging to the family of Orthomyxoviridae. Three types (A, B, and C) can be distinguished 
based on structural, genetic and antigenic differences. Of these three types, influenza A and B 
viruses cause most severe human infections. Both influenza A and B viruses cause annual 
epidemics but influenza A virus is the only type that poses a (continuous) pandemic threat 
through the circulation of various antigenic subtypes in multiple hosts, particularly in their 
natural reservoir of wild waterbirds, from which new subtypes can enter the human 
population. 
2 
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Based on the antigenic properties of their two surface glycoproteins - haemagglutinin (HA) 
and neuraminidase (NA)- influenza A viruses can be subtyped into 16 different HA (HI-HI6) 
and 9 different NA (NI-N9) subtypes. All influenza A subtypes have been found to circulate 
in the natural reservoir of wild aquatic birds [10, 11]. However, in humans, only a limited 
number of subtypes (HINI, H2N2 and H3N2) have established themselves as stable lineages. 
These three subtypes of influenza viruses were responsible for three pandemics recorded in the 
past century: the 'Spanish flu' pandemic (HINI) in 1918, 'Asian influenza' pandemic (H2N2) 
in 1957, and 'Hong Kong influenza' pandemic (H3N2) in 1968. The most devastating 
pandemic ever was the 'Spanish flu' which killed estimatedly 50-100 million people and was 
most likely caused by direct transmission and adaptation to humans of a purely avian 
influenza virus. The 'Asian influenza' and 'Hong Kong influenza' pandemics each killed 
estimatedly 1 million lives and were caused by reassortant viruses from mixed human and 
avian origin [7, 12]. Currently, we are witnessing the new Influenza virus AlHlN1I2009 
pandemic that has emerged and spread globally from Mexico and the United States of 
America from April 2009 onward, thus far causing mostly mild seasonal flu-like disease with 
occasional severe illness particularly in those with underlying medical conditions and pregnant 
women [http://wwwwhoint/csr/donl2009_11_27a1enlindexhtml, accessed on March 12, 2009], 
[13]. This virus is the result of complex reassortment events between viruses of recent porcine 
origin and more distant porcine, human and avian origin [13]. 
Influenza A viruses have eight gene segments, contained within the host-derived viral 
envelope. The eight gene segments vary in size and each encodes one or two proteins which 
function differently in the life cycle of the virus (table 1.1). During the virus life cycle (figure 
1.1), HA binds to receptors identified as glycans terminated by an 2,3-linked sialic acid (SA) 
or an 2,6-linked SA present on the epithelium of host cells [11]. Receptor-bound viruses are 
3 
Chnpter J 
then internalized through receptor- mediated endocytosis, and viruses possessing cleaved HA 
(by host cell proteases into HAl and HA2) undergo fusion with the endosomal membrane in 
acidic pH (pH-5.0), mediated by the M2 ion channel, resulting in the release of viral 
ribonucleoprotein (vRNP) into the cell cytoplasm [14]. vRNPs is then translocated into the 
nucleus where it undergoes transcription (mRNA synthesis) and replication. The replication 
process includes synthesis of complete positive-sense complementary RNA (cRNA), minus-
strand viral RNA (vRNA), and vRNP complex. Progeny vRNPs made inside the nucleus are 
then exported into the cytoplasm with the involvement of Ml and NS2. Finally, the envelope 
proteins (HA, NA, and M2), matrix protein (M1), and vRNP are transported to the cell 
membrane where progeny virus particles bud [14]. The newly budded viruses are still 
connected to the host cell SA receptors, and only be liberated when the terminal SA residue of 
the receptor is cleaved by the NA [11]. 
Figurel.1 Influenza A virus life cycle. Figure reproduced from http://nursingcrib.com/wp-
content/uploads/image/flu%20virus.PNG, accessed on July 27,2010. 
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HA and NA protrude from the viral envelope and are the major targets of host neutralizing 
antibodies. During replication, because of the lack of proof-reading replication mechanism of 
the viral RNA polymerase, mutations in these two genes occur readily and under pressure of 
the immune response, virus variants possessing host immune escape mutations are selected 
for, leading to antigenic drift over time. This continuous adaptation results in yearly (seasonal) 
epidemics, requiring active surveillance for timely selection of representative vaccine strains 
[9]. 
The segmented genome facilitates easy exchange of genes between two or more viruses during 
co-infection of a single host cell. A sudden drastic change of antigenic properties may occur 
when such genetic exchange involves the HA and/or NA genes. This process is called 
antigenic shift, as opposed to the more gradual changes of antigenic drift. These two 
phenomena, drift and shift, result in high genetic diversity among influenza A viruses, that 
allow for interspecies transmission and evasion of host immune responses. At irregular 
intervals, pandemics occur when an influenza virus with a novel protein HA or NA (or both) 
acquires the ability for efficient and sustained human-to-human transmission in a population 
. that has no previous immunity against these surface proteins (HA and NA) [6, 9, 12]. The 
H2N2 and H3N2 viruses that caused pandemics in 1957 and 1968, respectively, arose through 
gene reassortments of HA (H3N2, H2N2), NA (H3N2) and PB 1 (H2N2, H3N2) of avian 
origin with the remaining genes from prevailing human influenza strains [9]. The current 
pandemic new influenza HI N 1 virus, most likely originated from swine and has a complex 
reassortment history involving recent gene exchange between porcine viruses and more distant 
reassortment between porcine, human and avian viruses [13]. In addition to reassortment, a 
novel pandemic virus can also arise through direct transmission and adaptation of purely avian 
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influenza viruses in humans. The HI N 1 virus that caused the devastating pandemic in 1918 is 
believed to have arisen from such adaptation [15]. 
Table 1.1 Genes and protein functions of influenza A virus (adapted from Wright et aI., 
[11]) 
Gene Segment Length Protein name Protein function ID (bp) 
I Polymerase 2 (PB2) 2341 Polymerase 2 Internal proteins, RNA transcription and (PB2) virus replication 
Polymerase 1 Internal proteins, RNA transcription and 
2 Polymerase I (PB I) 2341 (PBl) virus replication 
PBI-F2 Mitochondrial targeting and apoptosis 
3 Polymerase A (PA) 2233 Polymerase A Internal proteins, RNA transcription and (PA) virus replication 
Hemagglutin Surface glycoproteins, viral attachment. 4 Hemagglutin (HA) 1778 antigenic determinant, subtype specific (H 1-(HA) 16) determinant 
Interacts with viral RNA to form 
5 Nucleoprotein (NP) 1565 Nucleoprotein ribonucleoprotein (RNP), nuclear targeting, (NP) RNA transcription, type specific (A, B, and 
C) determinant 
Surface glycoproteins, viral release from host 
6 Neuraminidase (NA) 1413 Neuraminidase cells, antigenic determinant. subtype specific (NA) (NI-N9) determinant, target of 
neuraminidase inhibitors 
Membrane protein stability, type specific 
Matrix 1 (A,B,andC) 
7 Matrix (M) 1027 Membrane proteins, viral fusion, type 
Matrix 2 specific (A, B, and C) determinant. target of 
M2 inhibitors 
Non-structural Internal proteins, IFN-y antagonism 1 (NSl) 8 Non-structural (NS) 890 Non-structural Regulation of mRNA transcription, 
2 (NS2) localization of viral nucleic proteins 
1.2.2 Natural reservoirs and interspecies transmissions 
The nature reservoir of influenza A viruses are wild aquatic birds; mainly ducks, shorebirds, 
and gulls [16]. In these hosts, influenza A viruses have acquired optimal adaptation and 
therefore only cause asymptomatic infection or mild disease. The virus preferentially 
replicates in the gastrointestinal tract resulting in high-titer shedding of virus in the feces. 
6 
ClWPlt'r 1 
Therefore, the major route of transmission among aquatic birds is through ingestion of 
faecally contaminated water [16, I 7] . 
From their natural reservoirs of wild aquatic birds, influenza A viruses can be transmitted to 
other wild and domestic birds, including turkeys, chickens, and quails. In these new hosts, 
avian influenza viruses can cause a broad range of syndromes, from asymptomatic to mild 
upper respiratory infections to egg loss and systemic fatal disease. Among domestic birds, 
turkeys and chickens are more frequently involved in influenza outbreaks [17]. 
Occasionally, avian influenza viruses are transmitted to mammalian species, including 
humans, pigs, horses, whales, seals, cats and dogs [17]. Some viruses have adapted and 
established species-specific lineages in these hosts, e.g. HINI, H2N2 and H3N2 in humans, 
HINI and H3N2 in pigs, H3N8 in horses. 
1.2.3 Highly pathogenic avian influenza viruses 
Based on the severity of disease in turkeys and chickens, avian influenza viruses are classified 
as low pathogenic (LPAI) or highly pathogenic avian influenza viruses (HPAI) [17]. The high 
pathogenicity of HPAI viruses is determined mostly by the HA glycoprotein [17]. In the viral 
life cycle, HA attaches to cell receptors and allows entry of the viral genome into the host cell 
by enabling fusion of the host endosomal membrane with the viral envelope [17]. The latter 
function requires post-translational cleavage of the precursor HAO protein into HA 1 and HA2 
by host proteases to expose' a fusogenic domain in the N-terminal ofHA2 [16]. HAs ofLPAI 
viruses are cleaved only by trypsin-like proteases, which are present in a limited range of host 
cells, such as respiratory and gastrointestinal epithelia. Consequently, infections are limited to 
these organs. In contrast, HAs of HP AI viruses are sensitive to a broad range of proteases, 
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such as subtilisin-like proteases, which have an ubiquitous distribution thereby permitting 
viral replication in organs beyond the respiratory and gastrointestinal tracts [17, 18] and 
resulting in systemic infections [17, 19]. 
This promiscuity of HP AI HAs for cellular proteases is determined by the structure of the HA 
cleavage site. Sequence analyses of the HA show that HPAI viruses have a stretch of multiple 
basic amino acid residues, usually Lys-Lys-Lys-Arg (K-K-K-R) immediately upstream from 
the cleavage site, whereas LPAI viruses usually only have a single arginine residue (R) at this 
site [20-22]. HP AI viruses can evolve from LPAI viruses by acquiring these multiple basic 
amino acids at the cleavage site through insertion of a short repeat sequence during replication 
[12, 17]. Of the 16 known HA subtypes, only H5 and H7 so far seem to have the potential to 
become HPAI viruses [9]. 
1.3 Bird-to-human transmission of avian influenza viruses 
1.3.1 The species barrier 
In general, avian influenza viruses rarely cause human infections. Factors that limit direct 
transmission and replication of avian influenza viruses in humans are not fully understood but 
are believed to be determined by several viral gene products, including HA, NA and the 
polymerase complex [17]. 
The HA of human influenza viruses binds to glycan receptors terminated by a sialic acid (SA) 
linked to a galactose residue by a2,6 (SA a-2,6 Gal) linkages that are predominantly present 
on human respiratory cells while HA of avian influenza viruses preferably binds glycan 
receptors terminated by a sialic acid linked to a galactose residue by a2,3 (SA a2,3 Gal) 
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linkages that are present on avian epithelial cells [23-25]. This receptor specificity is believed 
to be a major factor that limits avian influenza viruses to readily infect humans [17]. 
It is known that pigs have both human-type (SA a-2,6 Gal) and avian-type (SA a-2,3 Gal) 
receptors [26], and therefore pigs are thought to play a role as intermediate host for genetic 
exchange between avian and human viruses, thereby potentially generating new human 
pandemic strains [27]. Indeed, both avian and human viruses have been found to co-circulate 
in pigs [26], and pig-originating avian-human reassortant viruses have also been isolated from 
children with influenza illness [27]. Moreover, the current HINI pandemic virus has the 
genetic signature of a swine influenza virus, with segments of both human and avian origin 
[13]. 
Beside receptor specificity of HA, specificity of NA also plays a role. NA of human influenza 
viruses preferably catalyses cleavage of the human SA a2,6 Gal linkage rather than of the 
avian SA a2,3 Gal linkage, and vise versa [9]. Considering the opposing functions of HA and 
NA, optimal viral replication requires a balance between the activity ofNA in removing sialic 
acids and the activity of HA in virus attachment and release [28]. The NA of H5N I viruses 
that currently cause poultry outbreaks and human infections has a 20 amino acid deletion in 
the stalk region which is believed to reduce enzymatic activity of NA thereby restoring the 
balance between HA and NA when crossing the species barrier from aquatic birds to terrestrial 
poultry [29]. 
The polymerase complex, in particular PB2, also seems to play an important role in 
determining host range and pathogenicity in mammalian hosts. Avian influenza viruses 
typically have Glu (E) at position 627 in the PB2 protein, while human viruses have Lys (K) at 
this position [9]. This mutation (E627K) allows avian viruses to replicate more efficiently in 
the upper respiratory tract of mice where the temperature is lower than in the respiratory tract 
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[30, 31] and this may playa role in transmission and replication of avian influenza viruses in 
mammals and humans [32, 33, 34]. The other mutation in PB2 gene that may also playa role 
in efficient replication and transmission of avian influenza viruses in mammals is the 
substitution of Asp (D) for Asn (N) at position 701 (D701N) [35]. Studies in animals have 
shown that avian influenza A H5Nl viruses with the D70lN can transmit as efficient as 
viruses with the E627K [34], confirming the compensation role of D70lN for the lack of 
E627K observed in patients [36]. 
1.3.2 Transmission and disease caused by avian non-H5Nl viruses 
Before the last decade of the previous century, direct transmission of avian influenza viruses 
to humans was thought to occur only under experimental conditions [37]. However, more 
recently, direct transmission of avian influenza viruses to humans during outbreaks in birds 
has been reported with increasing frequency. Besides H5N 1 influenza virus, several incidents 
of direct transmission of avian influenza viruses of H7 and H9 subtypes to humans have been 
reported. Since 1996, more than 100 cases of human infections with these two virus subtypes 
have been documented (table 1.2) [http://www.cdc.gov/fluJavian/gen-info/avian-flu-
humans.htm, accessed on October I, 2010] [38]. Most reported patients with H7 or H9 
influenza infection had symptoms of mild influenza or conjunctivitis alone or mild influenza 
with conjunctivitis [39-41]. So far, only one patient died of H7N7 infection, reported in the 
Netherlands in 2003. This patient had severe pneumonia, renal failure and respiratory 
manifestations of acute respiratory distress syndrome [41]. 
10 
ChapTer 1 
Table 1.2 Confirmed instances of avian non-H5Nl influenza virus infections of humans 
since 1996. 
Avian Source of No of Ref. Year influenza Country/area Symptoms Outcome 
subtype infection cases 
1996 H7N7 England Ducks 1 Conjunctivitis Recovered [39] 
Hong Kong, Uncomplicated [38]* 
1999 H9N2 Special Unknown 2 influenza-like Both Administrative illness recovered Region 
Uncomplicated [38]* 
2002 H7N2 Virginia, USA Poultry 1 influenza-like Recovered 
illness 
78 cases with [41] 
conjunctivitis, 5 
with conjunctivitis I died and 
2003 H7N7 The Poultry 89 and influenza-like 88 Netherlands illness, 2 with 
influenza-like recovered 
illness, and 4 with 
other symptoms 
Hong Kong, [42] 
2003 H9N2 Special Unknown 1 Influenza-like Recovered Administrative illness 
Region 
2003 H7N2 New York, Unknown 1 Influenza-like Recovered [38]* USA illness 
2004 H7N3 Canada Poultry 2 Conjunctivitis and Recovered [43] 
coryza 
United Conjunctivitis and All [44] 2007 H7N2 Kingdom Poultry 4 mild influenza-like recovered illness 
Hong Kong, [38]* 
2007 H9N2 Special Unknown 1 Influenza-like Recovered Administrative iIlnes 
Region 
Note: * indicates data were obtained from htt,p://www.cdc.gov/flulavian/gen-info/avian-flu-
humans.htm (accessed on October }. 20}0) [381. 
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1.4 Avian H5Nl influenza 
1.4.1 Emergence and spread of the virus 
A vian influenza H5N 1 viruses are classified as HPAI viruses [9]. Current circulating H5N 1 
virus lineages that cause worldwide epidemics among domestic birds are descendants of 
A/Goose/Guangdong/1196 (H5Nl: A/GS/GD/l/96-like virus) which was detected in sick 
geese in Guangdong province, People's Republic of China in 1996 [45, 46, 47]. In 1997, 
H5N 1 viruses caused poultry outbreaks and associated human infections in Hong Kong. The 
virus responsible for the Hong Kong outbreak (HK97) possessed an HA gene that was derived 
from A/GS/GDI1I96-like viruses and the remaining seven viral genes were derived from other 
viruses, possibly H9N2 (A/QuaillHongKong/G 1I97(H9N2» and H6NI 
(AlTeallHongKong/W312/97(H6Nl» viruses prevalent in quails and teals [1, 48]. 
After the Hong Kong outbreak, as a result of strict quarantine and infection control measures, 
HK97 H5NI virus has been eliminated [49, 50]. However, descendants from its progenitor, 
A/GS/GD/1I96-like viruses, continued to circulate in geese in Southern China - the region that 
has been considered as the epicenter of influenza viruses. In 1999/2000, A/GS/GD/1/96-like 
viruses were isolated from healthy geese and ducks imported to Hong Kong [51]. During this 
period of time (1999/2000), A/GS/GD/l/96-like viruses underwent multiple reassortment 
events in domestic ducks leading to a rapid increase in genetic diversity [52, 53]. 
Subsequently, a series of reassortants or genotypes (a genotype is a designation that reflects 
the constellation of eight gene segments of the virus which is given in capital letters) bearing 
the HA gene of A/GS/GD/1/96-like viruses (figure 1.2) were detected in chicken, ducks, and 
other terrestrial poultry in following years (200112002) [9, 45, 46, 51]. The detection of 
multiple genotypes in various domestic bird species suggests that the selection for virus 
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variants that are well adapted to multiple hosts and easy to transmit from species to species 
have occurred in these years. 
In 2003, genotype Z and V emerged as the predominant genotypes and spread to numerous 
countries in East and South East Asia [45]. Notably, these genotypes have acquired a 20 
amino acid deletion in the NA gene that allows them to transmit efficiently among terrestrial 
pOUltry [9]. While genotype V viruses spread to Japan and South Korea [45], genotype Z 
viruses spread to Vietnam, Laos, Cambodia, Thailand, Malaysia, and Indonesia causing 
extensive pOUltry outbreaks associated with human infections [45]. The introduction route of 
viruses into these countries was likely through the movement of poultry across borders [46, 
54]. However, since these countries are in parts of the East Asia - Australian flyway of 
migratory birds [55], it is also possible (but has yet proven) that H5NI viruses being brought 
into these countries by bird migration [56]. 
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Figure 1.2 Genesis of avian influenza A H5Nl viruses in Asia from 1999-2005. The eight 
gene segments (represented by horizontal bars) starting from top downwards are PB2, PB 1 , 
P A, HA, NP, NA, M, and NS. Each color represents a distinct virus lineage. Red represents 
the NGoose/Guandong/1I96-like lineage. Distinct genotypes (gene constellations) are denoted 
by a capital letter. Figure reproduced from Peiris et al., [9]. 
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In May 2005, an unprecedented outbreak of genotype Z H5Nl viruses occurred in migratory 
waterfowl in Qinghai Lake in western China leading to thousands of deaths [9, 57]. Notably, 
Qinghai Lake is a breeding site of migratory birds whose flyways extend to India, Siberia, 
Middle East, and East Africa (Central Asia and West Asia - East Africa flyways) and overlap 
with the Black Sea - Mediterranean flyway [55, 57]. Subsequently, the viruses rapidly spread 
westward causing poultry outbreaks and human infections in India, Turkey, Egypt, Nigeria, 
and many other countries in the Middle East and North Africa [5]. In 2006, this virus genotype 
was also reported in wild birds and poultry in European countries [9]. 
The spread of H5N 1 viruses in diverse species through a large part of the world combined 
with high rates of nucleotide substitution (estimated 4.77x 10-3 per site per year) in the HA 
gene [53] has resulted in considerable genetic/antigenic drift and the establishment of multiple 
genetically related sublineages (clades) in different geographical regions [46]. Currently, 
phylogenetic analyses of HA sequences of HP AI H5N 1 viruses have revealed the presence of 
10 clades (clades 0 to 9) [http://www.who.int/csr/disease/avianjnfluenzaIH5Trimmedtree.pdf, 
accessed on November 4, 2010] [58]. Early progenitor viruses from Hong Kong and China 
(1996-2002), including A/GS/GS/1/96-likeand HK97-like viruses, belong to clade O. The 
genotype Z viruses introduced to Vietnam, Thailand, Cambodia, and Malaysia in 2003-2004 
belong to clade 1. Clade 2 viruses are more divergent and have been divided into 5 further 
subclades (clades 2.1-2.5). The viruses introduced to Indonesia belong to clade 2.1. Those that 
caused outbreaks in wild birds in Qinghai Lake and subsequently spread to the Middle East, 
Europe, and Africa belong to clade 2.2. The genotype V viruses introduced to South Korea 
and Japan belong to clade 2.5 [45, 46]. In 2005-06, clade 2.3 (subclade 4) viruses emerged 
predominantly in Southern China and spread to Hong Kong, Laos, Malaysia, Thailand, and 
North-Vietnam [54, 59] causing poultry outbreaks and sporadic human infections [4, 59]. 
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Figure 1.3 Neighbor-joining tree of 121 reference HSNI HA sequences. Numbers 
following vertical bars indicate virus clades. Tree was reproduced from 
htnr/lwww.wbo.intlcsr/disease/avian influenzalH5Trimmedtree.odf [58] 
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1.4.2 H5Nl viruses in poultry in Vietnam 
HPAI H5NI viruses were first detected in healthy geese sold in markets during a two-day 
surveillance in 2001 in Hanoi - the capital of Vietnam [60]. Genetic analyses have revealed 
that these viruses are genetically similar to those isolated during the same period in Southern 
China [60, 61]. However, when they were introduced to Vietnam, and whether they were 
involved in any undetected outbreaks remain unknown. 
In December 2003, H5N 1 poultry outbreaks associated with human infections were reported 
in North and South Vietnam [62]. Influenza H5NI viruses responsible for these outbreaks 
belonged to clade 1 and genotype Z. Recent studies revealed that these clade 1 viruses were 
introduced into Vietnam 3-6 months before the first human cases were detected [53], and they 
were introduced by movements of poultry across the Vietnamese-Chinese border [54]. 
Subsequently, they spread from North to South [63]. However, due to the scarcity of data on 
H5N 1 influenza in Central Vietnam, it remains unclear whether the viruses spread gradually 
southward or pass over this region through North-South poultry trading or bird migration [63]. 
Phylogenetic analyses of the HA gene of H5NI viruses insolated in 2003-2005 revealed two 
distinct geographical groups: group N in the North and group S in the South [54], suggesting 
H5NI influenza viruses have undergone further evolution in Vietnam. 
Since the outbreak of December 2003, HPAI H5N 1 viruses have become endemic in domestic 
birds leading to the culling of tens of million poultry in 2004-2005 [63, 64]. Notably, 
outbreaks in Vietnam occurred in temporal patterns (waves). During December 2003 to 
December 2005, three continuous H5NI epidemic waves (I, II, and III) were observed: wave I 
began in December 2003 and lasted to June 2004, wave II started from June 2004 to June 
2005, and wave III continued from June 2005 to December 2005 [64, 65] (figure 1.4). The 
peak of these waves was in the months of high demand on poultry consumption: traditional 
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Tet festival (Chinese newyear; January-February: waves I and II), and November-December 
(wave III: weeding season). This leads to an increase of poultry rearing and trading activities 
that may contribute to enhanced infection transmission. In addition, the transmission in these 
months could be further enhanced by cool weather - as average temperature in these months 
are the lowest of the year and range from 15 - 20°C (25-30 °c year round) in the north and 25 
- 28°C (30-35 °c year round) in the south- that allow viruses to persist longer in the 
environment [64]. Indeed, these months have been identified as high-risk period for spread of 
H5Nl viruses in Vietnam [66] and other South East Asian countries [67]. 
In an attempt to contain H5N 1 outbreaks, a nationwide poultry vaccination campaign targeting 
chicken and ducks (2: 14 day old) was implemented in September 2005 [64]. Possibly, as a 
result of this mass-vaccination campaign, H5N 1 outbreaks did not occur in 2006. However, in 
the following year, outbreaks occurred in both northern (the Red River Delta) and southern 
(the Mekong Delta) Vietnam. While the outbreak peak in this year was still in the months of 
the Tet festival in the South, the outbreak peak in the North occurred in months of summer 
(May to June 2007) when the weather temperature is high (range from 27-30 0c) [64]. This 
change could be due to the introduction of new H5Nl variants, genotype V clade 2.3.4 
viruses, and replacement of genotype Z clade 1 viruses in northern Vietnam in 2006/2007 
[68]. Clade 2.3.4 genotype V viruses have also been detected in southern Vietnam recently, 
but this genotype has yet replaced genotype Z in this region. Our most recent data collected in 
February 2010 show that clade 1 viruses remain predominant (paper in preparation). 
In addition to genotypes Z (clade 1) and V (clade 2.3.4), genotype G viruses have also been 
detected in Vietnam. This virus genotype was introduced to Vietnam in late 2005 and was 
detected in a portal province with China where illegal poultry trading activities are high [46]. 
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Genotype G vIruses were then detected in some other prov1Oces 10 northern Vietnam. 
However, they have not yet been implicated in any large poultry outbreak in Vietnam [68]. 
It is likely that all identified H5Nl variants were introduced to Vietnam through the 
movement of pOUltry across Vietnam-China border. Therefore, surveillance for H5Nl viruses 
in imported poultry would be crucial, and in fact has been implemented at ports of entry in 
North Vietnam. As a result of this activity, early detection of new variants of H5Nl viruses 
(e.g genotype G and clade 7 viruses) have been reported [46, 69]. However, besides that, 
surveillance for H5NI viruses should extend to migratory birds since Vietnam is in part of the 
East Asia-Australian flyway [55] and is at risk for viruses being brought into by bird 
migration. 
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Figure 1.4 Temporal distribution of daily HP AI H5N1 reports recorded in Vietnam 
between January 2004 to December 2005. Figure reproduced from Gilbert et al [65]. 
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1.4.3 Transmission to humans and epidemiology of human cases 
Direct transmission of HP AI H5N 1 viruses to humans was first reported during a large poultry 
outbreak in Hong Kong in 1997. During this outbreak, 18 human infections were laboratory 
confirmed and 6 of them were fatal [2]. The source of infections was live poultry sold in 
markets [70]. After this outbreak, human H5N 1 infections were not reported until February 
2003 when influenza H5N 1 virus infections were confirmed in two Hong Kong residents: a . 
father and his child who had just returned from a holiday in mainland China. The father 
succumbed to the infection [71]. Another case ofH5NI infection occurred in November 2003 
in China and was retrospectively confirmed [72]. Subsequently, with the increasing spread of 
H5N 1 in pOUltry and migratory birds across large regions in the world, further human cases 
were reported from many countries in Asia, the Middle East, Europe and Africa. At the time 
of writing (February 2011), 519 human cases with 306 deaths (-60%) have been reported 
from 15 countries [5]. Most of the cases were identified during winter and spring seasons 
when influenza activity is high [9]. 
In Vietnam, H5Nl infection in humans was first reported in December 2003 [62]. Since then, 
more and more human cases have been reported. At the time of this writing (February 2011), 
119 human cases have been confirmed, 59 of which were fatal [5]. The temporal relationship 
between H5NI outbreaks in poultry and human infections in Vietnam from December 2003 to 
August 2007 have been studied by Minh et aI., [73]. However, a clear seasonal pattern of 
human H5NI cases has not been observed [73]. Nevertheless, in their studies, they found that 
human cases were detected at the same time or slightly earlier than the reported start of 
poultry outbreaks (figure 1.5) [73]. This indicates that in Vietnam, poultry outbreaks may have 
gone undetectable until human cases were confirmed. 
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Figure 1.5. Epidemic curves showing the daily number of H5Nl cases and poultry 
outbreaks recorded in Vietnam between December 2003 to August 2007. Vertical lines 
mark four periods, one year each, started on 1 September and ending on 31 August in the 
following year. Figure reproduced from Minh et a\" [73]. 
Most of human cases in Vietnam were identified in 2004 and 2005 with the majority in the 
North [74, 75]. The total number of cases in Vietnam in these two years was 90, accounting 
for 76% of the total reported cases from Vietnam [5]. 2005 was the year with the highest 
number of confirmed cases (61 cases) followed by 2004 (29 cases). Notably, in the South, 
human cases were identified mostly in these two years [36, 62, 76, 77]. After that, no further 
human cases have been reported in this region until March 2009 when HSNI virus was 
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confinned In a 3 year-old boy in Dong Thap province 
http://wwwpromedmailorg/pls/otnlf?p=2400:1 00 1 :2609219060520617:F2400 _P 1 00 I_BACK 
_PAGE,F2400 _PI 00 I_ARCHIVE_NVMBER,F2400 _P I 00 I_USE _ARCHIVE: 100 I ,2009032 
0IlI8,Y, accessed on 13 October 2010. During 2004-2005, 16 cases were admitted to 
hospitals involved in our studies (see chapter 2), and were enrolled in studies described in this 
thesis. However, the number of actual cases in the South in these two years exceeds the 
number of enrolment [78]: patients were admitted to other hospitals in the region and we were 
not able to access samples. Likewise, we were unable to access samples and data from 
con finned cases in northen Vietnam. 
In general, the major source of human infection in recent outbreaks has been sick poultry [9]. 
In most cases, factors associated with infection were direct handling of infected poultry, 
slaughtering or preparing sick poultry for consumption, consumption of uncooked or 
undercooked poultry products, or close contact with poultry [62, 79, 80]. Contamination of the 
environment with fecal material from infected birds is an alternative source of infection [36, 
81]. However, current data suggest that the transmission of H5NI virus from poultry to 
humans and from human-to-human remains inefficient [62, 80, 82, 83]. 
Since the emergence of avian influenza "H5N 1 in humans, clusters of cases have been 
identified in most of affected countries [81, 84, 78, 85]. Up to 25 November 2009, a total of 52 
clusters, involving 103 cases and accounting for: 22% of reported cases, have been 
documented (table 1.3)[78]. Interestingly clusters occurred predominantly within families and 
within those families almost exclusively among direct blood relatives (48/52 clusters) [78]. 
These data, coupled with the inefficient transmission of H5N 1 viruses among humans, suggest 
that genetic factors may be involved in human susceptibility to infection. 
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Table 1.3 Number of confirmed H5Nl cases (as of 25 November 2009) and clusters by 
country. Table reQroduced from Borby et at., [78]. 
ul, ( % ) of 
Total confirmed cases 
Jaboraror~ -confirmed ~o. of occurring in 
Country cases clusters clusters 
Azerhaijan 2 6/8 (75) 
BangJadc!;h I 0 0/ 1 (0) 
C~mhodia 8 1 1/8 () 2 
China. mainland 38 4 4/38 (lO) 
Djibouti 0 0/1 (0) 
Egypt 8 4 9/88 (IO) 
hina. 1I Ilg K ng 20 "') 4/20 (20} 
-
Indonesia 141 18 36,1141 C!-) 
Iraq 3 1 _/3 (67) 
Laos PDR .., 0 0/2 (0) 
Myatunar 1 0 0/1 (0) 
"igeria 1 1 1/1 (l00 
Pakistan 3 1 3/3 (100) 
TImiland _5 3 5/25 (20 
Turkey 12 2 6/ 12 (50) 
Vi tnam 111 13 .:..6/ 111 (23) 
Tota 1 (all COUll tries) 463 52 103/463 (22 
Convincing evidence for possible human-to-human transmission remains scarce. Presently, 
only two clusters of human-to-human transmission have been documented: one in Thailand 
and another in China [86, 87]. The family cluster in Thailand was identified in 2005 included 
three family members: a child, her mother, and her aunt. In this family cluster, H5Nl virus 
was possibly transmitted from the child to her mother and her aunt through prolonged close 
contact during care of the child [86]. Another family cluster was found in China in 2007 
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comprised two family members, a young man and his father. H5Nl virus was believed to 
transmit from the young man to his father [87]. In these two cluster families, both patients 
from whom H5N 1 viruses were transmitted to others died. 
Nosocomial person-to-person transmission possibly occurred during the outbreak in Hong 
Kong in 1997 [88, 89] but this was not observed in recent outbreak in Vietnam and Thailand 
[90-92]. 
1.4.4 H5Nl disease in humans 
Human infections with avian influenza H5NI virus mostly present as influenza-like illness 
with symptoms of fever, shortness of breath and cough with rapid progression to more severe 
respiratory disease, requiring mechanical ventilation, and in a substantial proportion to multi-
organ failure and death. Based on reported cases, the mortality of human H5N I infections is 
approximately 60%. At presentation, most patients have radiological evidence of pneumonia, 
characterized by extensive bilateral infiltration, lobar collapse, focal consolidation, and air 
bronchograms [62, 80]. Moreover, patients with H5Nl influenza may present with abdominal 
pains, bleeding from nose and gums, vomiting, and diarrhea [2, 62, 80]. The latter can be the 
only symptom at presentation [76, 93]. In severe cases, lower respiratory manifestations 
develop shortly after admission. Complications associated with fatal outcome include acute 
respiratory distress syndrome, and multi-organ dysfunction [62, 80]. During hospitalization, 
some patients may develop symptoms of acute encephalitis leading to fatal outcome [76]. In 
recovered patients, radiological evidence of lung damage may still be observed after several 
months [12]. 
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Patients with H5Nl influenza disease have relatively long lasting high pharyngeal viral loads. 
High pharyngeal viral loads were found to be associated with fatal outcome [36]. Pathological 
studies revealed evidence of active viral replication in trachea and lungs [94-96] and the 
presence of H5Nl viruses in type II pneumocytes of the lower respiratory tract [96]. Beside 
the respiratory tract, the presence of viral RNA was demonstrated in multiple bodily fluids and 
organs including blood, cerebrospinal fluid, rectum, intestines, liver, spleen and brain [94-96]. 
In addition, in a pregnant woman, viral RNA was detected in the placenta and fetus [94]. 
Patients with severe H5NI disease usually have lymphocytopaenia, often with conversion of 
the CD4:CD8 T-Iymphocyte ratio, thrombocytopaenia, and increased levels of serum 
aminotransferases. Some have hyperglycemia, and elevated levels of lactate dehydrogenase 
and creatine kinase [2, 62, 80]. Most of examined patients have increased levels of plasma 
pro-inflammatory cytokines including IPIO (interferon-inducible protein 10), MIG 
(macrophage attractant chemokines), IL-8, IL-6 and IL-IO, and the levels of these cytokines 
were positively correlated with pharyngeal virus loads and fatal outcome [36]. 
1.4.5 Specific molecular determinants of pathogenicity 
1.4.5.1 The hemaggutinin (HA) 
Similar to the pathogenicity in birds, the promiscuity of HPAI HAs for cleavage by a range 
cellular proteases may explain the propensity for viral dissemination in mammals, including 
humans (see section 1.2.3) In addition, the presence of avian-type receptors in the human 
lower respiratory tract may explain the high risk of severe pneumonia during human H5NI 
infection [83]. In contrast to the idea that human cells only express SA a2,6-Gal receptors, 
recent studies revealed the expression of SA a2,3-Gal receptors in human non-ciliated 
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respiratory epithelial cells [25]. However, different SA expression profiles were observed in 
different parts of the human respiratory tract: cells of the upper respiratory tract (nasal 
mucosa, paranasal sinuses, pharynx, and trachea) express mainly SA a2,6-Gal, whereas cells 
in the lower respiratory tract (type II pneumocytes and non-ciliated cuboidal epithelial cells) 
express both SA a2,6- and a2,3-Gal [97]. Since SA a2,3-Gal bearing cells are believed to act 
as primary target cells for H5NI virus infections, their presence in the lower respiratory tract 
may explain the propensity ofH5NI viruses to cause pneumonia in humans [83]. Compared to 
adults, cells in the upper respiratory tract of children express more SA a2,3-Gal, suggesting -
in accordance with epidemiological data - that children are more susceptible to H5N I 
infection [98]. More recent studies have shown binding and replication of H5NI viruses in 
upper respiratory tract epithelia as well, suggesting that other factors besides SA a2,3-Gal and 
SA a2,6-Gal linkage of receptors, potentially including other linkages and the spatial shape of 
the receptor, may be involved in infection and host specificity [99, 100]. 
1.4.5.2 The polymerases 
Three viral polymerase proteins, the Acid polymerase (PA), Basic polymerase 1 (PBI) and 2 
(PB2), and the nucleoprotein (NP) together form the viral replication complex. Certain amino 
acid changes in avian influenza viruses may provide a replication advantage, particularly in 
mammalian hosts. The presence of a lysine (Lys, K) instead of a glutamic acid (Glu, E) at 
position 627 in PB2 has been identified as a major determinant of efficient replication, 
virulence and host range of influenza A viruses in mammals [32]. Interestingly, Lys627 was 
also found in an H7N7 virus isolated from a man who died of severe pneumonia in The 
Netherlands in 2003, but was not found in viruses isolated from patients with mild disease or 
from chickens [41]. While Lys627 has not been identified in PB2 of avian H5NI viruses 
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isolated in Vietnam so far, some H5Nl viruses isolated from Vietnamese patients possessed 
the mutation [36, 54]. Studies in mice showed that the presence of Lys627 in PB2 is essential 
for virulence and systemic infections ofH5Nl viruses responsible for human diseases in Hong 
Kong in 1997 [33], but does not increase the tissue tropisms [101]. However, recent studies 
showed that Lys627 is important for efficient transmission of avian influenza A H5N 1 viruses 
in animal models [34]. 
A substitution of aspartic acid (Asp, D) to asparagine (Asn, N) at position 701 in PB2 is also 
associated with high pathogenicity and efficient transmission of avian viruses in mammals 
[102,34]. The virulence ofH5Nl viruses in mammals is attenuated by the absence of an Asn 
residue at position 701, resulting in an inability to replicate in mice [103]. In contrast, H5Nl 
viruses with D701N exhibits enhanced transmission efficiency in guinea pigs [34]. In H7N7, 
an Asn residue at position 701 has been shown to be involved in binding to mammalian 
import in la, thereby enabling more efficient transport of the replication machinery to the 
nucleus of the host cell. The identification of these single amino acid changes that abolish 
pathogenicity are important steps in our understanding of virulence. However, introducing 
these two mammalian virulence associated amino acids in any PB2 gene will not necessarily 
result in a hypervirulent virus [104]. Recent studies showed that viral virulence is possibly 
determined by the whole polymerase complex (PB2, PBI, and PA) rather than PB2 alone 
[105]. 
1.4.5.3 The NSI protein 
The NS 1 protein is the only non structural protein of influenza viruses. This protein seems to 
be playing important roles in the increased viral virulence of influenza viruses, mainly by 
protecting the virus from the antiviral effects of host interferon (IFN) responses [106]. NSI 
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exerts its IFN antagonism by binding dsRNA and by binding to the cellular RNA helicase 
retinoic acid inducible gene 1 (RIG-I), an upstream regulatory component of the IFN 
production cascade [107-109]. Furthennore, partial down regulation ofNF-kappaB pathways 
by NSI has been shown [107, 110]. 
Compared to human HINI and H3N2 viruses, the NSI gene of H5Nl viruses seems 
responsible for hyperinduction or dysregulation the cytokine response, particularly TNF-a, as 
shown in in-vitro studies using human-derived macrophages [111]. HINI virus bearing the 
NS1 of H5NI virus induced high pulmonary concentrations of ILIa, ILI~, IL6, IFN-y and 
IL8-like chemokines, and decreased concentrations of the anti-inflammatory cytokine IL lOin 
mice [112], and prolonged viral shedding in pigs [113]. The latter was associated with the 
presence of glutamic acid (Glu, E) instead of aspartic acid (Asp, D) at position 92 of the H5N1 
NS gene [113]. However, Glu92 has not been found in recent human H5NI isolates [9, 29]. In 
addition, amino acid changes at positions 149 and 42 appear to be critical for virulence, in 
chickens and mice, respectively [114, 115]. Furthermore, recent studies have revealed the 
presence of a 'postsynaptic density protein-95, disc large tumor suppressor protein, zonula 
occludes-I' (PDZ) ligand motif in the carboxy terminus of the NS 1 of avian influenza virus, 
including H5NI, as a potential virulence determinant [116]. 
1.4.5.4 Other proteins 
The M2 protein is a target of the adamantane drugs (amantadine and rimantadine). Recently, 
an increase in amantadine resistance, caused by mutations in the M2 gene, has been observed 
in both seasonal human H3N2 and HINI viruses, seemingly without antiviral pressure. 
Viruses from some 'H5NI clades invariably carry amantadine resistance conferring mutations 
[79, 117]. Resistance in these avian H5NI clades may be explained by the massive use of 
amantadine in Chinese poultry farming [118], but the fact that resistance increases in human 
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viruses in the absence of selective pressure by drug use, and the finding that mortality is 
higher in mice infected with amantadine resistant HI N 1 strains suggest that M2 may also be 
important for virulence [119]. 
The recently discovered PB I-F2 protein, which is translated from an alternate reading frame 
of the PB 1 gene segment, causes apoptosis in macrophages, reducing their ability to induce an 
immune response and therefore delaying viral clearance [120]. This reading frame is also 
present in H5NI, and is believed to contribute to the viral virulence [121, 122]. 
1.4.6 Laboratory diagnosis 
Preferred clinical specimens for laboratory diagnosis of suspected cases of H5Nl influenza 
include throat swabs or lower respiratory tract specimens in case of pneumonia [62]. 
Compared to nasal swabs, throat swabs show higher viral loads and therefore higher yields for 
the detection of H5NI virus [12], [This thesis]. For critically ill patients who require 
mechanical ventilation, endotracheal aspirate specimens can also be used as diagnostic 
specimens [12, 123]. Although H5Nl is a systemic disease, and clinical specimens collected 
outside the respiratory tract such as blood, stools, CSF, may contain detectable levels of viral 
RNA, these are not recommended for diagnostic use [124]. 
Current options for diagnosis of human infection with influenza A H5N 1 virus at the time of 
disease include antigen detection, virus culture and detection of viral RNA by reverse 
transcription polymerase chain reaction CRT-PCR) [9]. Although current methods for detection 
of viral antigen (e.g., direct immunofluorescence, enzyme immunoassay and rapid tests) are 
rapid and easy to perform, these methods are not useful for routine diagnosis of H5N 1 
influenza because currently available tests are unable to differentiate infection caused by 
29 
C!wple,. 1 
H5NI from circulating seasonal influenza virus subtypes [9, 12]. In addition, low sensitivity 
limits the use of rapid antigen tests for diagnosis of H5N 1 infection [79]. Virus isolation in 
embryonated chicken eggs or cell culture remains the 'gold standard' for influenza diagnosis, 
including avian influenza H5NI [12]. However, factors that limit its usefulness include time to 
diagnosis (culture is relatively slow and requires 2 to 3 days) and biosafety level 3 (BSL3) 
laboratory requirements [12]. Therefore, RT-PCR rather than virus isolation is the method of 
choice for diagnosis of clinical specimens from suspected cases [9]. RT-PCR is sensitive, 
specific and only requires 6 to 8 hours to produce a result [9]. When using real-time RT-PCR 
(rRT-PCR), the per-sample tum around time can be shortened to 4-6 hours. Besides its 
sensitivity and specificity, the use of rRT-PCR allows for minimizing the risk of carryover 
contamination as it requires no post-amplification manipulation of generated nucleic acid 
amplicons [9, 12]. In addition, rRT-PCR also allows for (semi-) quantitative analyses of the 
virus load in clinical specimens important for studying viral factor in pathogenesis and 
possibly for monitoring treatment response [36, 77], [This thesis]. 
Detection of H5 specific antibodies by hemagglutinin-inhibition or (micro)neutralization 
assays are not useful for timely diagnosis because antibodies are usually not yet detectable 
during the acute stage, serological analysis ideally requires paired sera, and the most sensitive 
method, i.e. (micro)neutralization, requires virus culture in BSL3-facilities. However, 
serological assays are very important for retrospective diagnosis (in the case of absence of 
acute respiratory specimens) and sero-epidemiology studies [79]. 
1.4.7 Treatment 
At present, two classes of drugs are available for the treatment of influenza virus infections: 
the adamantanes (amantadine and rimantadine) and the neuraminidase inhibitors (zanamivir 
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and oseltamivir). Adamantanes target the M2 ion channel of influenza A viruses, preventing 
replication [9]. During the Hong Kong H5N I outbreak in 1997, amantadine was used to treat 
several patients [2]. However, amantadine was not used in recent outbreaks due to a high rate 
of adamantane resistance [79]. Patients with H5Nl disease have mostly been treated with the 
neuraminidase inhibitor oseltamivir [62, 79]. 
Oseltamivir inhibits viral replication through binding to the active site of the neuraminidase 
enzyme, thereby interfering with its function to hydrolyse host cell receptors and releasing 
progeny viruses from infected cells [125]. In uncomplicated influenza, treatment with 
oseltamivir is only beneficial when initiated early «48 hours) in the course of illness [79]. 
When given later, it may not affect the course of mild seasonal influenza since the host' 
immune system is clearing the infection by then. In more severe and prolonged illness, it may 
still be of benefit to give oseltamivir after 48 hours of disease. For most of H5Nl infected 
patients studied in this thesis treatment was started relatively late when symptoms had already 
progressed, possibly explaining its limited effect [79]. 
Compared to H5Nl viruses from the 1997 outbreak, clade I H5Nl viruses are more 
susceptible to oseltamivir carboxylate in vitro but animal models suggest that higher doses and 
longer treatment durations may be required for antiviral efficacy [126, 127]. Compared to 
clade 1 viruses, clade 2 viruses are 20 to 30-fold less susceptible to oseltamivir in vitro [79]. 
Viruses with oseltamivir resistance conferring mutations have been shown to evolve during 
treatment [77, 128], and may be associated with fatal outcome [77]. Oseltamivir resistant 
viruses remain susceptible to zanamivir [128], which is at this time only available as a locally 
active inhaled drug. Intravenous formulations of zanamivir and the neuraminidase inhibitor 
peramivir are under development, possibly providing more options for treatment of influenza 
illness, including H5Nl influenza [79]. 
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1.5 The aims of this thesis 
Since the re-emergence of human H5N 1 infections in 2003, the clinical understanding of 
H5N I disease and its pathogenesis has increased but remains limited due to the relatively 
small number of cases, therefore additional clinical studies of human H5N I disease remain 
important. 
The neuraminidase inhibitor oseltamivir is the only readily available treatment option for 
human H5N 1 infection, but little is known about the effectiveness and optimal dosage of the 
drug in H5N 1 disease. Furthermore, we have reported the emergence of oseltamivir resistant 
variants in two patients during therapy resulting in treatment failure [77]. 
To contribute to the current knowledge, in the work that led to this thesis it was aimed 1) to 
study the clinical and virological features of 16 human H5NI infections identified in 2004-05 
in southern Vietnam, and 2) to study the antiviral efficacy of treatment with oseltamivir and 
the emergence of drug resistance in 8 patients who were followed during treatment. 
Furthermore, it was shown that H5NI viruses prevalent in Vietnam during 2004-05 belonged 
to clade I of genotype Z [54]. Sequence analyses revealed that, compared to strains isolated 
from birds, some human H5NI strains have amino acid changes, mostly in the HA and PB2 
genes. However, little is known about the correlation between amino acid changes, 
particularly in the PB2 gene, and disease severity as well as the role of amino acid changes in 
HA in adaptation to human receptor recognition. Against this background, I aimed 3) to 
understand the molecular characteristics of isolated human virus strains, 4) to identify possible 
virulence determinants and, if possible, their correlation with clinical outcome, and 5) to 
identify amino acid changes in HA that potentially affect receptor specificity. 
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In recent years, clade 2.3.4 H5NI viruses have been found to co-circulate with clade 1 H5NI 
viruses in some southeast Asian countries, including Vietnam. The co-circulation of two 
distinct genetic clades provides a challenge to laboratory diagnosis of H5Nl infection since 
assays for H5N I detection are usually designed based on clade-specific amplification of the 
HA gene. To improve H5N 1 diagnostics in Vietnam, I aimed 6) to develop a highly sensitive 
real-time peR for generic detection of currently circulating H5NI influenza viruses important 
for timely diagnosis and outbreak control. 
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Chapter 2 
PATIENTS AND METHODS 
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2.1 Patients and clinical samples 
Between January 2004 and February 2005, 16 patients with influenza virus A H5Nl disease 
were confirmed in 4 hospitals in southern Vietnam. Three of these hospitals are tertiary 
hospitals for southern Vietnam based in Ho Chi Minh City: the Hospital for Tropical Diseases 
(HTD), Paediatric Hospital One (PHI), and Paediatric Hospital Two (PH2). At the start of 
avian influenza A H5N 1 outbreaks, these three hospitals were designated as hospitals for 
receiving and treating patients with suspected infection (patient who has fever, respiratory 
symptoms and a history of poultry exposure or exposure to a H5NI-confirmed patient). 
Suspected patients identified in other hospitals in southern Vietnam were referred to one of 
these three hospitals. The remaining hospital of this study was a provincial hospital, the Dong 
Thap Provincial Hospital (DTPH), Cao Lanh district, Dong Thap province. DTPH is a primary 
level hospital situated in the Mekong Delta approximately 250 km southwest of Ho Chi Minh 
City. 
The Virology Laboratory of the Oxford University Clinical Research Unit (OUCRU) based in 
HTD was responsible for diagnosis of avian influenza A H5NI infection. 
The 16 patients were renamed as Patients 1-16 (table 2.1). Informed consent was obtained 
from all patients or their guardians during hospitalization. From these 16 patients, 
epidemiological data were obtained by interviewing them or their relatives who cared them at 
home or during their hospital stay. Clinical data and laboratory test results were obtained by 
means of patient files. These clinical data were collected by clinicians at the Hospital for 
Tropical Diseases, Peadiatric Hospital Number 1 and 2, and Dong Thap Provincial Hospital as 
part of a study on clinical characteristics of human H5N 1 influenza that I was involved in. 
This study was directed by Professors Tran Tinh Hien, Menno de Jong, and Jeremy Farrar. 
The clinical data of most of these patients have been published previously as case series or 
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case reports (appendix 1). Pennission for use of these clinical case notes and database was 
obtained from Professor Tran Tinh Hien, vice-director of the Hospital for Tropical Diseases 
and Prof Jeremy Farrar, director of OUCRU. 
All respiratory clinical specimens obtained from these 16 patients were used in studies 
described in this thesis. These specimens included diagnostic nasal and throat swabs obtained 
from 15/) 6 patients and sequential throat swabs obtained during and after oseltamivir 
treatment from 8116 patients (table 2.1 and chapter 4). In addition, during admission, other 
non-respiratory clinical specimens including blood specimens from all 16 patients, rectal 
swabs from 7 patients, and CSF from one patient (table 2.1) were also obtained and used . 
Table 2.1 Clinical samples available for analysis from 16 patients. 
Patient Patiellt Diag1lostic Follow-up Extra 
group respiratory respiratory Rectal 
swab swab swab 
I II No Yes No Yes 
2 II Yes Yes No Yes No 
3 II Yes Yes Yes Yes No 
4 II Yes Yes Yes Yes No 
5 T Yes Yes No Yes No 
6 ] Yes Yes No Yes No 
7 I Yes Yes No Yes No 
8 II Yes No No Yes No 
9 I Yes No No Yes No 
10 I Yes No Yes Yes No 
II I Yes No Yes Yes No 
12 I Yes No No Yes No 
13 II Yes No Yes Yes No 
14 IT Yes No Yes Yes No 
15 II Yes Yes No Yes No 
16 II Yes No Yes Yes Yes 
For studies described in chapter 6, beside 10 respiratory clinical specimens obtained from 10 
of the 16 index patients with clade I H5N 1 virus infection (see chapter 5), 48 additional 
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clinical samples from 29 patients with confirmed clade 2.1 and 2.3.4 H5N1 influenza viruses 
were used (table 2.2). All H5Nl clinical sample use in this chapter included 14 nose swabs, 31 
throat swabs, 8 pharyngeal aspirates, I rectal swab 2 plasma, and 2 pleural fluids. The clade 
2.1 clinical samples were collected from patients with HSN I disease in Indonesia and the 
clade 2.3.4 samples were obtained from Vietnamese patients in northern Vietnam, between 
2004 and 2008 (table 2.2). 
To validate the specificity of the assay described in chapter 6, throat swab samples from 19 
patients with seasonal influenza (HI N 1: n= 10; H3N2: n=9) confirmed by conventional R -
PCRs and/or viru isolation as described previously [62], and 29 throat swab samples from 29 
patients with non-influenza respiratory illne s admitted to the Hospital for Tropical Diseases 
Ho Chi Minh City during the H5N1 outbreaks in 2004 - 2005 were also used. 
Ethical approval for use of these specimens has been received from institutional review boards 
in Vietnam Indonesia and the Oxford Tropical Research Ethical Committee. 
Table 2.2 Additional H5 1 ample u ed 
linical ose Throat Tracheal Plasma Pleural Stool Total No of 
samples / swab swab aspirate fluid patient 
virus clade I I 
lade I· 2 7 I 0 0 0 10 10 
Clade 2.1 7 17 1 0 0 0 25 2S 
Clade 2.3 5 7 6 2 2 1 23 4 
Total 14 31 8 2 2 1 58 39 
ote: * indicate samples were obtained from 10 ofthe16 patients described in chapter 3. 
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2.2 Methods 
2.2.1 Sample collection 
On admission and during hospitalization, nose and throat, and if possible, rectal swab 
specimens were collected using rayon swabs with plastic shafts. Nose swabs were collected by 
inserting a swab stick into the nostril with most secretions. The swab was left in place for 5-10 
seconds to absorb secretions. Throat swabs were collected by wiping the swab stick over the 
tonsils and posterior pharyngeal wall without touching the buccal mucosa or tongue 
[http://wwwwhoint/csr/resources/publications/surveillance/CDS _ EPR_ ARO _ 2006_1 pdf, 
accessed on October 12, 2009]. Rectal swabs were collected by spreading the patient's 
buttocks, inserting the swab stick into the anus and further into the rectum, and rotating the 
swab gently before taking it out. During specimen collection, personal protective equipments 
including N95 mask, non-sterile latex gloves, face shield, gown and head-cover were used 
according to WHO guidelines [http://www.searo.who.int/LinkFiles/CDS_CDS-Guidelines-
Laboratory.pdf, accessed on May 13,2008] [129]. 
After swabbing, swabs were immediately placed into a sterile vial containing 2 ml of Viral 
Transport Medium (VTM) (Minimum Essential Medium Eagle with Hanks' salts, 
supplemented with 0.5 percent gelatin and antibiotics [Sigma-Aldrich, Singapore, Singapore]) 
or PBS (phosphate-buffered saline) [62]. 
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Clinical specimens 
from confirmed 
H5Nl patients 
Sealed plastic bags 
OUCRU BSL2 Virology 
Laboratorv in cold condition 
Throat, nasal, and rectal 
swabs in 2 ml VTM or 
PBS 
150 III ali quoted and 
lysed in BSC 
Viral RNA 
RT-PCR 
Store at -80°C until 
analysis 
Figure 2.1 Flow chart illustrating how clinical specimens were handled 
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All swab specimens were immediately transported to the OUCRU Virology Laboratory in 
individual sealed bags and under cold conditions (4°C). Upon receiving clinical specimens, 
from each vial of sample, 150 III was immediately aliquoted for nucleic acid extraction and 
RT-PCR. Clinical specimens were handled under biosafety level 2 conditions in a biosafety 
cabinet class II until lysed to ensure protection from HP AI H5N I viruses and other potential 
pathogens present in the specimens. This is in accordance with WHO guidelines on laboratory 
diagnosis of avian influenza A H5NI [129]. The remaining sample was stored at -80°C until 
further analysis (figure 2.1). 
CSF and peripheral blood were collected by means of lumbar and vein punctures, respectively. 
Serum was separated from cells by centrifugation for 5 minutes at 2.500 x g. Serum and CSF 
were then stored at -80°C until analysis. 
2.2.2 RNA extraction 
Viral RNA was extracted using the QIAamp Viral RNA Mini Kit (Qiagen, West Sussex, UK) 
and/or in-house silica absorption method as described by Boom et aI., [130]. 
2.2.2.1 RNA extraction using QIAamp Viral RNA Mini Kit 
In the QIAamp Viral RNA Mini Kit (Qiagen), 140 ,.d of clinical sample or virus culture 
supernatant were added to 560 J.lI lysis buffer containing RNA carriers (included in the kit), 
and incubated at room temperature for 10 minutes. 560 III of 95% ethanol was added to the 
lysate, which was subsequently transferred into a collection tube with silica filter and 
centrifuged at 16363 x g for I minute. The flow-through was discarded and the collection tube 
was washed with 500 J.lI AWl buffer (included in the kit) and then with 500 J.lI AW2 buffer 
(included in the kit). The collection tube was spun at 16363 x g for 3 minutes to remove any 
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trace of extraction buffers which may inhibit the RT-PCR. Viral RNA bound to the silica filter 
was eluted in 60 JlI of elution buffer (included in the kit) and was used in cDNA synthesis. 
2.2.2.2 RNA extraction using Boom assay 
In the silica absorption method, all extraction reagents including lysis buffer L6 containing 
4M guanidinium thiocyanate (Promega Corporation, Wisconsin, USA), activated silica 
(Promega Corporation, Madison, WI 53711 USA) in IX TE (Tris-HCI, EDTA) pH 8.0 for 
nucleic acid absorption, washing buffer L2, 70% ethanol (DBH Prolabo, Singapore), acetone 
(DBH Prolabo, Singapore) and IX TE pH 8.0 buffer) were prepared at the Virology 
Laboratory of OUCRU according to Boom et aI., [130]. Briefly, 100 JlI of clinical sample or 
virus culture supernatant was mixed with I mllysis buffer L6 on a vortex mixer. Twenty JlI of 
activated silica were added to absorb nucleic acids and the mixture was incubated at room 
temperature for 10 minutes. The silica with absorbed nucleic acids was pelleted by 
centrifugation and the liquid phase was discarded. The pellet was treated twice with 1 ml L2 
washing buffer, and twice with I ml 70% ethanol. Finally, the pellet was washed with I mlof 
acetone and air dried at 56°C for 10 minutes. Silica-bound nucleic acids were eluted in 100 JlI 
of IX TE buffer pH 8.0 at 56°C for 10 minutes. The aqueous phase containing viral RNA was 
collected and was used for making cDNA. 
2.2.3 Primer and probe design 
PCR primers were designed using Primer Express software version 2.0 (Applied Biosystems). 
This software package includes specific applications including PCR primer design, sequencing 
primer design, and TaqMan probe design. The software generates a set of possible primers and 
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probes based on a reference or consensus sequence of the gene of interest. Parameters that can 
be set include primer position and length, GC content, melting temperature, etc. Generated 
primer sets are scored between 1-1000 points; the lower the score, the better the primer set 
(e.g. minimal risk of aspecific hybridization and formation of secondary structures due to self-
complementarity or primer dimer formation). 
The NAl-609FINAl-811R shown in table 2.3 is the one of the primer sets designed by this 
software. The reference sequence used in designing this primer set was a consensus nucleotide 
sequence of NA gene generated from NA sequences of a large selection of avian influenza A 
H5Nl strains available in GeneBank [131]. 
The design of TaqMan probes is similar to that ofPCR primers except TaqMan probes should 
have a T m of at least 5 °C greater than the T m of primers. 
2.2.4 Reverse transcription - Polymerase chain reaction (RT-PCR) 
In this thesis, RT-PCR reactions were performed either in one step (chapter 6) or two step 
(chapters 3-5). One step RT-PCR combines RT and PCR reactions in one tube and primers 
used in one step RT-PCR reactions are sequence specific primers. Two step RT-PCR reactions 
separate the RT from the PCR. In two step RT-PCR, viral RNA was first converted into 
cDNA using either random hexamers (Roche Diagnostics, Indianapolis, IN, USA) or a 
universal primer - the Uni12 primer (Sigma-Aldrich). Uni12 primer is a universal primer that 
anneals to the 3' UTR of all eight gene segments of influenza A virus (regardless of its 
subtype) allowing full length gene segment cDNA synthesis [132]. The synthesized cDNA 
then served as template in subsequent PCR reactions (chapters 3-5). 
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2.2.4.1 Two step RT-PCR 
2.2.4.1.a Reverse transcription (RT) 
RT was performed in total volume of 20 III containing 5 III of viral RNA, 4 III of 5X first-
strand buffer (Invitrogen, Carlsbad, CA, USA), 500 mM of each deoxynucleoside triphosphate 
(dNTP; dATP, dTTP, dCTP, and dGTP) (Roche Diagnostics), 40 units RNA inhibitor (RNase 
OUT, Invitrogen), 0.2 III (40 units) of reverse transcriptase (Superscript III, Invitrogen), and 
0.4 IlM ofUnil2 primer or 21lg of random hexamers. Reverse transcription (RT) was carried 
out at 25°C for 10 minutes (only for random hexamers), 50°C for 60 minutes, followed by 
enzyme inactivation at 70 °c for 5 minutes. The RT reaction was performed in an Eppendorf 
Mastercycler (Eppendorf, Cambridge, UK). 
A negative control using H20 instead of RNA template was included in each experiment to 
ensure that there was no viral RNA contamination of the reagents. cDNA was stored at -20°C 
until used. 
2.2.4.1.b PCR 
PCR was used extensively in this thesis. Several types of PCR amplification including 
standard PCR, touchdown PCR, hot-start PCR, qualitative and quantitative real-time PCR, 
were all used depending on the aim of experiment. 
Standard peR: Standard PCR was conducted using 2 III of cDNA in total volume of 25 III 
containing 2.5 Jil of lOx PCR buffer, 1.5 mM magnesium chloride, 0.4 mM of each dNTP, 0.4 
JiM of each primer, and I unit of High Fidelity Taq Polymerase of the Expand High Fidelity 
System (Roche Diagnostics). The initial cycle of the PCR program was 3 minutes at 95°C, 
followed by 40 cycles of 20 seconds at 94°C, 30 seconds at 50 DC, 30 seconds at 72 DC, and a 
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final extension step at 72 °c for 7 minutes. The PCR was performed using Eppendorf 
Mastercycler (Eppendorf) or DNA Tetrad Thermal Cycler (MJ Research, Waltham, MA, 
USA). PCR products from amplification using normal primers were analyzed using agarose 
gel (1.5%) electrophoresis as described by Ausubel et aI., [133]. Gels were analyzed using Gel 
Doc XR system (Bio-Rad, Hercules, CA, USA). Products from amplification using 
bionitylated primers were analyzed in pyrosequencing machine, the PyroMark ID (BioTage, 
Uppsala, Sweden) (table 2.3). 
Toue/I-down peR: Touch down RT-PCR was used to diagnose influenza H5NI infection in 
group I patients (see table 2.1). Primer sequences for diagnosis using touch-down PCR were 
obtained from Yuen et aI., and Bright et aI., [2, 3], or kindly made available by Dr Takehiko 
Saito, The National of Infectious Diseases, Tokyo, Japan (table 2.4). 
The purpose of touch down RT-PCR is to reduce nonspecific PCR amplification, thus 
providing more reliable diagnostic results [62]. The increased specificity is due to higher 
annealing temperatures in the initial cycles of the reaction. Unlike standard RT-PCR, the 
annealing temperature of initial cycles is slowly decreased during each subsequent 
amplification cycle. Higher annealing temperatures only pennit highly specific primer 
binding, which allows generation of higher quality amplicons for subsequent amplification 
cycles. 
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Table 2.3 Primers for standard peR and their application. 
Primer Primer Nucleotide sequence (5'- Target Source Application 
set name 3') gene {Q2sition} 
NA1- Designe GCTTTACTGTAATGAC NA 
609F d using TGACGG (609-630) Direct amplification Primer 
Express of a portion of the NA gene that NA1- softwar AGATACCCATGGCCGA NA 
contains the H274Y 811R e TT (811-794) 
mutation 
version 
2.0 
PCR- GGGAAAGTGGTTAAAT NA Direct amplification 
274F CAGTCGA (721-743) of a portion of the 
NA gene that 
2 Biotin- contains the H274Y PCR- NA mutation. PCR 
274R CCATGCCAATTATCCC (812-833) products were then TGC 
analyzed in 
Designe pyrosequencing 
PCR- d using GCCAATCCAGTCAATG HA Direct amplification 
HA134F BioTag ACC (295-313) of a portion of the 
e primer HA gene that 
3 design Biotin- contains the A 134 V PCR- softwar AAGGAGGACTTTCCCT HA mutation. PCR HA134R e GGTA (476-457) products were then 
version analyzed in 
1.0.6, pyrosequencing 
PCR- CTCAGCATGTCCATAC HA Direct amplification HA151- CAGGG (444-464) of a portion of the 186F HA gene that 
contains the 1151 F IL 
4 PCR- Biotin- and E186D HA mutations. PCR HA151- GAAATATAGGTGGTTG (622-644) products were then 186R GGTTTTG 
analyzed in 
e~roseguencin8 
Note: Positioning is based on the 1st nucleotide of the starting codon. 
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Table 2.4 Primer set for diagnosis of influenza A H5NI infection in group I patients. 
Target Size of Primer Primer peR Primer 
set name Nucleotide sequence (5' to 3') gene product source (position) (bp) 
HS-I GCCATTCCACAACATACACCC HA 
HSa 
(914-934) 
3S8 Yuen ct a., 
HA(l242- [2]. HS-2 TAAATTCTCTATCCTCCTTTCCAA 126S) 
HA Dr Takehiko HS-SlSf CATACCCAACAATAAAGAGG (515-534) aito, The 
National of 
H5b HA 708 bp Infectious 
HS-]220r GTGTTCATTTTGTTAATGAT (1201- Diseases 
1220) Tok.)'o, 
Japan. 
Nl-I'" TTGCTTGGTCAGCAAGTG A NA(482-SOl) 
61Sbp Bright et al.. 
NA(1077- [3]. NI-2 TCTGTCCATCCATTAGGATCC 1097) 
Note: Asterisk (*) indicates a T to A modification at the 3' end to enhance specificity was 
performed. Positioning is based on the 151 nucleotide of the starting codon. 
In this thesis, touch down PCR reactions were carried out in a total volume of 25 fll , 
containing 2 fll of cDNA, 2.5 fll of lOx PCR Gold buffer (Applied Biosystems Inc., Foster 
City, CA, USA), 2.5 rnM magnesium chloride, 0.4 mM of each dNTP (Roche Diagnostics), 
0.8 flM of each primer, and 1 unit of AmpliTaq Gold DNA polymerase (Applied Biosysterns). 
Thermocycling conditions were 95°C for 10 minutes (pre-amplification hot start); 10 cycles 
of95 °c for 30 seconds, annealing at 60°C (for the NI primer set) or 50°C (for the H5 primer 
sets) for 30 seconds (the annealing temperature was decreased with] °C per cycle), and 72 °C 
for 1 minute) and 40 cycles of 95°C for 30 seconds, 55°C (for the Nt primer set) or 45 °c 
(for the H5 primer sets) for 30 seconds, and 72 °C for 1 minute. Seven microliter of PCR 
product was analyzed by agarose gel (1-2 % (w/v)) electrophoresis. 
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Hot-start peR: Hot-start PCR is more specific than conventional PCR [134]. In this thesis, 
hot-start PCR was used to amplify the whole genome of MDCK cultured H5N 1 viruses and 
part of the HAl of 'egg-adapted' H5NI viruses. The nucleotide sequences of PCR primers 
(table 2.5) for whole genome amplification were adapted from Guan et aI., [1]. These allowed 
amplification for the entire genome of influenza A H5NI virus in 15 fragments (table 2.5). 
PCR reactions for amplification using these primers were performed at the Department of 
Microbiology, State Key Laboratory of Emerging Infectious Diseases, Faculty of Medicine, 
The University of Hong Kong, Hong Kong SAR, China in cooperation with Dr Gavin Smith. 
The reaction was conducted in a total volume of 25 J.ll, containing 2 J.ll of cDNA, 2.5 J.lI of lOx 
PCR Gold buffer, 1.5 mM magnesium chloride, 0.4 mM of each dNTP (Roche Diagnostics), 
0.4 JlM of each primer, and 1 unit of AmpliTaq Gold DNA polymerase (Applied Biosystems). 
Thermocycling conditions were 95°C for 10 minutes (pre-amplification hot start); 40 cycles 
of 95°C for 20 seconds, 55°C for 30 seconds, and 72°C for 2 minutes, and final extension at 
72 °c for 10 minutes. Three microliter of PCR product was analyzed on agarose gel (1 % 
(w/v». 
The single primer set (H5-1 028F /H5-1 028R) (table 2.5) for amplification of a portion of HA 1 
was designed using Primer Express software version 2.0 (Applied Biosystems). PCR reactions 
for this primer set were carried out in a total volume of 25 J.lI, containing 2 J.lI of cDNA, 2.5 J.lI 
of lOx Hotstart PCR buffer (Qiagen), 1.5 mM magnesium chloride, 0.4 mM of each dNTP 
(Roche Diagnostics), 0.4 JIM of each primer, and 1 unit of Hotstart Taq DNA polymerase 
(Qiagen). Thermocycling conditions were 95°C for 10 minutes (pre-amplification hot start); 
40 cycles of 95°C for 20 seconds, 50°C for 30 seconds, and 72°C for 2 minutes, and final 
extension at 72 °c for 10 minutes. Seven microliter of peR products was analyzed on agarose 
gel (1 % (w/v». 
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Table 2.5 Primers for whole genome and part of the HAl amplification. 
Fragment Primer Nucleotide sequence (5' to 3') Target Size of Source 
name gene PCR 
product 
(bp) 
H5-1 AGCAAAAGCAGGGGTMTAAT HA 1120 Adapted 
H5-1120R CCCTGCCATCCTCCCTCTAT from Guan et 
2 H5-830 TATGCMTAYAAAATTGTCAAG 911 aI., [1]. 
H5-1741R GTGTTTTTAAYTAMAATCTG 
3 Nl-3 CAAAAGCAGGAGATTAAAATG NA 1136 
Nl-1139R CATCCGTTTGGATCCCAAAT 
4 Nl-561 AAGTGCTTGTCATGATGGCA 896 
Nl-1457R GTAGAAACAAGGAGTTTTTKGAAC 
5 NS-I AGCAAAAGCAGGGTGACAAA NS 888 
NS-888R AGAAACAAGGGTGTT I I ITA 
6 NP-8 GCAGGGTAGATAATCACTCAC NP 1020 
NP-I028R GAATGGCATGCCATCCATACC 
7 NP-701 ATGAGAGAATGTGCAACA 864 
NP-1565R AGTAGAAACAAGGGTATTTTTC 
8 M-8 GCAGGTAGATATTGAAAGATG M 1015 
M-I023R GAAACAAGGTAGTTI I I I ACTC 
9 PA-1 AGCAAAAGCAGGTACTGAT PA 940 
PA-940R TTCATGCATTTGATCGCATC 
10 PA-717 CTATGTGGATGGATTCGAAC 1001 
PA-1718R ACATACAGGAACATGGGCCT 
11 PA-1386 GGCTACTGAGTACATAATGAAGGG 865 
PA-2233R AGTAGAAACAAGGTACCTTTTTGGAC 
12 PBI-1 AGCAAAAGCAGGCAAACCAYTTG PBl 1511 
PBl-511R AAAAAGCTTGTGAATTCAAA 
13 PBl-1118 CGGACACAAATACCAGCAGA 1219 
PBI-337R GAAACAAGGCAIIIIIICATGAAGG 
14 PB2-1 AGCAAAAGCAGGTCAAWTATATTCA PB2 1566 
ATATG 
PB2-566R CCCACATCATTGATGATG 
15 PB2-949 GTGGATATATGCAAGGC 1380 
PB2-329R GTCGTTTTTAAACAATTCGAC 
H5-1028 H5-1028F CGACAGAGCAGGTTGACACAATA HA 1028 Designed 
H5-1028R GTACCCATACCAACCATCTACCATTC 
Note: M=A+C; Y= T+C; K=G+T; W= A+T. 
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Real-time peR: Real-time PCR is more sensitive and specific than standard PCR because an 
additional oligonucleotide probe is used for detection of specific PCR product allowing 
thermocycling conditions to be more flexible. Real-time PCR results are expressed as Ct 
(Cycle threshold) value, which is defined as the cycle number at which the fluorescent signal 
generated by hybridization of probe to product passes the threshold value in the early 
(exponential) phase of amplification [135]. Fluorescent reporter oligonucleotides used in this 
thesis were TaqMan probes. These probes have a fluorophore and a quencher at either end and 
normally all fluorescence is quenched. When the probes hybridize to their PCR target 
templates and are subsequently hydrolyzed by the 5'- exonuclease activity of the DNA 
polymerase, the distance between quencher and fluorophore becomes sufficient for the 
fluorophore to emit a detectable signal. During amplification, emitted fluorescence will be 
detected by a charge coupled device (CCD) and is displayed as fluorophore curves in the real-
time PCR diagram. 
In this thesis, real-time PCR was used in a two-step format to diagnose influenza A infections 
and to subtype H5 and Nl subtypes in group II patients (see table 2.1). The sequences of the 
FluA-specific primer-probe set were kindly provided by Dr Marcel Beld, Department of 
Medical Microbiology, Academic Medical Centre, Amsterdam, The Netherlands [77]. The 
sequences of the H5 and N 1 primer-probe sets were designed using Primer Express (see 
section 2.2.3). PCR reactions were conducted in a total volume of 25 JlI containing 2.5 Jll of 
lOx Hotstart PCR buffer (Qiagen), 0.4 mM of each dNTP (Roche Diagnostics), 5 mM 
magnesium chloride, 400 nM of each primer, 40 nM of Taqman probe, and 1 unit of Hotstart 
Taq (Qiagen). Real-time PCRs were performed using the Chromo 4 (MJ Research) or the 
iCycler (Bio-Rad) real-time PCR machines. The thermocycling conditions were as follows: 95 
°c for 15 minutes (pre-amplification hotstart); 45 cycles of 95°C (denaturation) for 20 
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seconds, 50-60°C (annealing) for 30 seconds, and 72 °c (extension) for 30 seconds. 
Fluorescent signals were measured in each cycle at the end the extension step. The nucleotide 
sequence of primers and TaqMan probes as well as their annealing temperature (Ta) are 
shown in table 2.6. 
Table 2.6 Primer and TaqMan probe sequences with annealing temperatures for 
diagnosis of group IT patients. 
Primer- Name Target gene Nucleotide sequence (5'-3') Ta 
probe (position) ('C) 
set 
FluA- INFA-16Ss M GACAAGACCAATCCTGTCACYTCTG 60 
specific (166-190) 
INFA-216r M AAGCGTCTACGCTGCAGTCC 
(242-258) 
INFA-probe M FAM-
(214-238) TTCACGCTCACCGTGCCCAGTGAGC-
TAMRA 
H5- AvH5-F HA CCGGAATGGTCTTACATAGTGGA 50 
specific* (296-318) 
AvHS-R HA GTCGTTGAAATCCCCTGGGTA 
(347-367) 
AvHS-probe HA FAM-
(293-317) AGGCCAA TCCAGTCAA TGACCTCTG-
TAMRA 
Nl- AvNI-F NA TGGATCGGGAGAACCAAA 55 
specific* (1012-1029) 
AvNI-R NA TGGATCCCAAATCATTTCAA 
(1052-1071) 
AvNl-probe NA F AM-CACT AA TTCCAGGAGCGGC-T AMRA 
(1030-1050) 
Note: Asterisk (*) indicates oligonucleotide seguences were designed using Primer Express 
software version 2.0. F AM == 5' - carboxyfluorescein; TAMRA == tetramethyl-6-
carboxyrhodamine. Positioning is based on the 1 SI nucleotide of the starting codon. 
2.2.4.2 One step RT-PCR 
A one-step real-time RT-PCR format was used to develop a molecular method for generic 
detection of the HA gene of avian influenza A H5Nl viruses of both clade 1 and 2 (see 
chapter 6 for more information). The sequences of primers and probes (table 2.7) for this 
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application were designed using Primer Express (Applied Biosystems). To enhance the 
thermal stability and specificity, the TaqMan probe was further modified by incorporation of 
locked nucleic acid (LNA) nucleotides. LNA nucJeotides contain common nucleobases (A, T, 
G, and C) in which the ribose ring is ' blocked ' by a methylene bridge connecting the 2 ' -0 
atom and the 4 ' -C atom which forces the probe-target hybrid in a linear rather than the normal 
helical confirmation of double stranded DNA, thereby significantly increasing base pairing 
specificity and thermal stability of the bond [http://wwwexiqoncomllna-technology, accessed 
on October 12, 2009][136]. 
The rRT-PCR was performed using iScript™ One-Step RT-PCR Kit Probes (Bio-Rad) in 
Chromo 4 real time PCR machines (Bio-Rad). The reaction was conducted in a total volume 
of 25 ~l containing 12.5 ~l of 2X RT-PCR Reaction Mix (supplied with the iScript Kit), 400 
nM of each primer, 120 nM of probe, 0.5 ~l of iScript Reverse Transcriptase (supplied with 
the Kit), and 5 ~l of template. rRT-PCR conditions were as follows : one cycle of 50°C for 15 
minutes, followed by 5 minutes at 95 °c, and 45 cycles of 15 seconds at 95°C and 1 minute at 
53 °c. 
Table 2.7 Primers and LNA and normal TaqMan probe designed for this study 
GenH5-F TTGGTTACCATGCAAACAAYT 61 61-81 
GenH5- TRTCTTGGGCRTGTGTAACA 61 122-141 R 
GenH5- F AM-CAGGTTGACACAA T AA TGGAAAAG- 61 91-114 Probe BHQl 
GenH5- F AM-CAGGTTGACACAA TAATGGAAAAG-LNA BHQ1 66 9]-114 Probe* 
Note: a y = T or C, R = A or G. LNA reSIdues In the probe are indicated in bold. 5' - FAM = 
5' - carboxyfluorescein, BHQ = Black Hole Ouencher. b The position in the HA gene is 
indicated. 
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2.2.4.3 Quantitative peR 
In real-time PCR with TaqMan probes, the fluorescence emitted after hydrolysis of the 
fluorescent reporter dye during amplification is proportional to the amount of PCR product 
and thus allows quantitative assessment of the amount of initial target [135]. This can only be 
done when a standard curve control consisting of serial dilution of known concentrations of 
target sequence is included in each run. The control standard can be RT-PCR product, 
synthetic DNA, genomic DNA or recombinant plasmid DNA [137]. 
In this thesis, quantitative PCR was employed to determine the viral RNA load in clinical 
specimens obtained before, during, and after oseltamivir treatment (see chapter 4). The real-
time PCR assay for this application was the FluA-specific real-time PCR, described in section 
2.2.3.1. Standard curve control used in quantitative analysis was a pCR2.l plasmid in which 
FluA-specifc was cloned as described in section 2.2.7. In the preparation for standard controls, 
white colonies were analyzed by PCR using M13 forward and reverse primers (included in the 
TOPO TA Cloning kit). PCR products were analyzed by agarose gel (1.5%) electrophoresis 
and were then purified using the QIAquick PCR purification kit (Qiagen) as described in 
section 2.2.4.I.b. Presence of the correct insert was confirmed by DNA sequencing using the 
CEQ8000 sequencing platform (Beckman Coulter). A single bacterial clone containing the 
insert of interest was selected for propagation in liquid LB medium at 37°C for 16 hours. Cells 
were harvested by spinning down at 2500 x g for 5 minutes. Constructed plasmid was purified 
using the QIAprep® Miniprep Kit (Qiagen) following the manufacturer's instructions 
[http://wwwbiochemarizonaedul AZ-ST AR T /graphics/Q IA prep _ Miniprep _ Handbookpdf, 
accessed on July 27, 2007]. The plasmid was linearized using restriction enzymes EcoID (New 
England Biolabs, Ipswich, UK) and DNA concentration was determined by measuring UV 
absorption at 260 nm using the NanoDrop ND 1 000 (Thermo Fisher Scientific, Wilmington, 
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DE, USA). The number of plasmid copies was calculated using an online calculator 
[http://~rww.uri.edu/research/gsc/resources/cndna.html, accessed on May 28, 2006]. Finally, 
the plasmid was diluted in TE to 106, 105, 104, 103, 102 and 101 copies per microliter and 
served as external standard curve control. Quantitation of viral RNA load was performed in 
batch-wise fashion to avoid intra assay variation [135]. 
2.2.5 DNA sequencing 
2.2.5.1 peR product purification 
PCR product was purified prior to sequencing using the QIAquick® PCR purification kit 
(Qiagen). The use of this kit was done following the manufacturer's instructions. Briefly, PCR 
product was added with 100 J.1l of buffer PB (provided in the kit) and the mixture was 
transferred to a QIAquick spin column (provided in the kit) and was centrifuged for 1 minute 
at 16363 x g. The flow-through was discarded and the column was washed with 0.75 ml buffer 
PE (provided in the kit) and centrifuged for 1 minute at 16363 x g. The flow-through was 
discarded and residual PE buffer was removed by an additional centrifugation at 16363 x g for 
2 minutes. The DNA product was then eluted in 25 J.11 buffer EB (included in the kit). The 
purity of DNA product was assessed by 2% agarose gel electrophoresis and the concentration 
of DNA product was estimated based on band brightness of DNA fragments included in a 
molecular mass ruler (Bio-Rad). Approximately 10-50 ng of PCR product was used for each 
sequencing reaction. 
2.2.5.2 Whole genome sequencing 
Whole genome sequencing of MDCK-cell cultured influenza H5Nl viruses was performed in 
collaboration with Dr Gavin Smith, Department of Microbiology, State Key Laboratory of 
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Emerging Infectious Diseases, Faculty of Medicine, The University of Hong Kong, Hong 
Kong SAR, China. PCR products of 15 reactions that cover the entire genome of avian HSN 1 
influenza virus were purified, assessed for concentration and subjected to dye-termination 
reactions (to incorporate fluorescent labeled nucleotides). To sequence single PCR fragments, 
beside 3' and 5' end PCR primers, additional primers to amplify internal regions of the 
fragment were usually needed. For example, to sequence the HS-IIHS-1120R amplicons, in 
addition to the PCR primers (H5-1 and H5-1120R) two sequencing primers: H5-370 and H5-
540R (table 2.8) were used to allow reliable sequencing of the entire fragment. The nucleotide 
sequences of additional sequencing primers are shown in table 2.8. 
In dye-termination, approximately 20-50 ng of PCR product was used for each reaction 
containing 4 J.11 of 2.5x BigDye® Terminator v3.1 Cycle Sequencing premix (Applied 
Biosystems), 2 J.11 of v3.1 sequencing buffer (supplied with the kit), S pg of single primer and 
20-50 ng of PCR product in a total volume of 20 J.11. The thermocycling conditions were 96 °c 
for 1 minute followed by 25 cycles of 96 °c for 10 seconds, 50 0C for 5 seconds, and 60 °c for 
4 minutes. 
Dye-terminated sequences were purified using Centri-SepTM 96-Well Plates according to the 
manufacturer's instruction (Applied Biosystems). The use of these plates allows simultaneous 
purification of 96 samples in approximately 15 minutes. Purified products were analyzed in 
the 3730x DNA Analyzer (Applied Biosystems) using the standard separation method. DNA 
sequences were analyzed using Sequencing analysis software v5.3.1 (Applied Biosystems). 
54 
ChapTer 2 
Table 2.8 Additional primers used in whole genome sequencing 
PCR Additional Primer sequence (5"-3') Source fragment * seguencing Qrimer 
H5-370 CCC AGG OOA TIT CAA CGA CT A T 
H5-540R GCT CCT CTT TAT TGT TGG G 
NI-412R GTT CTG CAT TCC AAG TGG GA 
3 Dr Gavin NI-561 AAG TGe TTG TCA TGA TGG CA 
NS-540 GAG GAT GTC AAA AAT GCA AT Smith, 
5 Department NS-640R CTT CTC CAA GCG AA T CTC TG 
NP-227 TAA CAA TAG AGA GAA TOO T of 
6 
NP493R Microbiology, GTT GAT CCT TGC A TC AGA G 
M-408R AT A CAA CTG GCA AGT GCA CC State Key 
8 
M-445 GeC ACT TGT GAG CAG ATT GC Laboratory of 
9 PA-622R TCA AA T CTT TCT TCA A TT GT Emerging 
10 PA-1028 TGG CAG AAC TCC AAG ATA ATT G Infectious 
11 PA-1620 OOA GCC ACA CAA GTG GG 
Diseases, 
Faculty of 
PBI-331 TIT GAA AAC TCA TGT CTT GAA AC Medicine, 
PBI-435R CTG GTT TCT A TT CAA TGT CCA G 
12 The 
PBI-689 TGA CCC TGA ACA CAA TGA C University of 
PBI-863R GCC TTC TTC TCA TTC CCT CC Hong Kong, 
13 PBI-2000R TTG CAACAG CAT CAT ATTCC Hong Kong 
PB2-298 OOT GTC TCC CCT AGC TGT AA SAR, China, 14 
PB2-544R GAT GTC AA T A TT CT A GeT CCC 
PB2-1566R CCC ACA TCA ITG ATG ATG 
15 
PB2-1850 CTA CCA TIT GCR GCA GC 
Note: Asterisk (*) indicatesPCR fragment numbering is based on table 2.3. R= A+G 
2.2.5.3 Partial HAl sequencing 
Sequencing of a portion of the HAl gene of 'egg-adapted' H5NI viruses was performed at 
OUCRU using an 8-capillary electrophoresis sequencer: the CEQ8000 (Beckman Coulter Inc, 
Fullerton, CA, USA). In addition to PCR primers (H5-1028F and H5-1028R), two primers 
(H5-514F: ACGCTGCAGACAAAGAATCCAC and H5-570R: 
TCCCAACGGAAA T AT AGGTGG) to target the internal region of the PCR fragment were 
used. Approximately 10-30ng of purified PCR product was used for each sequencing reaction 
containing 4 J1l of CEQ Dye Tenninator Cycle Sequencing Quick Start premix (Beckman 
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Coulter), 10 pg of primer and water up to 20 Ill. Thermocycling conditions were 30 cycles of 
denaturation at 96°C for 20 seconds, annealing at 50°C for 20 seconds and elongation at 60°C 
for 4 minutes. 
Dye-terminated sequences were precipitated in 95% (v/v) cold ethanoVdH20 (-20°C) in the 
presence of sodium acetate. Precipitation was performed in 0.5 ml tubes for each sample. 
After spinning down at 4 °C at 16363 x g for 15 minutes, DNA pellets were rinsed twice with 
200 III of 70% (v/v) ethanoVdH20 (-20°C). The pellet was then vacuum dried in the DNA120 
Speed V AC® (Bio-Rad) for 20 minutes and re-suspended in 40 III of Sample Loading Solution 
(supplied in the sequencing kit). The sample was then available for analysis in the CEQ8000 
sequencer. The CEQ8000 Long Fast Read method was used for all separations. DNA 
sequences were analysed using the CEQuence Investigator software (Beckman-Coulter). 
2.2.5.4 Direct sequencing 
Direct sequencing the HA gene (for confirmation of diagnostic test in chapter 3 and gene 
analysis in chapter 5) and for a portion of the NA gene that covers the H274Y mutation 
(chapter 4) was performed at OUCRU using the CEQ8000 platform (Beckman Coulter). PCR 
primers NAI-609FINAI-81IR (table 2.3) were used in these sequencing reactions. 
2.2.5.5 Post sequencing analysis 
2.2.5.5.a Sequence assembly 
Single-stranded DNA sequences generated by different sequencing primers were assembled 
using the Lasergene software version 6.0 (DNA STAR, Madison, WI, USA) or Vector NTI 
ContigExpress (Vector NTI 7.1, Invitrogen). This software allows assembly of many small 
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DNA fragments, supplied as either text files or chromatograms from automated sequencers, 
into longer contiguous sequences. Assembled sequences were then saved or exported into 
BLAST (Basic Local Alignment Search Tool, available from 
http://blast.ncbi.nlm.nih.govlBlast.cgi),BioEditsoftware(BioEditversion7.0.1,Isis, 
Parmaceutical, Inc, city, USA), or PAUP version 4.0 (Sinauer Associated, Inc, Massachusetts, 
USA) [138] for sequence comparison, residue analysis and construction of relationship 
phy logenetic trees. 
2.2.S.S.b Multiple sequence alignment and phylogenetic tree analysis 
The nucleotide sequences of genes of interest were compared to reference sequences obtained 
from publicly available sequence databases and/or from reference influenza laboratories (such 
as Hong Kong University) using BioEdit. The alignment was then edited, if necessary, and 
was exported as nexus-formatted files into MrModeltest version 2.2 (Evolutionary Biology 
Centre, Uppsala University, Uppsala, Sweden) [139] for appropriate DNA substitution 
determination. The generated model was used in construction of Neighbor-joining and 
maximum-likelihood trees with gaps treated as missing data using PAup·. Estimates of the 
phylogenies were calculated by performing 1000 NJ bootstrap replicates. 
2.2.6 Pyrosequencing 
Pyrosequencing is a real-time DNA sequencing technique based on the kinetics of the 
polymerase chain reaction. This technique can be used for short sequence (SQA) and single 
nucleotide polymorphism (SNP) analyses. The technology involves preparation of single 
stranded DNA template, addition of enzymes and nucleotides, detection of emitted 
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fluorescence and determination of nucleotide sequences. The chemical process of 
pyrosequencing involves the release of pyrophosphate (PPi) occurring when a dispensed 
nucleotide is successfully incorporated into a DNA strand by DNA polymerase during 
elongation. Through a cascade of enzymatic reactions, PPi is converted into visible light, 
which is detected with a charge-coupled device camera and quantitatively displayed as a peak 
in the Pyrogram™ [140]. In addition to SQA and SNP applications, pyrosequencing also 
allows quantitative analyses of subpopulations present in the sample [140] as the peak height 
in the Pyrogram is proportional to the ratio of successfully incorporated nucleotides at each 
position. In this thesis, pyrosequencing was used to assess the presence of wildtype or mutant 
alleles in influenza virus gene fragments that were amplified by peR and cloned into a 
plasmid, that was used to transform Escherichia coli bacteria (chapter 4). In addition, 
pyrosequencing was used to quantitatively analyse for the presence of wild type and mutant 
H5N 1 alleles directly in clinical specimens (chapters 4 and 5). 
2.2.6.1 Pyrosequencing primer design 
Primers for pyrosequencing were designed using PSQ assay design software (version 1.0.6, 
Biotage, Uppsala, Sweden). Each primer set consists of 3 primers: a forward and reverse peR 
primer (one of which is biotinylated) to amplify the DNA sequence that contains the region of 
interest, and a sequencing primer that hybridizes close to the position of interest On the 
(biotinylated) forward or reverse DNA strand. Similar to the design of peR primers described 
in section 2.2.3, the reference sequence used in the PSQ software was a consensus nucleotide 
sequence of the NA and HA gene of avian influenza A H5N 1 virus. peR primers are shown in 
table 2.3 (primer set number 2, 3, and 4) and sequencing primers are shown in table 2.9. 
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Table 2.9 Sequencing primers for pyrosequencing analysis. 
Primer 
set· 
2 
3 
4 
Pyrosequencing 
primer 
Seq-274F 
Seq-HA134F 
Seq-HA151F 
Seq-J-IA 186F 
Sequence (5'73') 
CGAATTGGATGCTCCTA 
TCATTAGGGGTGAGCT 
GAAATGTGGTATGGCTT 
TCCTAATGATGCGGC 
Target 
gene 
NA 
HA 
HA 
HA 
Note: Asterisk (*) indicates numbering is based on table 2.2. 
2.2.6.2 peR and pyrosequencing analysis 
Application 
Quantitative pyrosequencing 
analysis of oseltamivir-
conf~rri~g mutat~on (H274Y). 
Qualltat1ve analys1s of wild-type 
(274H) or mutant (274Y) 
bacterial clones. 
Quantitative pyrosequencing 
analysis of wild-type and mutant 
variants at position 134 (A 134V) 
in the HA gene. 
Quantitative pyrosequencing 
analysis of wild-type and mutant 
variants at position lSI 
(1151 F/L) in the I-IA gene 
Quantitative pyrosequencing 
analysis of wild-type and mutant 
variants at position] 86 (N186D) 
in the HA gene. 
The reverse transcription and peR were performed as described above. peR product for 
pyrosequencing was processed according to the manufacturer's instructions (Biotage, Uppsala, 
Sweden). Briefly, 25~1 of each biotinylated peR product was mixed with 22 ~I binding buffer 
(Biotage) and 3 ~I streptavidin-coated sepharose beads (Amersham Biosciences, Uppsala, 
Sweden). To allow efficient immobilization of the biotinylated DNA product, the mixture was 
incubated at room temperature in a vortex mixer for 5 minutes. The mixture was then applied 
to a filtered vacuum to remove unused peR materials including non-biotinylated peR primers 
and dNTPs. Subsequently, the beads were rinsed with 70% v/v ethanol and treated with 
denaturation solution (Biotage) to remove the non-biotinylated peR strand. Finally, beads 
were released directly into a 96 well plate containing 40 ~I of annealing buffer (Biotage) and 
30 pmoles of sequencing primer. To allow the sequencing primer to anneal to the target DNA, 
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the plate was heated up to SO °c for 2 minutes and slowly cooled down to room temperature. 
The plate was then inserted into the PyroMark™ID machine (Biotage). Pyrosequencing was 
performed using Pyro Gold Reagents kits (Biotage). The SNP method was used for all 
analyses in this thesis. All resulting pyrograms were quantitatively or qualitatively (table 2.9) 
analyzed using the PyroMark™ID software (version 1.0.5). 
To confirm the quantitative pyrosequencing results of H274Y in clinical specimens (chapter 
4), PCR products from direct amplification of the NA gene using the NAI-606FINAI-SllR 
primer set were cloned into pCR2.} plasmids as described in the bellow section (section 
2.2.7). All white colonies from a single transformation were selected for PCR and subsequent 
analysis in pyrosequencing. For this application, one of the M13 primers were modified with 
biotin (table 2.10) and used in combination with the other M13 primer to allow streptavidin 
capture for pyrosequencing analysis. 
Table 2.10 Original M13 and biotin modified M13 primers. 
Primer Sequence (5' -3 ') Note 
M13F GTAAAACGACGGCCAG Included in the TOPO T A 
Cloning kit. 
bM13F Biotin-GTAAAACGACGGCCAG Biotin modified at the 5'. 
M13R CAGGAAACAGCTATGAC Included in the TOPO T A 
Cloning kit. 
bM13R Biotin-CAGGAAACAGCTATGAC Biotin modified at the 5'. 
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2.2.7 DNA cloning 
In this thesis, molecular cloning was performed to generate control standard curves for the 
quantitative FluA-specific rRT-PCR assay (chapter 4) and the generic one-step rRT-PCR for 
clade 1 and 2 H5N I virus detection (chapter 6), and to confirm the results of quantitative 
H274Y pyrosequencing analysis (chapter 4) using TOPO TA cloning kits (Invitrogen, 
Carlsbad, CA, USA). TOPO TA cloning kit includes linearized plasmid vector pCR2.1-
TOPO, E.coU strain TOP 10, plasmid specific primers (forward and reverse M13 primers), 
pUC18 control plasmids, salt solution, and SOC medium. The TOPO TA cloning kit allows 
PCR product with an A (deoxyadenosine) overhang at the 3' end (generated by nontemplate-
dependent terminal transferase activity of Taq polymerase) to be inserted into a 3'T-overhang 
in the lacZ operon of a linearized pCR2.1 plasmid, also containing an ampicillin resistance 
cassette [141]. In the cloning, 1 microliter of purified DNA products was used to be inserted 
into the pCR2.1-TOPO plasmid. The reaction mixture was then used for chemical 
transformation of recipient TOP 10 E.coli cells. The cells were recovered in SOC medium for 
1 hour at 37°C and were cultured on LB plates containing 50J.lglml ampicillin (to select 
transformed bacteria) and 40J.lglml X-gal (bromo-chloro-indolyl-galactopyranoside) in 
dimethylformamide (Invitrogen, Carlsbad, CA, USA). After 16 hour incubation at 37°C, 
colonies transformed with plasm ids containing an insert are easily discriminated from colonies 
transformed with self-ligated plasmids through their colour: insertion of a fragment causes 
disruption of lacZ and the bacteria lose the ability to break down X-gal. Because X-gal 
produces a blue colour when broken down, colonies transformed with self-ligated plasmids 
tum blue whereas colonies transformed with insert containing plasmids stay white. White 
colonies were selected for further analysis. 
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2.2.8 Virus isolation 
In this thesis, H5Nl viruses were originally isolated in MDCK (Madin Darby Canine Kidney) 
cells. Other avian influenza virus subtypes were isolated in embryonated chicken eggs. The 
isolation was performed in a bio-safety levellII laboratory. Before adding of sample to cells 
or eggs, samples were treated with a cocktail of 7 antibacterial and antifungal agents (table 
2.11) in phosphate buffered saline (PBS) pH 7.2 to eliminate growth of all bacteria and fungi 
present in respiratory, fecal and other non-sterile samples. After addition of these 
antimicrobial agents, the mixture was vigorously shaken using a vortex mixer, left at room 
temperature for 30 minutes, and filtered using a 0.45 micro-pore filter (Nalgene Syringe filter, 
city, USA). The flow through was immediately used for virus isolation . 
Table 2.11 Antibiotics and their final concentrations in treated pecimens. 
No Antibiotic Final concentration 
-
1 Penicillin G 2000 U/ml. 
2 Streptomycin 200 Ilg/ml. 
3 Polymyxin B 2000 Ulml. 
4 Gentamicin 250 IAg/ml. 
5 Ofloxacin 60 Ilg/ml. 
6 Su Ifamefhoxazo Ie 200 lAg/mI. 
7 Nystatin 500 U/ml. 
2.2.8.1 Virus isolation in MDCK cell 
MDCK cells purchased from the European Collection of Cell Cultures ( ACC, Wiltshire, UK) 
were grown in growth medium (Minimun ssential Medium [M M]- agle with Earle's salts 
(GIBCO, Invitrogen) supplemented with mycoplasma free fetal bovine serum (Sigma-
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Aldrich), HEPES-buffer (GIBCO), MEM Non-Essential Amino Acids (Sigma), L-glutamin 
(GIBCO) and Penicillin-Streptomycin (GIBCO) in T -25 ml plastic flasks. After 2-3 days of 
incubation at 37°C, when the cells reached approximately 80% confluency, growth medium 
was discarded and the cells were washed twice with MEM-Eagle with Earle's salts IX 
(GIBCO). Each T-25 ml plastic flask was then inoculated with 200 III of sample at 37°C for 
30-60 minutes. Then, all medium was discarded and 5 ml of virus infection medium (MEM-
Eagle with Earle's salts (GIBCO) supplemented with MEM Vitamin solution (GIBCO), Folic 
acid (Sigma), Biotin (Sigma), Bovine Serum Albumin (Sigma) containing 21lg/ml of TPCK-
trypsin (New England Biolabs, Ipswich, UK), and containing amphotericin-B (Sigma), L-
glutamin, Penicillin-Streptomycin) was added. Cytopathogenic effect (CPE) was visually 
assessed daily. Cultures were harvested 3 to 7 days after inoculation (CPE>- 75%). 
2.2.8.2 Virus isolation in embryonated chicken eggs 
Influenza A viruses can be cultured in the allantoic and amniotic cavities of embryonated 
chicken eggs [142]. In this thesis, H5Nl and non-H5Nl avian influenza viruses were isolated 
in the allantois of embryonated chicken eggs (10-11 day old). These eggs were obtained 
locally. After eggshells were sterilized with iodine, each egg was injected with 200 III of 
sample into the allantois and influenza viruses were harvested after two days of incubation at 
35°C. 
Embryonated chicken eggs were also used in the 'egg-adaptation' experiment to identify 
possible HA mutations involved in human or avian receptor recognition. In this experiment, 
MOCK isolated H5NI viruses were passaged 5 times in eggs (chapter 5). 
63 
ChapTer 2 
2.2.8.3 Identification of influenza virus 
Avian influenza A H5Nl virus growth in MDCK cells and embryonated chicken eggs was 
confirmed by the H5-specific (the H5b) and Nl RT-PCR assays (as described in section 2.2.4 
and table 2.4). 
2.2.8.4 Titration of influenza virus 
F or determination of analytical sensitivity of the assay described in chapter 6, a representative 
clade 1 (strain ANietnamlCL115/2005(H5Nl» was titrated in MDCK cells. In brief, MOCK 
cells grown in 6 well-IC plates (Coming Incorporated, Coming, NY 14831, USA) were 
inoculated with serial to-fold dilutions. After incubation at 37°C for 1 hour, each well was 
overlayed with 2,5 ml of complete carboxymethyl cellulose liquid overlay medium 
[carboxymethyl cellulose 3% (GIBCO) in MEM-Eagle with Earle's salts (GIBCO) 
supplemented with MEM-vitamine (GIBCO), folic acid (Sigma), biotin (Sigma), bovine 
serum albumin (Sigma), Penicillin-Streptomycin (GIBCO), HEPES (GIBCO), NaHC03 
(Sigma), and TPCK-trypsin (New England Biolabs, Ipswich, UK)] and incubated at 37°C with 
5% CO2 for 2-3 days. Medium was then discarded and the plate was gently washed two times 
with PBS (Sigma). Subsequently, Iml cold methanol (Sigma) was added to each well and cell 
were fixed at -20°C for 30 minutes. After methanol was discarded, the plate was rinsed with 
tap water. Then Iml naphtol blue black (Sigma) was added to each well at room temperature 
for 30 minutes. The plate was then rinsed gently with tap water and was dried at room 
temperature. The number of plaques was then counted under a magnifier (Bio-Rad). Virus 
stock at a concentration of 104 PFU/Jj.1 was then diluted ten-fold in MEM (up to 10.2 PFU/Jj.I). 
From each resulting dilution, viral RNA was extracted and subjected to one-step rRT -PCR as 
described in section 2.2.4.1. 
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2.2.8.5 Other influenza virus strains 
For sensitivity and specificity analyses of the molecular assay described in chapter 6, in 
addition to clade 1 human H5Nl viruses isolated from 13/16 enrolled patients, 4 clade 2.3.4 
H5N 1 viruses isolated from patients admitted to the National Institute of Infectious and 
Tropical Diseases, Hanoi, Vietnam in 2007, I human clade 2.1 H5Nl isolate 
(NIndonesia/5/2005(H5Nl); kindly provided by Dr Takehiko Saito, The National Institute of 
Infectious Diseases, Tokyo, Japan, 9 human influenza A viruses of subtype HINI (n = 4) and 
H3N2 (n = 5), isolated from patients with seasonal influenza from Dong Thap Province, 
Vietnam, in 2006, and 7 avian influenza viruses of subtypes H3 (n = 1), H4 (n = 3), H5 (n = 
2), and H6 (n = 1), isolated from poultry in Long An and Vinh Long and Dong Tbap 
Provinces, Vietnam, in 2006 were used. All viruses were cultured in MDCK cells (ECACC, 
Wiltshire, UK) and were subtyped using subtype-specific RT-PCRs described previously [62, 
143]. 
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Chapter 3 
HPAI AVIAN INFLUENZA A (H5Nl) VIRUS IN HUMANS IN 
SOUTHERN VIETNAM, 2004-2005 
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3.1 Introduction 
The first recorded instance of human infection with HP AI H5N 1 virus occurred in Hong Kong 
in 1997 during a large-scale poultry outbreak that resulted in 18 infections, 6 of whom were 
fatal [2]. After that outbreak, further human cases were not identified until February 2003 
when avian influenza A H5N 1 viruses were confirmed in two Hong Kong residents: a father 
and his child who had returned shortly after a visit to mainland China. The father succumbed 
to the infection [6]. Later that year, with increasing and widespread poultry outbreaks, human 
cases were also reported from Vietnam, Thailand, Cambodia, Indonesia, and Laos. At the time 
of this writing (February 2011), 519 human cases have been reported from 15 countries in 
Asia, Eurasia, the Middle East and Africa, with 306 deaths (-60%). Although poultry H5Nl 
outbreaks have also been reported in Europe, no human infections have been reported from 
this continent. In Vietnam, since December 2003, 119 confirmed human H5N 1 cases have 
been reported, 59 of them were fatal [5]. 
Human infection with avian influenza H5N 1 virus presents as influenza-like illness with 
symptoms of fever, shortness of breath and cough. Complications include rapid progression to 
acute respiratory distress syndrome (ARDS) and multi-organ dysfunction [62, 80]. Factors 
associated with severity and outcome include age, delayed initiation of treatment, lower 
respiratory tract damage, leukopenia, thrombocytopenia, hypoalbuminemia, and increased 
AST and urea nitrogen levels [62, 75, 79, 144]. In this chapter the clinical features of 16 H5Nl 
infected patients who were admitted to the Hospital for Tropical Diseases (HTD), Paediatric 
Hospital One (PHI) and Two (PH2) in Ho Chi Minh City, and Dong Thap Provincial Hospital 
(DTPH), Cao Lanh District, Dong Thap Province, all in southern Vietnam, between January 
2004 and January 2005 were retrospectively studied. Until 26 January 2005, the number of 
patients enrolled in this study accounted for 43% (16/37 cases) of confirmed cases within 
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Vietnam and 30% (16/54 cases) of total reported cases in the world. 
[http://www.who.intlcsr/disease/avian_influenzaicountry/cases_tabJe_2005_01_26/en/index.ht 
ml] [145]. In addition, this chapter also studied virological factors in these patients associated 
with outcome. 
3.2 Results 
3.2.1 Identification of HSNI-infected cases 
During January 2004 and February 2005, 16 H5Nl-infected patients, divided as groups I and 
II patients (table 3.2), were diagnosed by means of RT-PCR. Diagnosis of influenza A H5NI 
infection was performed in the virology laboratory of OVCRV. Group I patients were 
admitted to studying hospitals in January and February 2004 and were among the first 
confirmed patients with H5Nl infection in Vietnam. The clinical features of all of these 
patients (717 patients) have been reported previously (appendix 1)[62, 77]. Group II patients 
were admitted during December 2004 to February 2005 except one patient, Patient 16, who 
was admitted in February 2004 and was retrospectively confirmed to have H5NI influenza in 
stored specimens (appendix 1) [76]. 
Diagnostic clinical specimens (nose and throat swabs) from group I patients were tested with 
two H5 specific primer sets (H5a: H5-11H5-2 and H5b: H5-5l51H5-1220) and an Nl specific 
primer set (N I-lIN 1-2). The nucleotide sequences and PCR conditions for these primers are 
described in chapter 2 (section 2.2.4.1 b and table 2.4). The use ofthese primers for detection 
of influenza A H5Nl viruses was recommended by WHO at the time of the initial outbreak 
[62] but had not been rigorously validated for detection in clinical specimens ofHSNl viruses 
circulating at that time. 
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After the identification of the above initial 7 patients under outbreak circumstances, there was 
a demand for more sensitive and specific assays. Therefore, I developed a TaqMan rR T -PCR 
assays for detection of influenza A H5N I directly in clinical specimens. The sequences of 
primers and probes as well as PCR conditions for these assays are described in chapter 2 
(section 2.2.4.1 b and table 2.6). The FluA-specific assay has been validated and shown to be 
sensitive (see following sections) and specific for influenza A viruses without cross-reaction 
with influenza B viruses [146]. The sequences of primers and probes for the H5-specific and 
Nl-specific assays were designed based on consensus sequences of few H5Nl strains 
available m GenBank at that time (e.g., NThailandl3(SP-83)/2004[H5Nl], 
ANietnaml1203/2004[H5NlD using Primer Express software as described in chapter 2. The 
sensitivity of the H5 and NI rRT-PCR assays were evaluated by comparing to the FluA-
specific assay and the conventional H5b assay. The latter has been shown to be more sensitive 
than the H5a assay in detection of H5 RNA [62]. Table 3.1 shows that both the H5 and Nl 
rRT-PCR assays are as sensitive as the FluA-specific assay and lO-time more sensitive than 
the H5b assay. These assays were tested with RNAs of H3N2 (AlPanama/2007/99), HINl 
(NNewCaledonia/20/99), and B (B/Singapore/222179) (kindly provided by Dr Takehiko 
Saito, National Institute of Infectious Diseases, Tokyo, Japan) and showed that there was no 
cross-reaction. 
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Table 3.t: Comparison of the sensitivity of FluA-, BS- and Nt-specific rRT-PCRs versus 
the conventional BSb assay. 
Virus RNA Test Dilution (1 O-fold) 10-5 10-6 10-7 
FluA-specific 
+ + -rRT-PCR 
HS- specific 
+ + -H5NI rRT-PCR 
(AlHKl213/97) Nl-specific + + 
-rRT-PCR 
H5b 
conventional + - -
RT-PCR 
Note: A plus indicates positive PCR. and a minus indicates negative PCR. 
Diagnostic clinical specimens from group II patients were initially tested with the FluA-
specific TaqMan rRT-PCR and were subsequently subtyped for influenza H5Nl using the H5 
and Nl subtype-specific TaqMan rRT-PCR assays. Further confirmation for the presence of 
H5N 1 viruses in clinical specimens of these 16 patients was performed either by direct HA 
gene sequencing or virus isolation as described in chapter 2 (sections 2.2.5 and 2.2.8). The 
final diagnostic results are shown in table 3.2. 
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Table 3.2 Final diagnostic results 
------, ..-----
Conventional RT-PCR II Real-time RT-PCR 'I 
Further confirmation 
(primer sequences are shown in (primer and probe sequences are of diagnostic results 
Group Patient table 2.4 in chapter 2) shown in table 2.6 in chapter 2) 
H5a H5b Nt FluA H5 NI Direct HA Virus 
primer set primer set specific specific specific specific gene isolation 
sequencing 
5 
_L + ___ L + ..-JL .. + , NA JL. NA -lL NA + + _.~l. 
6 + + NA NA NA NA + 
7 ~!C- ----ll- . + ""'r- + --f- NA JC NA ·~r NA l[ NA -ll~ + - _ L_ 
" 
---1...- _ L_. 
9 + + + NA NA NA + + 
10 JI-= + ~I .J. _ + ~i-. + -II _ L_ NA ~[ NA -Jr NA -][ NA 
II + + + NA NA NA NA + 
12 JL + 
-=L + jl- + -'11 .JL NA ][ NA J[ NA lr- + -:-![". + 
1 NA NA NA + + + NA + 
2 ll- NA ~r NA _'L NA ~I- + -1r-~ + - .,~ + --r- NA -"r- + _ J l. __ L _ . _11_ .'l. _ 
3 NA NA NA + + + NA + 
4 ,\ NA ]~ NA ! NA II + ---~[- + 'I + -1'- NA ']1 - + ,. ----.-.I L __ _.J _ 
- jl- it _ 
II 8 NA NA NA + + + NA + 
13 ~I NA .- r- NA lC NA J~ ..J! .. _ __ J I :-If NA ~-.-.. .J~ + + + I + 
14 NA NA NA + + + NA 
15 ll-I .. NA _J[ NA ][ NA ~--:C + ~~C + __ .L + -Jl NA 
16 NA NA NA + NA + 
Note: The table represents diagnostic results of throat swab samples. NA denotes not available. A plus (+) indicates a positive result 
and a minus (-) a negative result. 
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3.2.2 Demographic information 
The sixteen H5Nl-infected patients ranged in age from 4 to 35 years with a median of 18 
years. Patients 15 and 16 were initially admitted to Dong Thap Provincial Hospital (DTPH) 
when they both were on the second day of illness and were then transferred to PH I. These 
patients came from 10 provinces of sounthern Vietnam (table 3.3 and appendix 2). Eight of the 
sixteen patients were pre-school or attending school children and the rest were young adults 
(table 3.3). 
Table 3.3 Baseline information of patients with confirmed H5Nl infection 
Patient Residential location Age Sex Hospital of Occupation 
in Vietnam admission 
I Dong; Thap 13 Female DTPHIPHI Student 
2 Dong Thap 35 Female HTD Housewife 
3 TayNinh 16 Female HTD Worker 
4 Tien Giang; 18 Female HTD Seller 
5 Ho Chi Minh City 8 Female PH2 Student 
6 Lam Dong 23 Male HTD Framer 
7 Binh Dinh 24 Male HTD Student 
8 Vinh Long 26 Female HTD Housewife 
9 Ho Chi Minh City 13 Male PH2 Student 
10 Soc Trang 16 Female HTD Student 
11 Lam Dong 18 Male HTD Farmer 
12 Lam Dong 20 Male HTD Farmer 
13 Tra Vinh 10 Male HTD Student 
14 Tra Vinh 35 Female HTD Farmer 
15 An Giang 25 Female HTD Housewife 
16 Dong Thap 4 Male DTPHlPHI Pre-school 
boy 
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3.2.3 Epidemiologic information 
The sixteen patients in this study were identified in a period of 5 months in 2 years: January, 
February and December 2004 (9 patients), and January and February 2005 (7 patients). Of the 
16 patients, a history of exposure to poultry or H5N I-confirmed patients was obtained from 14 
patients through questionnaires completed by patients or relatives. As shown in table 3.4, 
Patients 1, and 2 had no direct contact with poultry and the source of exposure in Patient 16 
was less clear. For the 11 of 14 patients with a history of exposure, the median time between 
exposure and onset of illness was 3 days (range: 2 to 4) and the median time between the onset 
of illness and hospitalization was 6 days (range: 2 to 8). 
Patient 2 was the mother of Patient 1. The mother was admitted to HTD 6 days after onset of 
illness and died on the following day. On the day ofthe mother's hospitalization, the daughter 
(Patient 1) also developed symptoms of influenza. Two days later, she was admitted to DTPH 
and transferred to PHI. Detailed data on contact between mother and daughter were not 
available. However, shortly before the onset of illness (2 days) in both patients, chickens had 
died around their home. H5NI influenza viruses were successfully isolated from throat swab 
specimens of both mother and daughter, but sequence analyses showed differences in HA 
between both isolates (see figure 5.1 in chapter 5). 
Patient 16 was a four-year old boy with symptoms fitting the case definition of viral 
encephalitis who was enrolled in a study of viral encephalitis study at PHI (see following 
sections). Influenza H5NI infection in this patient was confirmed by RT-PCR and virus 
isolation in stored specimens about two months after hospitalization. Similar illness was 
reported in his sister. The boy became sick on February 10 2004 and was admitted to DTPH 
on February 12, and transferred to PHI on February 15. He died on February 17. His sister 
became sick on 27 January 2004 and was admitted to DTPH on February I, and died on 
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February 2 2004. Since there was no clinical suspicion of influenza, no diagnostic specimens 
were collected. Before their hospitalization, both patients were cared for by their parents who 
had no other children. The family lived in a one-room house. The sister swam regularly in a 
canal near their home, and that canal was the source of washing and drinking water for the 
family. During the previous weeks many dead chickens, discarded by their owners during 
ongoing poultry outbreaks, had reportedly been floating in the same canal. In addition, 
backyard poultry had been present in and outside the family's house until February 2004, at 
which time all were culled as part of routine measures to contain the nationwide outbreak of 
H5Nl influenza in poultry [76, 147]. 
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Table 3.4 Epidemiologic data of the 16 patients 
'-Patient Admission date Days since onset Days between History of exposure 
No. of illness exposure and 
onset of illness 
1 22 Jan 2005 2 2 Many chicken and ducks died around her home. H5N 1 influenza in 
her mother (Patient 2) was confirmed two days before her 
hospitalization. 
2 20 Jan 2005 6 2 Many chicken and ducks died around her home. 
3 26 Dec 2004 7 3 Direct handling of sick chickens. 
4 5 Jan 2005 6 2 Direct handling of sick chickens. 
5 16 Jan 2004 8 3 Direct handling of a sick duck. 
6 4 Feb 2004 . 7 3 Direct handling of sick ducks and chickens. 
7 6 Feb 2004 6 Unknown No history of e~osure. 
8 18 Jan 2005 4 3 Direct handlin& of sick chickens. 
9 21 Jan 2004 6 2 Frequently attended cockfights, held rooster and chickens. Walked 
through a live-poultry market 50 meters from house on his way to 
school. 
10 26 Jan 2004 5 3 Direct handling of dead or d~ing chickens. 
11 30 Jan 2004 6 4 Direct handling of 50 chickens including dead chickens. 
12 2 Feb 2004 5 3 Direct handling of chickens. 
13 4 Jan 2005 4 Unknown No history of exposure 
14 11 Jan 2005 6 3 Direct handling of sick chickens. 
15 17 Jan 2005 7 3 Direct handling of sick chicken. 
16 12 Feb 2004 2 Unknown His sister died of undiagnosed disease few days before. Many 
chickens and ducks in his house and in a canal nearby from which 
water was used for washing and drinking. 
-
------~ --
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3.2.4 Clinical symptoms at presentation 
The clinical features of 16 HSNI-confirmed patients are summarized in table 3.S. At 
presentation, all patients had fever (median 39.1; range, 37.S to 40.3). Statistical analysis 
revealed that the body temperature of patients who died was not different from those who 
survived (Mann-Witney U test, P=O.IS). Fifteen patients presented with symptoms of 
respiratory infection including cough and rapid respiratory rate (median, 40 breaths per 
minute; range, 24 to 60) and there was not different in respiratory rate between patients who 
died and those who survived (Mann-Whitney U test, P=O.8S). Patient 16 did not have any 
symptoms of respiratory infection at presentation, instead he had symptoms of gastrointestinal 
infection including vomiting and severe diarrhea. No patient had symptoms of conjunctivitis. 
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Table 3.5 Clinical characteristics ofthe 16 patients on admission 
Patient Cough Dyspnea Sputum Diarrhea Myalgia Temper- Blood Respiratory Crackles Wheeze Time Out come 
ature eC) pressure rate (day) to 
(breaths/mi initiation 
nute) of 
treatment 
(since 
onset of 
illness) 
1 + + + + + 38.5 104/64 40 + 
-
2 Died 
2 + + - + - 39.6 110170 40 + + 6 Died 
3 + + + + + 40 110/60 40 + - 7 Died 
4 + + +* + 
-
40 100/60 60 + - 6 Died 
5 + + + + 
-
39.5 110/60 50 + 
-
12 Recovered 
6 + + +* + + 38.7 120/80 28 + - 7 Recovered 
7 + + + + - 39.7 110/80 46 + + 6 Recovered 
8 + + + + 
-
39.7 110/60 60 + 
-
4 Recovered 
9 + + + + - 38.6 90/60 60 + - 6 Died 
11 + + +* + + 37.5 100/60 48 - - 5 Died 
12 + + + + - 38 110/80 26 + - 6 Died 
13 + + +* + - 39 120/60 40 + - 5 Died 
13 + + - + - 40 100160 24 - - 5 Died 
14 + + + + + 38.5 60/40 48 + - 6 Died 
15 + + + 
-
-
40.3 106/60 36 + 
-
7 Recovered 
16 
- - -
+ - 38 80/30" - - - Not 
treated Died 
- -
---------
Note: * denotes the sputum was blood stained. a blood pressure was measured on the fifth day of illness 
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3.2.5 Basic laboratory values at presentation 
Hematology and biochemical tests for the patients were performed on admission; results are 
shown in table 3.6. Almost all patients presented with leucopenia, most marked in the 
lymphocyte subset: the median total leukocyte count on admission was 2,495 per cubic 
millimeter (range: 567 to 7,300, normal range: 4,000 to 11,000). However, no statistical 
difference in the total leukocyte count between fatal and surviving patients (Mann-Whitney U 
test, P=0.74). The median lymphocyte count in 14 patients was 525 per cubic millimeter 
(range: 129 to 1,020, normal range: 1500 to 4000) and was not different between patients who 
died and those who survived (Mann-Whitney U test, P=I). In six of these patients, the value of 
CD4 and CD8 cell counts was available and the median ratio of CD4-positive cells to CD8-
positive cells was 0.68 (range: 0.59 to 1.08, normal range 1.6 to 2.0). The median of AL T 
(alanine aminotransferase) and AST (aspartate aminotransferase) of nine patients was 72.5 
Unit per liter (range: 39 to 1,020, normal range <37) and 105.5 Unit per liter (range: 20 to 
1058, normal range <40), respectively (table 3.6). 
78 
Table 3.6 Laborat t * - - Dr: valUe a_ ----~------
Patient! Leukocyte Lymphocyte Neutrophil Platelet CD4: ALT AST Serum Serum Oxygen Out come 
Variable count (per count (per count (per count CD8 level level creatinine glucose saturation 
mm3) mm3} mm3} (per ratio (U/litcr) (U/liter) (~mol/liter) (mmol/liter) during 
mm3) receipt of 
40% oxygen 
(%) 
1 4800 NA NA 183000 NA NA NA NA NA NA Died 
2 567 129 400 137000 NA 467 534 105 NA 77 Died 
3 2040 587 1047 105000 NA NA NA 106 NA 51 Died 
4 4820 882 3800 98500 NA NA NA NA NA NA Died 
5 1200 300 700 117000 0.71 354 320 34 NA 95 Survived 
6 2100 700 1300 62000 1.08 89 110 121 4.9 90 Survived 
7 2630 550 1980 78400 1.05 42 58 83 NA 83 Survived 
8 2430 427 1885 85300 NA 39 21 89 NA NA Survived 
9 2700 900 1300 81000 NA 254 1058 14 NA 85 Died 
10 3000 500 2500 70000 0.62 47 20 71 19 67 Died 
11 1700 500 1100 69000 0.75 NA NA 89 13.5 81 Died 
12 1900 800 1100 62000 0.59 NA NA 43 11.7 80 Died 
13 2330 386 1760 82400 NA NA NA 81 NA 89 Died 
I 14 2560 490 1900 55300 NA 56 70 85 NA 79 Died 
15 4070 1020 2730 200000 NA 45 101 68 NA NA Survived 
I 16 7300 NA 6060 314000 NA 1020 400 NA NA NA Died 
Median 2495 525 1670 83850 0.68 72.5 105.5 83 NA 81 
- -----
• Normal ranges are as follows: leukocyte count. 4000 to 11000 per cubic milliliter: neutrophil count. 2200 to 8250 per cubic milliliter; lymphocyte count, 
1500 to 4000 per cubic milliliter: CD4:CD8 ratio. 1.6 to 2.0; platelet count. 150000 to 400000 per cubic milliliter: ALT. below 37U per liter; AST. below 40U 
per liter; serum creatinine concentration. 82 to 106 »mol per litter; and serum glucose concentration. 3.9 to 6.4 mmol per liter. NA denotes not available. 
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3.2.6 Virological findings 
3.2.6.1 Validation of quantitative FluA rRT-PCR assay 
The FluA rRT-PCR assay (primer-probe sequences and PCR condition are shown in table 2.6 
and section 2.2.4.3 in chapter 2). However, prior to use, the assay was validated for sensitivity 
and quantitative precision. 
3.2.6. La Analytical sensitivity and linearity 
The analytical sensitivity of the FluA rRT -PCR was detennined using serial 10-fold dilutions 
of quantified ssDNA plasmids (106 copies to 1 copy). The preparation of control plasmids is 
described in chapter 2 (section 2.2.4.3). The assay was shown to be extremely sensitive, 
consistently detecting 10 copies of ssDNA plasmid per reaction (100%; 10110 replicates). The 
assay also could detect 1 copy of ssDNA plasmid per reaction (figure 3.lA). However, the 
detection rate at this level was 60% (6110 replicate tests). The linearity of reactions using 
quantified plasmids had a correlation coefficienct of If = 0.992 (figure 3.1B). 
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Figure 3.1 Analysis of the analytical sensitivity (A) and linearity (B) of the FluA-specific 
assay. The test was carried out in quintuplicate using ssDNA plasmid at concentration 106 
copies to 1 copy (from left to right) per reaction. 
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3.2.6.1.b Range of quantitation and precision 
To determine the reproducibility of the assay, 10-fold dilutions of quantified plasmid (106 - 10 
copies/reaction) were examined in 5 consecutive days (inter-assay variation) with 
quintuplicates of each dilution (intra-assay variation). The results showed that the coefficient 
of variation (CV) of both inter- and intra- assay analyses was less than 1 % and 3%, 
respectively (table 3.7). 
Table 3.7 Inter-assay variation of the quantitative FluA assay 
Threshold cycle (Ct) 
Copies per reaction 
106 105 104 103 102 10 
Mean (± SD) 21.62 24.95 28.32 31.67 35.32 38.60 (0.54) (0.24) (0.23) (0.31) (0.26) (0.97) 
Inter-assay 
Coefficient of 2.5 0.96 0.81 0.98 0.74 2.5 
variation 
Mean (± SD) 20.97 24.43 27.97 30.99 34.5 37.81 (0.17) (0.1) (0.04) (0.15) (0.18) (0.18) 
Intra-assay 
Coefficient of 0.81 0.41 0.14 0.48 0.52 0.48 
variation 
3.2.6.2 Virus load in respiratory specimens 
Of the 16 patients, viral RNA was detected in nasal swabs of 12/16 patients and in throat 
swabs of all 16 patients. The median of viral RNA loads in nasal swabs was 5.4 logto copies 
per ml of VTM (ranged from below the level of detection to 7.4 logto copies per ml) (table 
3.9). The median of viral loads in throat swabs was 6.2 10gJO (ranged from 4.3 log to to 7.8 
10gJO). Throat viral load was higher in patients who died compared to those who survived (7.3 
log10 vs 6.0 logl0) but statistical significance has not been established (Mann-Whitney U test, 
P=0.221) (figure 3.2 and table 3.8). When plotting the viral loads in throat against the time 
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after onset of illness, no clear decline of viral loads in throat was observed (Pearman rho 
correlation R = -308; P = 0.246) and viral RNA was still detectable at high levels up to 8 days 
after the onset of illness (figure 3.3) 
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Figure 3.2 Viral loads in throat of patients with fatal and non-fatal outcome. Median, 
guartiles, range and P value are shown. 
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Figure 3.3 Viral loads in throat in relation to the time of on et illness. Circle indicates 
individual value. 
3.2.6.3 Virus detection in non-respiratory specimens 
Viral RNA was detectable in blood of 9111 patients who died but not in the blood of those 
who survived (0/5). The difference in detection rates in blood between fatal and surviving 
cases was statistically significant (Fisher Exact test, P=0.005). The median of viral loads in 
blood was 4.5 IOglO per ml of serum. H5N 1 virus was successfully isolated from blood of one 
patient. In the same patient (Patient 16) viral RNA was detectable and virus was isolated from 
CSF and a rectal swab (table 3.8). 
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Including the latter patient, viral RNA was detectable in rectal swabs of 517 patients who died 
and the median of virus loads in these swabs was 4.8 10gJO copies per ml ofVTM. Beside from 
patient 16, we were unable to isolate viruses from remaining rectal swabs (table 3.8). Rectals 
swabs from surviving patients were not available. 
Table 3.8 Virological data 
Detectable Virus Viral load Organ Specimen RNA isolation 
Median Fatal Not fatal P value 
Nasal swab 12/16 (76%) 5.5 (und.- 5.8 (und.- 4.7 (und.- 0.214 7.6) 7.6) 5.6) 
Respiratory 13/16 
Throat swab 16/16 6.2 (4.5- 7.3 (4.7- 6.0 (4.3- 0.147 (100%) 7.8) 7.8) 7.0) 
Rectal swab 517 (71%) 117 4.8 (3.6- NA NA NA 5.8 
-
Non- 4.5 (3.2- 4.5 (3.2-
respiratory Blood 9/\6 (56%) 116 (17%) 5.7) 5.7) undo NA 
CSF 111 111 NA NA NA NA 
Note: und indicates under detection limit 
3.2.7 Treatment and outcome 
All 16 patients were treated empirically with broad spectrum antibiotics (ceftriaxone, 
gentamicin, amikacin) on admission. Fifteen patients were treated with the neuraminidase 
inhibitor oseltamivir at a dosage of 2mg/kg/day or 75mg twice daily. The median time since 
onset of illness to antiviral therapy was 6 days (range, 2 to 12 days). However, no statistical 
difference in illnessday at treatment between fatal and surviving patients was observed (Mann-
Whitney U test, P=O.17). Antiviral treatment was initiated immediately up on admission in 14 
out of 15 patients (table 3.9). Treatment for patient 5 was delayed for 4 days since admission 
84 
ChapTer 3 
because this was the first patient with H5Nl disease identified in southern Vietnam and it took 
this period of time from clinical suspicion to a laboratory diagnosis of this new suddenly 
emerging pathogen. Treatment was continued for up to five days in 10 patients, five of whom 
survived. The median time of hospital stay for the five surviving patients was 25 days (range, 
8 to 34 days). 
Patients 5, 10, and 11 received 1 to 2 mg of methylprednisolone per kilogram four times a day 
for one, three and four days, respectively. 
Patients 1, 5, and 7 required continuous positive airway pressure with supplemental oxygen. 
Patients 2,3,9, 10, 11, 12, 13, and 14 required mechanical ventilation within a short time (48 
hours) after hospitalization. 
Despite antiviral treatment and the implementation of intensive supportive health care, 11 
patients died in this series, resulting in a case fatality rate of 69%. The median time to death 
from onset of illness was 10.5 days (range, 5 to 21 days). 
Patient 16 was the only patient who was not treated with neuraminidase inhibitor oseltamivir 
because he had no typical symptoms of H5NI influenza. This patient was identified during 
analysis of samples from patients enrolled in study on viral encephalitis in PHI [76]. On 
presentation in DTPH, the patient had fever, headache and severe diarrhea that resulted in 
clinical diagnosis of gastrointestinal bacterial infection. 
The patient was treated with intravenous (IV) fluids, paracetamole, cefiriaxone, and 
gentamicin. As his clinical condition worsened after 3 days of treatment (increasing of 
diarrhea and drowsiness), he was transferred to PHI. On admission, physical examination 
showed tachypnea (36 breaths per minute), bilateral crackles and wheezes, and a Glasgow 
Coma Score (GCS) of 12. The patient was treated with IV fluids, and antibiotic therapy was 
changed to ceftazidime and amikacin. Approximately 12 hours after admission, he had 
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generalized convulsions and became comatose (GCS 7). A clinical diagnosis of viral 
encephalitis was made and treatment was extended with phenobarbital and mannitol. The 
patient died two days after. 
Table 3. 9 Treatment, duration of hospital stay and outcome 
Oseltamivir 
Days since Duration of Duration of 
treatment start 
Patient onset of treatment hospital stay Outcome 
since onset of 
illness (days) (days) 
illness 
1* 2 2 5 7 Died 
2 6 6 1 1 Died 
3 7 7 5 12 Died 
4 6 6 5 15 Died 
5 8 12 5 27 Recovered 
6 7 7 5 25 Recovered 
7 6 6 5 34 Recovered 
8 4 4 5 10 Recovered 
9 6 6 3 11 Died 
10 5 5 5 8 Died 
11 6 6 3 3 Died 
12 5 5 1 1 Died 
13 4 5 1 1 Died 
14 6 6 5 6 Died 
15 7 7 5 8 Recovered 
16" 2 Not treated 0 3 Died 
Note: * DialWostic specimens were obtained on day 5 of illness. # pialWostic specimens 
were obtained on day 7 of illness. 
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3.3 Discussion 
Since the re-emergence of influenza virus A H5Nl among birds in 2003, the virus has reached 
endemic levels in Vietnam, continues to cause poultry outbreaks, and is associated with 
sporadic human infections [4, 59]. At the time of this writing (February 2011), 119 infections 
have been reported from Vietnam, 59 of which were fatal [5]. 2005 was the year with the 
highest number of confirmed cases (61 cases) followed by 2004 (29 cases) [5]. The total 
number of cases in Vietnam in these two years was 90 accounting for 76% of the total 
reported cases from Vietnam [5]. In this thesis, the clinical data of human H5Nl disease are 
presented from 16 cases. Most human H5N 1 infections were detected in provinces of northern 
Vietnam 
[http://wwwmohgovvnlhomebyt/vn/upload/info/attach/1132044424 781_ KemtheoBaoca09073 
doc, accessed on March 19, 2009], where we have limited access to samples and data. Despite 
that, the clinical features in most of these cases appear to be characteristic of most cases of 
human disease caused by recently emerged H5NI virus. 
For the current series, the prominent clinical features on admission were those of a severe 
influenza syndrome with fever, cough, diarrhea, and shortness of breath. The incubation 
period from exposure to poultry and the onset of illness was two to four days. The most 
striking laboratory findings were thrombocytopenia, increased levels serum transaminases, 
and especially marked lymphopenia with a pronounced inversion of the CD4:CD8 ratio in the 
six patients in whom it could be measured. The patients were all children or young adults (4 -
35 year-old). These clinical features at presentation (of most patients) were similar to those in 
the concurrent outbreaks of human H5N 1 disease in Thailand, Cambodia and other countries 
from which data are available [75, 79, 80, 123, 148]. 
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Patient 16 was the only patient who had a clinical course that significantly differed from the 
rest of the patients in the current series. On presentation, while other patients had a clinical 
syndrome of severe influenza-like illness, this patient had clinical symptoms that led to an 
initial clinical diagnosis of infectious diarrhoea. A similar patient with clinical symptoms of 
fever and severe diarrhea alone on presentation has also been identified in Thailand in 2004 
[93]. However, the most striking clinical feature of this patient was the progression of illness 
from severe diarrhea to convulsions and coma within a few days after hospitalization. 
Although clinically apparent pneumonia developed during a late stage of illness (the last day 
of his life), respiratory disease was not considered as the most relevant clinical problem of this 
patient. Instead, acute viral encephalitis was considered as the most likely diagnosis. Acute 
encephalitis is a rare complication of influenza infection and has particularly been reported in 
Japanese patients. Successful isolation of virus from CSF specimens is extremely rare [149]. 
However, in this patient, H5N 1 virus was isolated from blood and CSF samples suggesting the 
virus may have caused acute encephalitis. This notion was supported by evidence for the 
presence of virus particles in neuron cells of an H5Nl infected patient [94]. Studies in ferrets 
and mice have shown that H5N 1 virus has a capability to cause systemic infection and 
encephalitis [150-152]. However, it remains unclear how H5Nl virus reaches the central 
nervous system: haematogenously through crossing of the blood-brain barrier or continuously 
by spread from peripheral nerve endings [150, 151, 153]. 
The mortality in our case series was similar to the mortality rate of laboratory confirmed cases 
reported to WHO [5] but significantly higher than that of a case-study in 29 patients identified 
in the same period of time in northern Vietnam [144]. However, the reasons for this difference 
are unclear. 
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Despite the relatively late presentation in the course of illness, viruses could be isolated from 
respiratory specimens of most H5N 1 patients. Compared to nasal specimens, viral RNA levels 
in throat swabs were much higher. Highest viral loads in throat occurred in patients who died 
suggesting that the level of viral replication influences outcome. Viral RNA was detectable in 
blood of most patients who died but not in those who survived suggesting that, in addition to 
high virus loads in the respiratory tract, hematogenous spread is also associated with poor 
outcome. Beside the implications for pathogenesis and transmission, these observations 
indicate that throat swabs should be used as diagnostic specimens for H5NI infection. In the 
mean time this has been widely accepted, in part based on our observations [124]. 
Although feacal material potentially contains PCR inhibitors, viral RNA could be detected in 
rectal specimens of the majority of patients (5/7). This confirms earlier reports of viral RNA 
detection in gastrointestinal specimens [76, 96]. However, H5NI virus was only isolated from 
rectal swab of one patient [76]. This may be due to limitations of culture sensitivity or loss of 
replication-competent virus during long-term storage of the swabs. In addition, the limited 
success in isolation from rectal swabs could also be due to the presence of non-specific 
inhibitors in feacal materials that inhibit viral replication during cultivation [154]. 
The detection of viral RNA in serum of more than half of the subjects, including 4 of 5 
patients with H5Nl RNA-positive rectal swabs, suggests that gastrointestinal infection may be 
a result of viral dissemination from the respiratory tract. However, data from this study also 
suggest that initial gastrointestinal infection could have occurred at least in one patient who 
presented with diarrhoea and in whom H5N 1 virus was isolated from the rectum. 
Observational studies have suggested that gastrointestinal infection could occur following oral 
ingestion of infected food or virus particles [80] and this has been confirmed in studies using 
animal models [153]. 
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The timing of hospitalization of these 16 patients coincided with concurrent outbreak waves of 
avian HSNI influenza virus among poultry in Vietnam [64]. Most of the patients in the current 
series had close contact with poultry during the week before the onset of illness. The contact 
in ten patients of the current case series involved holding, killing, or culling sick or dead 
chickens or ducks for consumption within the patient's home environment or small 
homesteads nearby, where a relatively small number of chickens were kept. A case-control 
study of 28 patients who had HSNI influenza infection during 2004 in Vietnam showed that 
preparing sick or dead poultry for consumption is the major risk factor of HSN 1 infection 
[ISS]. As in other studies reported so far [79], none of the patients in this case series were 
involved in mass culling of poultry or worked on large poultry farms suggesting that people 
who have daily closed contact with poultry may have some form of pre-existing immunity to 
the virus. However, this could not be established in a sero-survey among cullers and farmers 
[IS6]. 
All the patients of the current series were children and young adults. Previous demographical 
analyses of 169 cases have revealed that incidence and fatality are highest in people at these 
ages. In contrast, people at the age of 40 or older seem less likely to be infected by HSN 1 
viruses [IS7]. This age distribution contrasts with seasonal influenza that mostly affects 
elderly persons [1S8]. This skewed nature of age distribution of HSNI infection may be 
explained by differences in exposure or cross-protection of pre-existing immunity acquired 
from natural infection or vaccination with heterotypic influenza vaccine in older persons [IS9, 
160]. 
Two possible family clusters were identified in this study. The first cluster consisted of a 
mother and her child. When considering the timing of their illnesses, mother-to-child 
transmission could have occurred. However, genetic analysis of the HA gene sequences of 
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isolated viruses revealed that they are not indentical (> 1 % divergence; 15 nucleotide 
difference in the HA 1) and clustered differently in a phylogenetic tree (figure 5.1 in chapter 5) 
suggesting that mother-to-child transmission was very unlikely. This is because HA gene 
sequence identity is the only convincing evidence for person-to-person transmission [86, 87]. 
Nevertheless, in this family cluster, the possibility of mother-to-child transmission can not be 
fully excluded because genetic changes may have occurred during infection and/or culture 
[chapter 5]. The second cluster consisted of a brother-sister pair, however clinical samples 
from the sister (sister of Patient 16) were not available therefore phylogenetic relationship 
analyses could not be performed. Nevertheless, the interval between their illnesses (9 days) 
makes the possibility of sister-to-brother transmission unlikely. The source of their infection 
remained unclear, but could have occurred from ingestion of water from the canal near their 
home that might have had high virus concentrations due to healthy infected ducks or dead 
chickens. No illness was reported in family members of the other fourteen patients, even 
though they seemed to have had very similar exposure to pOUltry. Similar observations have 
been reported from a surveillance study in Cambodia [82]. These findings suggest that a range 
of other factors (e.g., viral virulence and host genetics) may be involved in efficient bird-to-
human (and human-to-human) transmission. 
Oseltamivir was administered to fifteen of the patients, ten of whom died. This high fatality 
rate may be partially due to the delay of hospitalization resulting in late initiation of antiviral 
therapy which is believed to be a major factor affecting outcome [79]. Although one patient 
survived even when treatment was delayed until day 12, and another patient died despite 
initiation of treatment when maximum clinical benefits could be expected (within two days 
after onset of illness), the effect of the use of and early initiation of oseltamivir in H5Nl 
infection has been suggested, but in uncontrolled observations [79]. 
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Amantadine and rimantadine (adamantanes) were not given to any of these patients because 
molecular and in vitro susceptibility analyses revealed a high rate of resistant viruses [29, 
161]. Indeed, genetic analysis of the M2 gene of H5N 1 virus strains isolated from 13 patients 
in the current series showed that they all had mutations conferring amantadine and 
rimantadine resistance in the M2 gene [chapter 5]. 
In vitro studies have shown that cells infected with H5NI produce a broad range of 
pro inflammatory cytokines and chemokines, including IFNa, IL6, IL8, IL 1 0, IPIO, RANTES, 
and MCP 1 [111, 162], and do this to a greater extent than when infected by seasonal human 
influenza viruses. Previously, we have found that, in accordance with in vitro findings, 
patients with H5N 1 infection have high plasma levels of those cytokines and chemokines, 
which correlate with viral loads in throat and with poor outcome. These observations suggest 
that, besides high levels of viral replication, the ensuing inflammatory response contributes to 
the pathogenesis ofH5NI disease [36]. 
While there is a theoretical benefit of immunomodulatory treatment, the challenge may be to 
balance the beneficial effects of immunomodulation and the potential hazardous effects of 
interfering with the immune response when there is ongoing viral replication. 
Corticosteroids were given in three of our patients, one of whom died. The number of patients 
treated with corticosteroids in this current series was too small to allow the assessment of any 
effect. However, experience from a retrospective case study of 29 patients in northern 
Vietnam showed that methylprednisolone has no effect on outcome [144]. Recently, 
retrospective analysis from clinical data from 67 patients in Vietnam revealed that, in contrast 
to expectations that steroids would be helpful for modulating the intense inflammatory 
responses to the infection and improve outcome [36], the use of corticosteroids was a risk 
factor for fatal outcome [75]. Nevertheless, data in these studies could be biased by non-
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random selection of more severe cases for treatment with steroids. For this reason, we believe 
that controlled clinical studies to assess the role of corticosteroids or other immunomodulatory 
strategies remain important and needed. 
Although the results of diagnostic tests using conventional RT-PCR with the H5b and Nl 
primer pair were reliable, after the first wave of human outbreaks [73, 163] 
[http://nursingcribcom/wp-contentiuploads/image/flu%20virusPNO, accessed on July 27, 
2010], diagnostic testing was switched to rRT-PCR because of concerns about sensitivity, 
time to results and reliability of the assay. Although the infection in 2 of 9 patients diagnosed 
by rRT-PCR was not confirmed by virus isolation or direct sequencing of the HA gene, the 
test results are not doubted because, in addition to the fact that these patients had typical 
radiographic and clinical features of severe H5N 1 disease: 1) real-time diagnostic assays using 
TaqMan probes are general excellent in sensitivity and specificity and do not require post-
amplification analysis limiting the chances of contamination [135, 164], 2) three different 
genes (M, HA and NA) were amplified, 3) the risk of contamination has been minimized by 
physical separation of lab rooms for preparation of reagents, extraction of nucleic acids, and 
amplification and analysis, respectively, combined with a strict unidirectional work flow [77]. 
In conclusion, data from this study show that typical symptoms at presentation of this small 
case series were fever, cough, and shortness of breath. Nevertheless, H5N 1 infected patients 
may have atypical symptoms at presentation and unpredicted manifestation during hospital 
stay. Such atypical symptoms of H5Nl infection could be a limiting factor for establishment 
of early suspicion, diagnostics and treatment as well as timely outbreak control. 
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Chapter 4 
OSELTAMIVIR TREATMENT: VIRAL LOAD AND THE 
EMERGENCE OF RESISTANCE 
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4.1 Introduction 
NA inhibitors are the most important class of drugs for the treatment of influenza. These drugs 
exert their effect through inhibition of the viral NA. Currently available NA inhibitors are 
oseltamivir (Tamiflu; Roche) and zanamivir (Relenza; G1axoSmithKline). They bind to the 
active site of the NA enzyme, and thereby interfere with hydrolysis of host cell receptors 
bound to the HA of newly formed viruses budding out of infected cells and thus prevent the 
release of progeny viruses and a new cycle of infection (figure 4.1) [125, 165]. Zanamivir has 
a poor oral bioavailability, and is therefore administered directly via inhalation, which limits 
its usefulness in systemic illness, in elderly and very young patients «7 years old), in 
comatose patients and in people with asthma or chronic obstructive pulmonary disease 
[http://wwwfdagov/cder/news/relenza/defaulthtm, accessed on 28 August 2009]. In contrast, 
oseltamivir is administrated orally which favors the use of this drug in treatment and 
prophylaxis [166]. 
Standard dosage of oseltamivir for treatment of influenza in adults and adolescents (2:13 years) 
is 75 mg twice daily for 5 days, and weight-adjusted twice daily dosages (-2mg per kg body 
weight) for five days in children 2: 1 year old [http://wwwrocheusacom/products/tamiflu/pipdf, 
accessed on January 9, 2009]. Treatment with oseltamivir reduces the duration and severity of 
acute uncomplicated influenza in otherwise healthy children and adults [167, 168], but clinical 
benefit in uncomplicated disease is optimal when treatment is started within 48 hours of onset 
of illness [169]. 
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Figure 4.1 Mechanism of action of neuraminidase inhibitors. 
Neuraminidase catalyses the cleavage of host cell receptors important for release of progeny 
influenza virions (panel A). The release of progeny virions is blocked by neuraminidase 
inhibitors (Panel B) [figure reproduced from Moscona A [12511. 
Unlike adamantane drugs, resistance to neuraminidase inhibitors has occurred infrequently in 
clinical trials. Estimated resistance rates vary from 4% to 8% in outpatient children [168, 170] 
and 0.4% to 1% in adults [171] after one course of treatment. However, recent treatment 
studies in Japanese children showed oseltamivir-resistance conferring mutati.ons in the NA 
gene in 16.7% (7/43) ofHINI and 18% (9/50) ofH3N2 virus strains isolated from specimens 
obtained after therapy [172, 173]. These high resistance rates possibly reflect primary 
infections associated with high replication rates combined with possible underdosing at that 
time due to different (non-weight-based) dosing schedules in Japan at that time. In late 2007, 
surveillance for antiviral susceptibility of influenza viruses in European countries revealed that 
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approximately 14% of circulating HINI were oseltamivir resistant possessing a His274Tyr 
(H274Y) mutation (table 4.1), the most frequently encountered resistance associated mutation, 
in the neuraminidase gene [174]. Since then, resistant seasonal H1N 1 viruses have been 
detected with rapidly increasing frequency in Europe and other regions in the world [175], 
[http://wwwwhointlcsr/disease/influenza/hln1 _table/enlindexhtm I, accessed on March 25 
2010]. In vitro studies have shown that HINI viruses with the H274Y mutation exhibit more 
than lOOO-fold reduction in susceptibility to oseltamivir [175]. 
Table 4.1: Reported mutations in the neuraminidase conferring reduced susceptibility to 
neuraminidase inhibitors. Table modified from Crusat et al., [176]. 
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Oseltamivir is the recommended treatment of avian H5N I influenza virus infection in humans 
[http://wwwwhointlcsr/disease/avian_influenza/guidelines/ClinicalManagement07pdf, 
accessed on January 9, 2009] and is believed to improve outcome [79]. However, as with 
seasonal and pandemic HINI viruses [177], H274Y oseltamivir resistant variants may emerge 
during treatment. 
While monitoring H5NI viral load during oseltamivir treatment, I identified two patients in 
whom oseltamivir-resistant variants with an H274Y mutation (N2 numbering) in the NA gene 
emerged [77]. H5NI viruses with such a mutation have been shown to have an approximate 
1000 fold increase oflC50 values for oseltamivir [128]. 
This chapter describes the identification of mutant viruses in these patients, treatment and 
disease progress in one patient, and the kinetics of mutant virus replication in the other. I also 
discuss possible causes of resistance emergence and possible treatment options to improve 
outcome. 
4.2 Results 
4.2.1 Patients and clinical samples 
Patients included in our virus load monitoring study were patients with 1) confirmed HSN 1 
infection, 2) who received at least one standard dose (75 mg) of oseltamivir, and 3) from 
whom at least one nose or throat sample in 2 ml of VTM was obtained during treatment. 
Following these criteria, 8 out of 16 HSNI-infected patients (see chapter 3) were selected for 
this study. These 8 patients are Patients 1 to 8 shown in chapter 3. Baseline information and 
available clinical samples from these patients are shown in table 4.2. 
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Table 4.2 Patients and clinical specimens. 
Patient Day of Throat swab (days Outcome 
illness since admission)$ 
1 2 3 and 8 Died on day 8th 
day if illness 
2 6 1 and 2 Died on day 7 of 
illness 
3 7 1,2, and 6 Died on day 19th 
of illness 
4 6 I,3,4,6,and9 Died on day 21 th 
of illness 
5 12 1,2, and 3 Survived 
6 7 I,2,3,5,and7 Survived 
7 6 1, 2, 3, 4, and 6 Survived 
8 4 1,3,5, 10, and 11 Survived 
Note: $ day of admission was denoted as day 1. See table 3.9 in chapter 3 for more 
information. 
4.2.2 Treatment and outcome 
All patients were treated with the recommended dosages of oseltamivir [177], and the drug 
was given orally or through nasogastric tubes in case patients were intubated. Patient I was a 
13 year old girl who presented to Dong Thap provincial hospital (DTPH), Dong Thap 
province, on January 22, 2005 with a one-day history of fever and cough. The day before, her 
mother - Patient 2 - died of influenza A (H5N I) infection, one day after start of oseltamivir 
therapy. Therefore, H5N I infection was immediately suspected at presentation of patient I 
and she was given an initial 75-mg dose of oseltamivir and transferred to PHI in Ho Chi Minh 
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City, where she was given another dose of oseltamivir 6 hours later. Treatment with standard 
dose of oseltamivir twice daily was continued. 
Patients 2-8 presented to our hospitals relatively late in the course of their illness. Patient 2 
was the mother of Patient I. She was admitted to our hospital on day 6 of illness. She was 
treated with a standard dose of oseltamivir and died one day after admission. Patients 3 and 4 
presented to our hospital on day 6 and 7 of illness, respectively. They completed a full course 
of 5 days of oseltamivir, but both died (on day 19 and 21 of illness, respectively). Patients 5-8 
presented at our hospital on day 8, 7, 6 and 4 of illness, respectively. Although oseltamivir 
therapy was initiated relatively late, they all recovered (see chapter 3 for further details). 
4.2.3 Viral RNA load during treatment 
Viral load in throat swab specimens was measured using quantitative FluA rRT-PCR as 
described in chapter 2 (section 2.2.4.3) and validations of this assay for quantitative analyses 
are shown in chapter 3 (section 3.2.6.1). Viral load data shown in this chapter were derived 
from a single run. As shown in table 4.3, the influenza A (H5Nl) viral RNA load in the 
admission throat swab specimen of Patient 4 was the highest among all current samples at 
admission. The mean viral RNA load on admission was 6.9 10glO, ranging from 5.7 to 7.7 
10glO. 
Viral RNAs in throat swab samples of Patients 5, 6, and 7 were undetectable with quantitative 
rRT-PCR analyses after two days of treatment. After 5 days of treatment, viral RNA was still 
detectable in samples of Patients 3 and 4. Strikingly, RNA of H5Nl virus was still detectable 
in samples obtained on the day 2nd and 3rd after completion of oseltamivir treatment from 
Patients 1 and 4, respectively (table 4.3). 
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Table 4.3 Influenza A (HSNl) RNA loads in throat specimens and results of virus culture and direct sequencing 
Pharyngeal influenza A (HSNl) virus load (copies/ml) 
Patient 
Day I Day 2 Day 3 Day 4 Day 5 Day 6 Day 7 Day 8 Day 9 Day 10 Day 11 
1 NA NA NA NA 5.4*$ NA NA 6.7*$ NA NA NA 
2 5 .9*$ 7.6$ NA NA NA NA NA NA NA NA NA 
3 6.0* 6.2 NA NA 4.5 NA NA NA NA NA NA 
4 7.7$ NA 5.1$ 5.9 NA 5.2 NA NA 5.9*$ NA NA 
5 5.7* 5.3 0 NA NA NA NA NA NA NA NA 
6 6.7* 5.7 0 NA 0 NA 0 NA NA NA NA 
7 5.7* 4.6 0 0 NA 0 NA NA NA NA NA 
8 6.1* NA 4.7 NA 3.6 NA NA NA NA 0 0 
Note: Viral load is presented as IOglO copies per ml ofVTM. Quantitative rRT-PeR analyses were performed in batch-wise fashion. 
NA indicates that a sample was not available. 0 indicates negative RT-PCR result. Brown indicates oseltamivir tIeatment. * 
indicates successful isolation of H5N 1 viruses from these specimens. $ indicates direct sequencing was performed. 
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Viral RNA loads shown in table 4.3 were used to plot against the timing of sample collection 
and oseltamivir treatment, and are displayed in figure 4.2. 
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Figure 4.2 Avian influenza A (HSNl) in throat swabs of 8 patients. Blue lines represent 
patients who survived from influenza A (H5Nl) infection. Red lines represent patients who 
died. The dashed-horizontal line denotes the limit of detection of the assay. Figure was 
modified from de long MD, Thanh TT et al., [771. 
Figure 4.3 shows viral loads in throat swabs rapidly declined to undetectable levels after two 
days with oseltamivir therapy in 3 surviving patients (Patients 5, 6, and 7). In the fourth 
surviving patient (Patient 8), viral load remained detectable at low level at day 4 of oseltamivir 
treatment. 
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Viral RNA loads remained detectable at high levels on the last day of oseltamivir treatment in 
three of the four patients who died (Patients I, 3 and 4) (figure 4.2). After completion of 
treatment, increasing viral RNA loads were detected using quantitative realtime RT-PCR in 
respiratory samples from patients I and 4. Patient 2 died during the second day of admission 
concurrently with a more than l.5 log increase of viral RNA loads. 
4.2.4 Virus culture 
Virus culture was performed on all follow-up pharyngeal swabs from the 8 patients using 
MDCK cells as described in chapter 2, in a BSL3 environment. Identification of positive 
cultures was performed using the H5b primers (table 2.4, chapter 2), specific for the HA of 
H5Nl. Viral RNA extraction and RT-PCR reactions were performed as described in chapter 2 
(section 2.2). An example ofH5 specific RT-PCR results is shown in figure 4.3. 
From 28 clinical throat swab samples available from the eight patients (table 4.2), nine 
influenza A H5NI virus isolates were cultured. Six isolates were cultured from admission 
throat swab samples of Patients 2, 3, 5,6, 7, and 8. Three isolates were cultured from throat 
swab samples collected during and 2 days after completion of oseltamivir treatment of Patient 
I, and from the sample collected three days after the completion of oseltamivir treatment of 
Patient 4. 
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100 bp 
Figure 4.3 Identification of cultured HSNI viruses using H5 specific RT-PCR. Lane I is a 
lOObp ladder. Lanes 2, 3, and 4 are amplicons indicative of the presence ofH5NI virus, with 
an expected size of 708 bp, from culture supernatant of follow-up specimens of Patients 1 and 
4. Lanes 5 and 6 are mock extraction control and negative reaction control, respectively. The 
peR band (-I OObp) present in the negative control lane likely represents primer-dimer 
fonnation. 
4.2.5 NA gene sequences of isolated viruses 
Sequencing of the NA gene of the 9 H5NI virus isolates was perfonned at the Department of 
Microbiology, Faculty of Medicine, University of Hong Kong, Hong Kong SAR, China, and 
at the Virology Laboratory of the OUCRU as described in chapter 2. 
DNA sequencing reactions were perfonned using capillary sequencing m an ABl Prism 
3700XL sequencer as described in chapter 2. The sequencing results generated by 6 individual 
sequencing primers were assembled and edited using Lasergene software version 6.0. The 
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sequences were then aligned and compared to reference sequences using BioEdit software 
version 7.0.1 (figure 4.4) . 
.-!..1 ,. , ,. , I ,. , ,. t I ' , " , I ,. " , ., I ,. ,. , , I ' , , ,. I ' , " ,. I ' , , , I ,. , ,. , I , .. t , " I " , , 
A ...:J 800 810 820 830 840 
Pat~ent 6-A TC. GTCG~ATTGG, TGCTCCTA~TT T CTAT~GGAATGCTCCTGTTATCC 
Patient 7-1. TC GTCGU TTGG. TGCTCCTAATTA CTATG. GG.A.ATGCTCCTGTTATCC 
Patient 8-1. TCAGTCGAATTGGATGCTCCTAATTA A.CT TG '.GGAATGCTCCTGTTATCC 
Patient 3-1. TCGGTCGAATTGG~ TGCTCCTAATTA b.CT ' TG", GGAATGCTCCTGTTATCC 
Patient 5-A TC.-.GTCG\ATTGGATGCTCCTAATTA A"CT TGAGGM TGCTCCTGTTATCC 
Patient 2-1. TCGGTCGAATTGGATGCTCCTAATTAT A.CTATGAGG TGCTCCTGTTATCC 
Patient 1-0 TCAGTCG TTGG TGCTCCTAJ>.TTAT CT TGAGGAATGCTCCTGTT TCC 
Patient l-PO TC GTCG TTGGATGCTCCTAATTA CT TG GGAA TGCTCCTGTT TCC 
Patient 4-PO TC GTCG TTGGATGCTCCTAATTA CTATGAGGhATGCTCCTGTT TCC 
A/gs/GD/96/1(HSN1) TCAGTCGAATTGAATGCCCCTAATTA CTAT~GGAGTGCTCCTGTTATCC 
A/HK/156/97 (HSN1) TCAGTTGAGTTG~b.CGCCCCTAATTAT TTACG GGAATGCTCCTGTTATCC 
..!..J ""I""I""I'''''f''''I''''I''''I''·'I''''I''''I'' B ...:J 260 270 280 290 300 
Patient 6-A ,ASHKI F KMEK KVVKSVELD. P -{ f EEC SC P DA E I TCVCRD N1.'J .., R 
patient 7-A ,ASHKI FKMEK KVVKSVE LDAP f EEC SCYPDA EI TCVCRn NWH St RI 
Patient 8-A AS HKI ID-iEK KVVKSVELDAP lri i EEC SC POI. E I T CVCRDNl H SNRI 
Patient 3-A AS HKI F1<MEK KVVKSVBLDAP Ni i EEC SCY£' DA EI TCVCRDNWH SNRI 
Patient 5-A ,AS I P 1<MEK KVVKSVELOAP N"::r: {EEC SC P DA EI TCVCRo m H S RI 
patient 2-1. ,ASHKI FKME K KVVKSVEL OAP N'l: {EEC SCYP DA EI TCVCRDNWH SNRI 
patient 1-0 ,ASHKI F KMEK KVVKSVELDAP I.rx {EEC SC P DA EI TCVCRDNtITH S~RI 
Patient 1-PO S HKI FKMEK K1JVKSVELDAP 1.rx f EEC SCYP DA E I TCVCRnNWH Sf RI 
Patient 4-PO SHKI F KMEK KVVKSVE LDAP f.rx )'EEC SCYP DA EI TCVCRDNWH £IN RI 
A/gs/GD/96/1 (HSN1) S KI F KMEK KVVKSVELNAP I.f:i EEC 3 CYP DA E I TCVCRDlruTH 3 Rl 
A/HK/156/97 (H5N1) SYKI FKIEK RVVKSVEL U p l EE(: SCYP DA EI TCVCRDm H S RI 
Figure 4.4 Sequence alignments of NA gene sequences of 9 HSNl virus isolates. 
AlGS/GD/1/96(H5Nl) and AlHKJ156/97(H5Nl) are reference NA sequences. The use of 
reference sequences allows positioning of the residue of interest. Suffixes denote vimses were 
isolated from samples collected at admission (A), during (0) and post (PO) oseltamivir 
therapy. Residues in black bighlight the nucleotide (panel A) and amino acid (panel B) of 
interest. 
Sequencing results show that the three viruses isolated from Patients 1 and 4 have a C to T 
substitution at position 823, resulting in an amino acid change from histidine (H) to tyrosine 
(y) at position 274 of NA, analogous to the earlier reported mutation conferring oseltamivir 
resistance (figure 4.4). 
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I further analyzed the sequencing chromatogram and fOlmd that the first virus isolate (isolated 
from the sample collected on day 4 of treatment) from Patient 1 had a double peak at position 
283, indicating a subpopulation of wild-type 274H variants among 274Y mutants (figure 4.5). 
However, subpopulations of wild-type variants were not observed in the raw sequencing traces 
of the second virus isolate from this patient (isolated from the sample collected 3 days later). 
Similarly, only mutant alleles were detected when analyzing the sequencing chromatogram of 
the virus isolated from Patient 4. All 6 viruses isolated from admission throat swab samples of 
the remaining patients had the wild-type 274H residue, without the presence of mutant 274Y 
subpopulation, indicating oseltamivir susceptibility. 
Figure 4.5 Sequencing traces of the NA gene ofH5Nl virus isolated from Patient 1 
on the fourth day of treatment. The arrow indicates the predominant T peak, with a 
smaller C peak at nucleotide position 823. Histidine (H) and tyrosine (Y) are encoded 
by AAC and TAe, respectively. A C~T mutation at this position results in the 
substitution oftvrosine 0) for histidine (H) at amino acid 274. 
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4.2.6 Direct sequencing 
To exclude the possibility of resistant variants emerging or disappearing during virus isolation, 
I performed direct sequencing in clinical samples collected at admission, during and after 
oseltamivir treatment from Patients 1, 2 and 4. Primers for RT-PCR amplification of a portion 
of the NA gene that covers the nucleotide of interest (chapter 2, table 2.3) were designed using 
Primer Express software version 2.0 and PCR reactions were performed as described In 
chapter 2 (section 2.2.4.1 b). The results of RT -PCR amplification are shown in figure 4.6. 
1 2 3 4 5 6 7 8 9 10 
500 bp ---.c::.::::: 
100 bp 
Figure 4.6 RT-PCR products from amplification of a 203bp fragment of tbe NA gene 
that covers the H274Y mutation. Lane 1 is a 100bp ladder. Lanes 2 to 8 are amplification of 
7 clinical samples obtained from Patients 1 (2 samples), 2 (2 samples) and 4 (3 samples). 
Lanes 9 and 10 are mock extraction control and negative reaction control. 
Sequencing reactions were performed using capillary sequencing in the CEQ800 sequencer as 
described in chapter 2. Chromatograms were checked for the presence of subpopulations. 
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Figure 4.7 Sequencing traces of the NA gene of H5Nl virus in clinical specimen obtained 
on the fourth day of oseltamivir therapy from Patient 1. Arrows indicate a mixture of wild-
!Jpe and mutant variants in the forward (Panel A) and reverse (Panel B) sequence). Histidine 
(H) and Tyrosine (Y) are encoded by GAG and ATG (from left to right) in the reverse 
sequence. respectively. 
Sequencing analyses of diagnostic samples of Patients 2 and 4, and a sample taken after 1 day 
of oseltamivir treatment of Patient 2, and a sample taken after 3 days of oseltamivir treatment 
of Patient 4 revealed wild-type 274H viruses only. Analysis of the chromatogram of the 
forward strand from the first sample of Patient 1 revealed a double peak of equal height 
corresponding to a T and a C at nucleotide position 823 (figure 4.7 A). In the reverse sequence 
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showed the peak. corresponding to a C at position 823 (wild-type) was lower than the T peak 
(figure 4.7B). Similar results were obtained when analyzing the raw sequences of the last 
samples obtained from Patient 1 and Patient 4. 
4.2.7 Viral subpopulations and replication kinetics of mutant viruses in vivo 
To gain more insight in viral subpopulations and replication kinetics of mutant viruses. I 
performed quantitative pyrosequencing analysis for clinical specimens. PCR and sequencing 
primers are shown in tables 2.3 and 2.9. respectively. and pyrosequencing assays using these 
primers are described in chapter 2 (section 2.2.6.2). Prior to use. the assay had been validated 
in triplicate analyses using mixed mutant - wildtype pJasmids at different concentrations (10 to 
106 copies/f.ll) and different ratios (0. 5. 10. 20. 40. 60. 80. 90. 95 and 100%). Wildtype and 
mutant plasmid controls were generated by cloning of PCR products from amplification of 
wildtype and mutant viruses using primers NAI-609F/81lR (table 2.3 in chapter 2) were 
cloned into qCR2.1 plasmids as described in chapter 2 (section 2.2.7). Based on the validation 
result shown in figure 4.8. quantitative pyrosequencing data with mutant variants less than 
10% were considered to be unreliable. Quantitative data generated by pyrosequencing were 
further verified using cloning of peR products (of the NAI-609F/811R primer set) followed 
by SNP pyrosequencing. as described in chapter 2 (section 2.2.6). Examples of 
pyrosequencing analysis are shown in figure 4.9. and data of viral quasispecies generated by 
pyrosequencing and cloning followed by sequencing are shown in table 4.4. 
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Figure 4.8 Pyrosequencing results of plasmid spiking experiments. E ighteen replicates 
were performed for each spiking ratio. Median, quartiles and range are shown. Spiking ratios 
and pyrosequencing are well correlated (Spearson, P < 0.001) . 
Table 4.4 274Y mutant variants in clinical specimens of Patient 1, 2, and 4 
Patient Sample (date 274Y mutant 274Y mutant (%) 
of collection (%) in in cloning 
since pyrosequencing followed by 
admission) * (STDV) sequencing 
(analyzed clones) 
1 8 69.5(± 12.6) 71.4 (10114) 
2 1 < 10 ND 
2 < 10 0(01156) 
4 1 < 10 ND 
4 < 10 0(01120) 
6 83.4 (±2.3) 80 (4/5) 
9 89.6 (±4.5) NO 
Note: (*) The displayed value is the mean of3 independent analyses. ND indicates verification 
was not performed. 
110 
Chap/er " 
A 
140 .""" ... ".".".".".,,""." .................... . 
130 .... " ... " .................. " ........ " ............ "" .... " ...... " .... " . 
120 
110 .......... .. 
ir:78.4% 
C:21.6% 
E S GAT ATe G A C 
B 
5 
~:80.0% 
c :20.0 
150 ..... " ................... " ....... "" ........................... " .. "." ............. _ ....... " .. 
140 ..................... " ..... . 
130 ........... " ...... " ......... " ... 
E S GAT ATe G A C 
5 
c 
150 ..... 
140 .... " ... " .. " ..... " ................. " .... "." ......................... " ............... ". 
130 . 
120 ."."" .. "" .. "." ..... ". "" ........... " ....................... . 
110 .................... " .... .. 
ES G AT AT eGA C 
5 
Figure 4.9 Representative pyrograms estimating mutant virus in clinical specimens. 
Panel A. B. and C are the last sample of Patient I. five-day oseltamivir treated and the last 
sample of Patient 4. respectively. Yellow indicates the C~T mutation. Blue highlights 
estimated results. Horizontal axis indicates the order of nucleotide dispensation. 
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Pyrosequencing analyses showed that 274Y mutant variants predominate (69.5%) in the last 
sample obtained from Patient 1. This result corresponds with the result obtained when 
analyzing the sample using the cloning - sequencing method (table 4.4). These analyses were 
not performed on the first sample ofthis patient, because of insufficient sample volume. 
The sample obtained on the fifth day of oseltamivir therapy from Patient 4 showed 
approximately 80% of mutant and 20% wild-type variants in both pyrosequencing and 
cloning-sequencing analyses. Without ongoing oseltamivir pressure, a similar proportion of 
mutant variant was observed in the last specimen of this patient (table 4.4). 
Virological data from Patient 4 suggest that this patient was infected by a 274H wild-type 
virus, and 274Y resistant variants emerged and were selected out during treatment. 
Quantitative estimations of wild-type and resistant viral proportions were made and plotted 
against the timing of sample collection and oseltamivir therapy (figure 4.10). This figure 
shows that oseltamivir susceptible viruses predominated during the first three days of 
treatment (table 4.4). Two days later, resistant viruses had become predominant while wild-
type variants still existed as a minor subpopulation. From the proportions of wild-type and 
mutant populations (table 4.4) and total pharyngeal viral RNA loads (table 4.3), estimations of 
absolute wild-type and mutant RNA copies were made by multiplying these values and plotted 
against admission days and treatment (figure 4.11). This figure shows that wild type virus 
continues to decline throughout the course of treatment, albeit not to undetectable levels, while 
resistant virus rapidly emerges and increases to high titers between days 3 and 5 of treatment. 
After stopping treatment wild-type virus starts to rise again while resistant viruses continue to 
increase, both indicating ongoing viral replication. Overall, these observations suggest 
suboptimal suppression of wild-type virus during oseltamivir treatment in this patient that 
allowed virus containing the resistance-conferring mutation to emerge and selectively outgrow 
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wild-type viruses. The emergence of the resistance mutation likely happened between days 3 
and 5 of treatment. 
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Figure 4.10 Proportion of 274H wild-type and 274Y mutant variants in Patient 4. 
Note: treatment was given from day 1 to day 6. 
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Figure 4.11 Viral RNA loads of 274H wild-type and 274Y mutant variants in Patient 4. 
Data for generating this figure were obtained from multiplying the virus loads shown in table 
4.3 with estimated virus subpopulation shown in table 4.4. Note: treatment was given from 
day 1 to day 6_ 
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4.3 Discussion 
In this study, I describe the emergence of oseltamivir resistant variants containing a H274Y 
change in the viral neuraminidase during oseltamivir therapy in two patients. Before these two 
cases, H274Y oseltamivir-resistant virus had been reported in another Vietnamese patient who 
developed symptoms of H5NI infection while receiving oseltamivir at a prophylactic dose of 
75mg once daily. After three days of prophylaxis, H5NI infection was diagnosed and the 
oseltamivir dose was increased to therapeutic dosage. Further analyses of the specimen 
revealed a minor subpopulation of resistant viruses. This patient survived but the role of 
antiviral treatment in this patient's outcome remains unclear [128]. In contrast, the two 
patients described in the current study developed antiviral resistance during treatment with 
therapeutic doses and both succumbed to the infection after 2 and 9 days after completion of 
therapy. 
Patient 1 was treated with oseltamivir at doses that were relatively high for her weight, 
particularly during the first day of treatment when the interval time to the second dose was 
shorter than recommended (6 hours). Notably, unlike most H5NI-infected patients, treatment 
in this patient was initiated within 2 days after onset of symptoms when maximum clinical 
benefits of oseltamivir therapy could be expected. Indeed, the clinical conditions of this 
patient remained stable during the first three days of treatment with localized lung damage and 
without the need for supplemental oxygen (appendix 3). However, on the fourth day of 
treatment, her condition suddenly worsened and she progressively became dependent on 
supplemental oxygen (appendix 3). A chest radiograph obtained on this day showed 
widespread progression of pneumonia in the right lung and at that time there was laboratory 
evidence of hepatic involvement (appendix 3). At the time of her death, viral load in her throat 
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had increased. These findings suggest that the emergence of drug resistance significantly 
contributed to therapy failure, followed by progression of disease and death of this patient. 
In the second patient (Patient 4), as in most of H5Nl-infected patients, oseltamivir treatment 
was initiated relatively late in the course of illness when pneumonia had already progressed. 
Nevertheless, virological analyses revealed the patient responded well to treatment initially 
during the first two days of therapy, and viral load in her throat was, although still detectable, 
declining sharply. While only wild-type virus was detectable on the third day of treatment, 
H274Y resistant variants predominated two days later when the viral load had increased again. 
The emergence of resistant virus and fatal course after initial virological response to treatment 
also suggests a causative role of resistance in the outcome of this patient. 
The progression of disease and increase in viral load after stopping treatment in both patients 
suggest that the H274Y change does not confer major reductions in viral fitness. Indeed, 
reverse genetic studies have shown that oseltamivir-resistant 274Y mutant H5Nl viruses 
replicate as efficiently as wild-type 274H viruses in cell cultures and retain their high 
virulence in mice [178] in contrast to resistant 274Y seasonal influenza variants [179]. 
The emergence of resistant influenza A (H5N 1) variants during oseltam ivir treatment was 
unexpected, but may have been predictable in view of observations in human influenza HINI 
and H3N2 viruses. Although the resistance rate in adults is around 0.4 to 1% [171], resistance 
rates of up to 18% have been reported in Japanese children who received oseltamivir treatment 
[172]. The difference in resistant rates between adults and children may be due to the lack of 
pre-existing immunity that allows relatively uninhibited viral replication which provides a 
greater opportunity for resistant virus to emerge. In addition, suboptimal drug levels may have 
been an additional reason for high resistance rates in Japanese children since at that time a 
non-weight-based dosing regimen potentially led to underdosing of young children. Because 
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no pre-existing immunity against H5N 1 influenza virus exist in the human population, all 
human cases can be regarded as primary infections. Our previous studies have indeed shown 
that H5NI-infected patients experience prolonged viral shedding and have higher viral loads 
in the throat as compared to those with human influenza HINI or H3N2 [36]. Furthermore, 
studies in animals show more efficient replication of the recent H5Nl influenza viruses when 
compared to H5N I virus strains which caused the Hong Kong outbreak in 1997, and higher 
doses and more prolonged treatment with oseltamivir for protection [180]. The standard dose 
of oseltamivir is based on clinical studies in uncomplicated seasonal influenza and it remains 
unclear at present whether higher doses are needed for treatment of H5N 1 influenza and other 
forms of severe influenza. A multinational randomized controlled clinical study evaluating the 
efficacy of standard dose versus double dose oseltamivir in hospitalized severe influenza, 
including H5Nl, is currently ongoing in Vietnam, Thailand and Indonesia [181]. In 
conclusion, human H5N 1 infections are characterized by high rates of viral replication while 
some doubts remain concerning the adequacy of drug levels: this combination provides fertile 
grounds for resistance development and our observations of resistance development in 2 of 7 
patients followed throughout the course of treatment should thus perhaps not be surprising. 
Indeed, the presence of subpopulations of wild-type variants in specimens obtained during and 
after oseltamivir treatment in the two patients in whom drug resistant viruses emerged, 
together with the evidence of their active replication, suggests that treatment with a standard 
dose of oseltamivir incompletely suppressed viral replication. Besides allowing the infection 
to proceed, such incomplete suppression provides opportunities for the selection of drug 
resistant variants, particularly when resistance only requires a single amino acid change in the 
second highest variable protein. 
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The presence of oseltamivir-resistant 274Y mutant viruses in clinical specimens was initially 
confirmed by Sanger sequencing. However, because Sanger sequencing does not allow 
quantitative analysis, an assay based on pyrosequencing was used to further estimate the 
presence of mutant variants in clinical specimens. Validation data using plasmids revealed that 
this pyrosequencing assay could reliably detect mutant variants when present at 10% or 
higher. This detection limit is consistent with previously published assays for H274Y 
detection [252] and can be explained by the high background noise in pyrosequencing that 
requires sufficient amount of sequencing template to produce light signal exceeding this 
background noise, thereby allowing reliable detection [140]. Virus mixtures can also be 
analyzed using the recently developed 454 pyrosequencing, which produces more accurate 
quantitative data [182]. However, 454 pyrosequencing was not available at the time. 
Structural studies have classified neuraminidase of influenza A viruses into two groups: 1 and 
2 [183]. The neuraminidase ofNl, N4, N5, and N8 influenza viruses belongs to group 1, and 
the neuraminidases of other subtypes belong to group 2 [183]. Group 1 neuraminidases 
contain a bulky and conserved tyrosine at position 252 that is close to the binding site. Tyr2S2 
interacts with His274 to create a binding pocket for oseltamivir. A substitution of tyrosine for 
histidine at position 274 prevents this confonnation leading to failure of oseltamivir to bind 
and thus oseltamivir resistance [184]. In contrast, the histidine at position 274 in the 
neuraminidase of group 2 viruses is not involved in creation of the binding pocket, therefore a 
mutation at this position would not cause drug resistance [184]. Zanamivir binds to the active 
site of neuraminidase without the need for the creation of binding pocket and is therefore not 
influenced by the presence of tyrosine at position 274 providing an option for treating patients 
with H274Y mutant variants [125]. 
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Because phannacokinetic analyses were not performed, we do not know whether the 
emergence of drug resistance is a consequence of suboptimal druglevels (eg. due to altered 
pharmacokinetics in severely ill patients or suboptimal nasogastric drug administration during 
intubation) resulting in inadequate suppression of viral replication or not. As most of patients 
infected with H5N 1 virus, during hospitalization one of the two patients in whom resistant 
virus emerged had diarrhea which may lead to suboptimal biological availability of drug. 
Nonetheless, adequate absorption of the drug has been shown in two H5Nl-infected patients 
even when administering the drug through a nasogastric tube and even in the presence of 
diarrhea [185]. 
Seven out of the eight patients in the current series were treated with oseltamivir relatively late 
in the course of illness when, in uncomplicated human influenza virus infections, the efficacy 
of treatment is suboptimal. However, clinical benefit of antiviral treatment is still expected 
when viral replication is ongoing. In this study, such benefit may be suggested by the rapid 
viral clearance in the four patients who recovered. However, based on this limited number of 
cases we cannot draw any conclusion on the efficacy of oseltamivir treatment for H5Nl 
influenza, but studies with larger numbers do suggest this effect [79]. Nevertheless, to avoid 
resistant mutant develop during treatment and thereby improve outcome, strategies such as 
using higher doses and prolonged regimens of oseltamivir or combination therapy should be 
considered. The potential antiviral efficacy and clinical efficacy of treatment with higher dose 
and longer treatment time are currently under evaluation in a larger randomized controlled 
trial in patients with severe influenza [181]. However, preliminary results showed that higher 
dose and longer treatment have similar antiviral and clinical efficacy compared to standard 
dose regiment (Prof. Menno de Jong, personal communication). Protocols to study 
combination treatment with zanamivir, particularly the intravenous form, are under 
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development [181]. Combination treatment with oseltamivir and amantadine has shown 
improved survival rates in mice infected with amantadine susceptible H5N1 viruses [186], but 
whether such combination benefits humans deserves further study. Clinical studies to assess 
combination treatment with other existing antiviral drugs, particularly ribavirin which has 
been shown to have synergistic effect in combination with oseltamivir and amantadine in vitro 
[187], should also be considered. Such combination regimens are currently under investigation 
in immunocompromised patients with influenza (Prof. Menno de Jong, personal 
communication). 
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Chapter 5 
GENETIC ANALYSIS OF INFLUENZA A (H5Nl) VIRUSES 
ISOLATED FROM HUMANS IN SOUTHERN VIETNAM IN 
2004-05 
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5.1 Introduction 
Avian influenza A (H5N I) viruses caused poultry outbreak and human infections for the first 
time in 1997 in Hong Kong. Genetic analyses revealed that the virus responsible for the 
outbreak possessed the HA gene most likely derived from A/Goose/Guangdongl1/96(H5NI) 
and other internal genes derived from AlQuaiVHongKonglG 1/97(H9N2» and 
AlTeaVHongKonglW312/97(H6NI) [1,48,51]. Although the H5Nl virus responsible for the 
Hong Kong outbreak has been eliminated as a result of strict quarantine and infection control 
measures, its putative precursors remained in nature and have reassorted with other avian 
viruses, generating multiple new genotypes [45,46,51]. 
In 2003, genotype Z emerged as the predominant genotype and spread to many countries in 
South East Asia including Vietnam, Thailand, Cambodia, Laos, Indonesia, and Malaysia [9]. 
Phylogenetic analyses for the HA gene revealed viruses belonging to genotype Z found in 
birds in Vietnam, Thailand, Cambodia, and Malaysia formed a sublineage of closely related 
viruses termed clade 1. Those that caused epidemics among birds in Indonesia belonged to 
another sub lineage termed clade 2.1. From 2005 onward, genotype Z H5Nl viruses have 
spread to Middle East, Africa and Europe. The viruses found in these regions belong to a 
single sublineage: clade 2.2 [45,46]. Clade 2.3 viruses are more divergent with at least 4 sub-
clades (2.3.1 to 2.3.4) have been identified but mostly from China [46]. 
Sequence analyses for host-specific residues have shown that H5Nl viruses isolated from 
humans have genetic signatures of avian rather than human influenza viruses [29, 188]. 
However, some clade 1 H5Nl virus strains have mutations in the HA gene associated with 
enhanced human-type receptor affinity [189]. Recently. it has been shown that the selection of 
these mutations occurs naturally in humans [190]. 
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This chapter aims to understand the molecular characteristics of H5N 1 viruses isolated from 
13 patients from southern Vietnam in 2004-05, to analyse drug resistance and virulence 
markers, and to investigate HA residues that are potentially involved in human receptor 
recognition. 
5.2 Results 
5.2.1 Virus isolates and sequencing 
As shown in table 5.1,17 virus strains were isolated from 13/16 enrolled patients. Sequencing 
for these strains was performed on the ABI 3170XL sequencer as described in chapter 2. 
Sequences of all eight gene segments were obtained from 10 strains. Gene sequences of most 
strains were deposited to Gen Bank (see accession numbers in appendix 11) except those of 
the A/VNMlCL 1 07-13/2005(H5N 1), A/VNMlCL2009-28/2005(H5N 1), 
A/VNMIPEV 16C/2004(H5N 1), A/VNMlPEV 16B/2004(H5N 1) and 
AlVNMlPEV16R12004(H5NI) (appendix 12). 
122 
11l1Jle :).1 VIrus Isolates ana gene sequences 
Sample of isolation Gene sequence available (bp in length) Genotype 
Patient 
No Virus isolate (day since initiation of 
PB2 PBI PA HA 
oseltamivir therapy) NP NA M NS 
1 ANNMlCL2009/05* Throat swab (3) 
1 
2236 1947 2166 1527 1459 1280 826 840 Z 
2 AlVNMlCL2009-28/05 Throat swab (6) 1970 
- -
1620 1459 1366 826 840 NO 
3 ANNMlCL 119/05* Throat swab (0) 2 2236 1947 2166 1527 1459 1280 826 840 Z 
4 ANNMlCLl 00/05* Throat swab (0) 3 2236 1947 2166 1527 1459 1280 826 840 Z 
5 ANNM/CLI07-13/05* Throat swab (8) 4 2270 - - 1659 1459 1366 826 840 
6 AlVNMlCLO 1/04* Throat swab (0) 5 2280 1947 2166 1648 1459 1280 826 840 Z 
7 ANNMlCL26/04* Throat swab (0) 6 2236 1947 2166 1694 1459 1280 826 840 Z 
8 ANNMlCL36/04* Throat swab (0) 7 1270 1947 2166 1527 1459 1280 826 840 Z 
9 AlVNM/CLlI5/2005* Throat swab (0) 8 2236 1947 2166 1527 1459 1280 826 840 Z 
10 ANNM/CL02/04* Throat swab (0) 9 854 
- -
1578 
-
1280 826 840 NO 
II ANNMlCL 17/04* Throat swab (0) II 
-
1947 2166 1526 1459 1280 826 840 NO 
12 AlVNMlCL20/04* Throat swab (0) 12 2236 - 2166 1694 - 1280 826 840 NO 
13 ANNMlCL 1 OS/2005* Throat swab (0) 13 2236 1947 2166 1527 1459 1280 826 840 Z 
14 ANNMlPEVI6T/04* Throat swab (0) 2236 1947 2166 1527 1459 1280 826 840 Z 
15 ANNMlPEV16C/04 CSF (0) 2236 1947 2166 1527 - 1280 826 840 NO 
16 
16 ANNMlPEVI6S/04 Serum (0) 2236 1947 2166 1527 - 1280 826 840 NO 
17 ANNMlPEVI6R104 Rectum swab (0) 2236 1947 2166 1527 1459 1280 826 840 Z 
-- - "----- .- - --
Note: A dash (-) indicates that gene sequence was not available. Asterisk indicates selected viruses for genotype and genetic clade 
determination. ND = not determined. 
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5.2.2 Phylogenetic analysis 
To determine the viral genotype and genetic clade, I performed phylogenetic analysis for the 
available sequence length of all eight segments. Only one virus isolate from each individual 
patient was selected for analysis (13 virus isolates from 13 patients) (table 5.1). Reference 
sequences for virus genotypes and clades were obtained from Dr Gavin J.D Smith, State Key 
Laboratory of Emerging Infectious Diseases, Department of Microbiology, The University of 
Hong Kong, Hong Kong SAR, China. Prior to construction of maximum-likelihood trees in 
PAUP* version 4.0 [138], nucleotide sequences were aligned using BioEdit version 7.0.1 (Isis, 
Parmaceutical, Inc, USA), and appropriate DNA substitution models were determined using 
MrModeltest version 2.2 [139] as described in chapter 2. Trees were rooted to distantly related 
sequences of other avian influenza VIruses e.g., AffernlHAJ61 (H5N3), 
AlParrotlUlster173(H7N3), and A/EquinelPrague/I/56(H7N7) [52]. Results of phylogenetic 
analysis indicated that all virus isolates in this study had HA and NA genes derived from the 
Goose/Guangdong/1I96-like (Gs/GD/1/96-like) lineage (figures. 5.1 and 5.2). Analysis of the 
remaining 6 gene segments shows that 9 of the 13 isolates belonged to genotype Z (figure 5.3 
and appendices 6-10). The remaining 4 isolates could not be determined to their genotype, 
because sufficient gene sequence data were not available (table 5.1). 
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rooted to AlEguinelPrague/1/56(H7N7). 
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Table 5.2 Virus genotype and clade 
Gene 
Virus strain HA PB2 PBl PA (Clade) NP NA 
A,B,C, 
A,B,G, B, C, D, E, G,V,Y, ANNMlCL 1/04 Y,V,W, G, Y, W, Z+, and Z D, E,Y, Z+, and Z Z+, and Z 
Z+, and Z 
ANNMlCL2/04 ND ND ND 
A, B, G, 
AlVNMlCL 17/04 ND Y,V,W, 
Z+, arid Z 
AIVNMICL20/04 ND 
AlVNM/CL26/04 
AlVNMlCL36/04 B, C, D, E, A,G,V, 1 
AlVNMlCL 1 00/05 G, Y, W, Y, and Z 
AIVNMICL 1 05/05 Z+, and Z G, V, Y, 
A, B, C, A,B,G, Z+, and Z AIVNMICL 115/05 Y,V,W, 
AlVNMlCL 119/05 
D, E,Y, Z+, and Z Z+, and Z 
AIVNMICL2009/0 
5* 
AlVNMlPEV16T/0 
4* 
AlVNMlCLI07- ND ND 13/05 
Note: Asterisk (*) indicates representative strain from Patients 15 and 16. ND = not determined. 
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M NS 
Z 
ND 
ND 
ND 
A,B,C, 
G,V, D,E, V, 
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5.2.3 Molecular characterization 
5.2.3.1 HA and the cleavage site 
In order to present a more complete picture of the HA gene properties, the deduced amino acid 
sequences of the HA gene of all index virus isolates were aligned and compared. As shown in 
table 5.3, all virus isolates had multiple basic amino acids (QRERRRKKRIG) at the cleavage 
site, which is a molecular trait of highly pathogenic avian influenza virus that permits viral 
replication in organs beyond the respiratory and gastrointestinal tracts of birds [17, 18]. While 
the ANNMlCLl05/05 virus had a K (Lys) at position -8 of the cleavage site, the rest of 
viruses had an R (Arg) at this position. The viruses had at least seven potential glycosylation 
sites (Asn-xxx-Ser/Thr/Cys) in HAl which may be associated with virulence [191] (at 
positions 10-12, 11-13, 22-24, 154-156, 165-167, 193-195, and 286-288). 
The receptor binding site residues at amino acid 222 and 224 of the HAl were Gin and Gly, 
respectively, indicating 'avian-type' A a2,3 Gal receptor specificity. None of the viruses had 
the Asnl82Lys or Gln192Arg mutations, which are associated with increased 'human-type' 
SA-a2,6 Gal receptor specificity [189]. 
The amino acid sequences of HAl were compared to the prototype vaccine strain 
[http://wwwwhointlcsr/disease/avian _ influenzalguidelines/2strains2006/enl, accessed on April 
13, 2010], ANN/1194/04 (H5NI) strain, isolated from a Vietnamese patient in 2004 [162]. 
The ANN/1194/04 (H5NI) has a single amino acid (Met175Leu) that is different from the 
HAl sequence of current avian isolates and the isolates presented here (table 5.3). 
Glycan-array analyses have shown that the VN/1194/04 is unable to bind to 'human-type' SA-
a2,6 Gal receptors [189]. Therefore, comparing HAl sequences of our human isolates to that 
of this strain may reveal mutations potentially associated with increased binding to SA-a2,6 
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Gal. As shown in table 5.3, all viruses had at least one mutation, in addition to Metl75Leu that 
differed from AlVNMl1194/04. The virus AIVNMICLl05/05 had an Ala134Val (A134V) 
mutation while other three vlruses AIVNMICL17/04, AlVNMlCL20/04, and 
ANNMlCLOI/04 each had a single mutation at positions 96(Asn~Asp) and 186(Glu~Asp) 
that was not found in any of the HA sequences ofHSNI influenza virus currently available in 
Genbank (as of April 2009). 
Interestingly, the AIVNMICL2009-28/05 had an IlelSIPhe (IlSIF) mutation. This mutation 
was not found in any others, including AlVNMlCL2009/0S, isolated from the same patient 3 
days earlier from a throat swab, suggesting possible adaptive changes to replication in 
humans. 
Viruses were unable to isolate from the admission throat swab sample of Patient 10, but 
because viral RNA load in this sample was sufficiently high (4.92E+07 RNA copies/ml 
clinical specimen, see chapter 4) that allowed me to perform direct HA gene sequencing. The 
obtained sequence of HAl was compared to that of the isolate (ANNMICLI07-13/0S) 
cultured from this patient 7 days later and this revealed 100% identity. Similarly, no amino 
acid differences were found among the HA gene sequences of 4 virus isolates cultured from 
different organs (respiratory tract, gastrointestinal tract, blood and central nervous system) of 
Patient 16 (tables S.1 and S.3). 
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Fauk 5..1 /£if ammo ac/u.l'equeoce.l' 0/ JU)CKcu/lureu Wru.l'es 
Vuus strain Comparison of mature HAl sequence 
Connecting 14 53 83 84 94 96 133 134 140 151 175 186 188 189 203 219 
p.eptide sequences 
ANNMI1194/04 
-
QRERRRKKRlG E R A N D N S A K I L E T K I V 
ANNMlCLO 1104 QRERRRKKRIG E R A N D N S A K I M !! T K I V 
-
AIVNM /CL02l04 
-
QRERRRKKRlG E R A N D N S A E ~I_ M E ! K V V 
ANNM ICL17/04 QRERRRKKRlG E R A N D !! s A K I M E T K I V 
---
AIVNM /CL20104 
-
QRERRRKKRlG E R A N D I! s A K _ 1_ M E T K ~I_ V 
A/VNM ICL26/04 QRERRRKKRIG E R A N D N S A K I M E T K I V 
-
AIVNM /CL36104 
-
QRERRRKKRlG E R A N D N S A K ~I_ M E T K I V 
AlVNM ICL I 00/05 
-
QRERRRKKRIG E K A !! N N S A ~ I M E T R I ! 
AIVNM leL lOS/OS QKERRRKKRlG E R V N V N A Y K ~I_ ! E ! K I V 
ANNMlCLl07-13/05 QRERRRKKRIG E R A N N N A A K I M E A K I V 
AIVNM ICLlIS/OS 
-
QRERRRKKRIG E R A N .N N S A K ~I_ M E A K I V 
AlVNM /CL119/05 QRERRRKKRIG E K A N N N S A ~ I M E T R I V 
-
AIVNM ICL2009/05 QRERRRKKRIG E R A N N N S A K ! M E ~ K I V 
ANNMlCL2009-28/05 QRERRRKKRIG E R A N N N S A K .E M E ~ K I V 
AIVNM IPEV16T/04 QRERRRKKRIG K R A N D N S A K I M E _ T _ K I V 
AlVNM IPEV 16C/04 QRERRRKKRIG K R A N D N S A K I M E T K I V 
AIVNM IPEV 16S/04 QRERRRKKRlG K R A N D N S A K I M E T K I V 
A/VNM IPEV16R104 QRERRRKKRIG K R A N D N S A K I M E T K I V 
Consensus sequence of QRERRRKKR/G g R A N D N S A K I M E T K I V 
HP AI H5N 1 viruses 
Note: ANNMll194/04 is a reference virus strain. Bold and underlined capital letters indicate amino acid difference as compared to 
ANNM/1194/04 and the concurrent avian consensus sequence. 
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5.2.3.2 NA and oseltamivir resistance mutation 
All human H5N 1 viruses in this study had a 20 amino acid deletion (aa 49-68) in the stalk of 
the NA molecule. This deletion is believed to restore the balance between HA affinity and NA 
activity allowing H5N 1 virus to replicate and transmit efficiently in land-based birds [29] and 
is one of the molecular characteristics of genotype Z viruses [45]. As a result of this deletion, 
our viruses lacked one potential glycosylation site at amino acids 50-52 in the NA sequence. 
The remaining three potential glycosy lation sites were at positions 88-90, 146-148 and 237-
237. 
I also analyzed the single amino acid substitution from His to Tyr at position 274, that is 
associated with resistance to oseltamivir, in the catalytic site of the NA enzyme [128]. As 
described in the previous chapter (chapter 4), three of the viruses isolated from two patients 
during and after oseltamivir treatment had Tyr at position 274 indicating oseltamivir resistance 
(see chapter 4). 
5.2.3.3 Mutation associated with adamantane resistance 
M2 protein is the target of the M2 inhibitors; the adamantane drugs [192]. However, influenza 
A viruses can become resistant to this class of drugs by acquiring a single mutation at any of 
the following four sites in the transmembrane region of M2: 26 (Leu26IlelPhe), 27 
(VaI27AlaiGly/Ile/Thr), 30 (AIa30SerlThr/Val) and 31 (Ser31AsnlArg) [161, 193]. The H5Nl 
viruses that caused human infections in 2003-2004 in Vietnam and Thailand were adamantane 
resistant [29, 194]. Previous studies showed that all H5Nl strains isolated from Vietnam, 
Thailand and Cambodia during 2003-05 had dual Leu26I1e - Ser31Asn mutations in the M2 
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protein [161]. In accordance with these findings, I found that all the viruses of the current 
study possessed similar dual M2 mutations associated with adamantane resistance. 
5.2.3.4 Virulence determinants and host-specific markers 
In addition to the multiple basic amino acids in cleavage sequence of HA, other factors may 
contribute to the increased virulence ofHSNl viruses [19S]. Studies in pigs have shown that a 
single amino acid change from Asp to Glu at position 92 in the NS 1 protein is associated with 
virulence [113]. However, GIu92 in the NSI was not found in our viruses. All viruses did have 
a PDZ binding motifGlu-Ser-Glu-Val (ESEV) (table 5.4) in the carboxy terminus of the NSI 
which may correlate with virulence in mammals and disease severity in humans [116]. 
Lys627 (instead of GIu) and Asn701 (instead of Asp) in PB2 protein are important for 
efficient replication and transmission ofHSNl viruses in mammals [32, 103]. The presence of 
these residues in virus strains of this study has also been examined and shown in table S.4. Of 
the twelve strains with available PB2 gene sequences, eight strains had Lys627, three strains 
had Asn701, and one strain neither had Lys627 nor Asn701. Interestingly, all the strains with 
Lys627 had Asp701, while three of the four strains with GIu627 had Asn701, suggesting that 
Lys627 and Asn701 may playa role in human adaptation. Of the eight strains with PB2 
Lys627, five strains were isolated from patients with fatal outcome. However, a statistically 
significant correlation between the presence ofPB2 Lys627 and disease outcome, could not be 
established (Fisher Exact Test, P=1). 
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Table 5.4 Virulence determinants and bost specific markers 
Virulence determinant (Low-+Higb) 
Host specific marker (Avian-+Human) 
Virus 
NSI PB2 PA NP M2 
D92E C-tenninal D701N E627K VIOOA QrrtS400L D37SG/E 128V 
AIVNMICLO 1/04 D ESEV D K V S D V 
AlVNM /CL02/04 0 ESEV N E V S 0 V 
AlVNM/CL 17/04 D ESEV V 0 V 
AlVNM ICL20104 0 ESEV D K V S 0 V 
AlVNM ICL26/04 D ESEV D K V S 0 V 
AlVNM /CL36/04 0 ESEV 0 K V S 0 V 
AIVNM ICL 100/05 D ESEV D E V S 0 V 
AlVNM /CL lOS/OS 0 ESEV D K V S E V 
AlVNMfCL 107- 0 ESEV D K V S 0 V 
13/05 
AIVNM ICLIIS/OS 0 ESEV N E V F D V 
ANNM ICI. 119105 D ESEV N E L S D V 
ANNM/CL2009/05 0 ESEV D K V S D V 
AtyNMlPEVI6T104 D ESEV D K V S D V 
Note: Underlined indicates the representative strain of single patient. A dash (-) indicates 
seguence data were not available. 
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Recent studies have revealed that Lys627 is one ofthe 13 important markers for avian viruses 
to be biologically active in humans [188]. The remaining markers in PB2 (SerI99, Met475, 
Asn567, and Arg702), PA (Leu28, Asn55, and Ser552), NP (AspI6, Pro283, Tyr313, Lys357), 
and M I (Ala 121) proteins reported by Finkelstein et al. [188] were not found in our isolates. I 
have also examined the presence of other human specific markers reported by Shaw et al [196] 
and found that all the viruses had the human specific marker Val28 in the M2 protein. This 
marker was also found in all clade 1 viruses isolated from Thai patients [29]. VNMJCL 1 05 
was the only virus possessing the human specific marker Glu375 in the NP protein (table 5.4). 
Interestingly, two virus strains: VNMlCLI19/05 and VNMICL115/05 each had a single amino 
acid change (VallOOLeu and Ser400Phe, respectively) in the PA protein. The human specific 
markers reported by Shaw et aI., in 2002 at these two sites were Alal00 and Leu400 [196]. 
5.2.4 Mutations in HA gene (HAl) potentially involved in human-type receptor 
recognition 
As shown in table 5.3, some H5NI virus strains have amino acid changes in the HAl relative 
to the consensus sequence of avian influenza A H5Nl virus and the VNMI1l94/04 strain. I 
hypothesized that these mutations may be involved in adaptation to the human host or 
recognizing human-type receptors. 
To identify if these mutations may be involved in human adaptation 7 virus strains isolated in 
MDCK cells (table 5.5) were passaged in the allantoic cavities of embryonated chicken eggs, 
where cells express only avian-type receptors (SA-a2,3-Gal receptor) [197]. After five 
passages, 'egg-adapted' viruses were harvested, and HAl (aa 18-342) was sequenced on the 
CEQ8000 platform as described in chapter 2. The deduced amino acid HAl sequence of 'egg-
adapted' virus was compared to that of the parent MOCK isolates. As shown in table 5.5, after 
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five passages in eggs, the Asp (D) residue at position 186 of VNMlCLO 1 /04 had mutated back 
to Glu (E), which is commonly found in strains of avian origin. 
The MDCK VNMlCL 1 05/05 parent strain had five amino acids in HA 1 that differed from the 
VNMlII94/04 strain. After five passages in eggs, the Val (V) at position 134 had mutated 
back to Ala (A) (table 5.5) while the other four residues were retained. Interestingly, the Phe 
(F) residue at position 151 in HA 1 of the VNMlCL2009-28/05 had not mutated back to 
reversed to lIe (I), but changed to Leu (L) (table 5.5). 
To confirm the presence of EI860, A 134V, and F151L. I performed quantitative 
pyrosequencing analyses directly on original clinical specimens as well as on primary and 
egg-adapted virus isolates. The design of PCR primers and sequencing primers for 
pyrosequencing as well as pyrosequencing procedures are described in chapter 2. As shown in 
table 5.6, no subpopulation of the 'human adapted' 186D variant (0%) was detected in the 
clinical specimen from which the VNMlCLOll04 was isolated. However, in the MOCK parent 
virus, this variant was predominant (94.6%) while the 'avian' 186E variant was detect~d as a 
minor subpopulation (5.6%), suggesting emergence and selection of 'human' 1860 during 
culture in MOCK cells and not during replication in vivo in the patient. 
Direct sequencing of the throat swab specimen from which the VNMJI05/05 virus was 
isolated revealed 26% 'avian' 134A and 74% 'human' 134V. In the MOCK parent strain 46% 
was A and 54% V, while in the egg-adapted strain 96.5% was A and 3.5% V. 
The 'human' 151F variant was predominant (94.9%) in the throat swab specimen of 
VNMJCL2009-28, while the I and L variants were detected as minor subpopulations (2.5% 
and 2.6% respectively) (table 5.5). The 151F variant was also predominant in the MOCK 
parent strain, whereas subpopulations of I and L were not detected. However. in the egg-
adapted strain, the L variant was predominant (98%) (table 5.6). 
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Table 5.5 HAl amino acid reserve and change after five generations in egg 
Virus strain 
Amino acid changes in HA 1 
I 53 83 94 96 133 2-34 1~ 151 175 1861188 1189 1198 I 265 1323 
ANNMlCL 1/01 I MOCK parent - M D 
- - -
~ 
-- --
~-~- -
Egg-adapted 
- - - - -
. 
-
M 
--~
MOCK parent 
- - - - -
-
E 
-
M V 
ANNMlCL2I04 I' ~ --
~~ ~ 
Egg-adapted 
- - - - -
E ~ V 
MOCK parent 
- -
0 M 
ANNMlCL20/04 1- - -- ~~ ~- -
Egg-adapted 
- -
0 
- - - -
M 
MOCK parent 
-
V V V - - I 1 -_1_- 1-- 1 K ANNMlCL 105/05 I - - -- - - ---~ ~ ~gg-adapted V V . - - - I . t • • - K 
MOCK parent N A M A 
ANNMlCL 115/05 1 - -~ ~ ---- .~ -
Egg-adapted - JL - - - - M - A 
MOCK parent K N R M R 
ANNMlCL 119/05 I - ~~ ---- -~ 
~-
--
t:gg-adapted K 
- JL - - - R - ~ - R 
ANNMlCL2009- IlJIOCK parent N A F M A ~ --
-
-
--
--
--
28/05 Egg-adaR!!d N A L M A 
that differ to avian strains. Blue indicates residues that changed during egg adaptation. 
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Table 5.6 Subpopulation estimation at the three positions of interest in HAl 
Virus strain 
HA positioll Amillo acid (%) 
(H5 nllmbering) Wild-type Mutant 
Throat swab E (100) D (0) 
VNMlCLOl/04 MOCK parent 186 E (5.4) D(94.6) 
Egg-adapted E(97.1) 0(2.9) 
Throat swab AG6) V (74) 
~ 
VNMJCL 105/05 MOCK parent 134 A (46) V (54) 
Egg-adapted A (96.5) V (3.5) 
Throat swab 1(2.5) 
F94.9, 
L (2.6) 
VNM/CL2009- MDCKparent 151 1(0) 
F (l00), 
28/05 L (0) 
Egg-adapted 1(0) 
F (2), 
L (98) 
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5.3 Discussion 
Insight into the molecular aspects of avian influenza A H5Nl virus infections, particularly 
those influencing the susceptibility to antiviral drugs, the host specificity and transmissibility, 
and virulence are crucial for disease management, infection prevention, and outbreak control. 
Studies in this chapter provide more such details on H5N 1 viruses isolated from humans in 
southern Vietnam in 2004-2005. 
Data obtained from phylogenetic analysis confirm that most (9/13) of H5Nl virus isolates 
collected during this study belonged to genotype Z. This genotype emerged in southern China 
in 2002, became the predominant genotype and subsequently spread to Vietnam in 2003 [45, 
46] causing large-scale poultry outbreaks and sporadic human infection [62]. Because of 
unavailable sequence data, we were unable to genotype the remaining (4/13) strains. However, 
since other known genotypes (such as G and V) have never been detected in southern Vietnam 
during that time [45, 46, 59, 198], these isolates most likely also belong to the prevalent 
genotype Z. 
Analysis of known host-specific markers revealed that all the viruses of this study had very 
few (2-3) human markers. Molecular analyses of the genotype Z viruses isolated from Thai 
patients in 2004 revealed similar findings [29]. These data suggest that these genotype Z 
viruses are purely avian viruses. 
In this study, a striking finding was that 75% (8/12) of the human viruses had E627K 
mutation. This mutation was not found in any H5Nl virus strains isolated from poultry in 
Vietnam during 2004-2005 [198]. This mutation is believed to confer increased viral 
replication and virulence in mammals [33]. In this study, a direct correlation between this 
mutation and disease outcome in patients could not be established. The E627K mutation has 
also been found in H5Nl viruses of the Qinghai-like lineage (clade 2.2) that spread to Middle 
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East, Africa and Europe [46, 199], but it seems not to correlate with virulence since the fatality 
rate of infection to these viruses was low [5, 200]. These observations together with sequence 
comparison of avian versus human strains [188] as well as studies in vitro [105] suggesting 
that the E627K mutation may be one adaptation of the virus to mammalian host. Data from 
this study also suggest that the lack ofE627K may be compensated by the presence ofD701N 
in PB2 gene. Recently, this compensatory role of D701N in term of transmissibility has been 
confirmed by studies in animals using reverse engineered H5N1 viruses [34]. 
All the viruses had dual mutations conferring amantadine resistance in the M2 gene. It has 
been shown that influenza viruses with these mutations have no replication defect [201]. 
H5N 1 viruses with these mutations may be acquired through the massive use of amatadine in 
poultry farming in China [118]. In Indonesia, low percentage (6.3%) of virus strains isolated 
in 2004-2005 had M2 mutations [161]. However, in recent years, without apparent widespread 
use of amantadine, analyses for M2 mutations of human specimens revealed a rapid increase 
in frequency from 25% in 2005 to 78% in 2006 and 87% in 2007, and patients with the M2 
mutated viruses had a significant higher virus load in throat as compared to those with wild-
type viruses [169]. In addition, M2 mutated viruses were mostly found in patients with fatal 
outcome [202]. These data may suggest a possible, but unknown role for these mutations in 
replication and virulence. 
Phylogenetic analysis of the HA gene revealed that all the viruses belong to clade 1 that 
predominated in Vietnam, Thailand, and Cambodia during 2003-05 [29, 123, 198]. Previous 
studies showed that the clade 1 viruses isolated from Vietnam during 2003-05 belonged to two 
different genetic groups (sub-lineage): virus strains from southern Vietnam belonged to group 
S, whereas those from northern Vietnam belonged to group N [198]. Recently, group N 
viruses found in northern Vietnam have been replaced by the recently emerged clade 2.3.4 
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H5NI viruses [59], but this trend has not been observed in Southern Vietnam [203]. The most 
recently isolated H5NI virus from southern Vietnam (February 2010, paper in preparation) 
still belonged to clade I. 
Three viruses isolated from two patients had the oseltamivir-resistance conferring H274Y 
mutation in the NA gene. H5N 1 viruses with this mutation have been shown to be 
approximately lOOO-fold less susceptible to oseltamivir, but remain susceptible to zanamivir 
[128]. Reverse genetic studies have shown that mutant H5NI viruses can replicate as efficient 
as wild-type viruses [178]. At present, three patients with selected oseltamivir resistance 
during treatment have been described - two in this thesis [77] and one in northern Vietnam 
[128]. This mutation has, thus far, not been found in any other genetic lineage ofH5NI [5]. 
Sequence comparison of the HA gene ofH5NI virus isolates cultured from different organs of 
the same patient (Patient 16) revealed 100% identity, suggesting no tissue-specific adaptive 
mutations were selected for during systemic viral dissemination in this patient. This is in 
accordance with data from HA gene sequencing analysis reported by Buchy et aI., [123] in 
which no difference in the HA sequences of H5NI viruses isolated from the respiratory tract, 
serum, and rectum was found. 
Although glycoarray analyses of reverse engineered H5NI viruses possessing the HA and NA 
genes of clade 1 viruses and the remaining genes from AlPuerto Rico/8/34 (H 1 N 1) virus have 
shown that viruses with an Ala134Val substitution are unable to bind to 'human-type' SA-
a2,6 Gal receptors [189], our data in this study suggest that Ala134Val, residing in the 130 
loop of the receptor binding domain, may affect receptor specificity and play a role in human 
adaptation. However, this residue may not function alone since the virus strain with this 
mutation had four other mutations in the HA 1. Direct sequencing revealed that this mutation 
was selected in vivo during replication in a human patient. Previously, Auewarakul et aI., have 
141 
ChapTer 5 
shown that this mutation is selected during viral replication in a Thai patient with fatal 
outcome [190]. However, in their studies, Alal34Vai was co-selected with the Leu129Vai 
mutation [190]. Reversely engineered viruses with an Ala134Val substitution were unable to 
recognize SA-u2,6 Gal, but virus strains with both the Ala134Val and Leu129Val mutations 
can bind to 'human-type' SA-u2,6 Gal receptors [190]. 
Data from this study suggest that the 1151 F mutation possibly was selected during viral 
replication in humans. It has been shown that the amino acid residue at position 151 (155 in 
H3 numbering) is involved in receptor binding [204]. The HA of avian influenza H5 viruses 
that preferentially recognizes 'avian-type' SA-a2,3 Gal receptors has 1151, whereas that of 
human influenza H3 preferably recognizes 'human-type' SA-a2,6 Gal receptors and has T151 
[204]. Although further studies are needed to address the role of FI51 in receptor binding, I 
postulate that the FI51 may be involved in 'human-type' SA-a2,6 Gal binding since this 
residue was selected in humans, and was outcompeted in the alantoic cavities of embryonated 
chicken eggs where cells express only 'avian-type' SA -a2,3 Gal receptors [197]. 
All the H5Nl virus strains of this study were initially isolated in MOCK cells. Previous 
studies have suggested that H5Nl influenza viruses [123], in contrast to human influenza 
viruses [205, 206], may quickly adapt to MDCK cells during in vitro culture. Data from my 
sequence analysis revealed that the Glu186Asp mutation in a single virus strain was possibly 
selected during culture in MOCK cells. Interestingly, Glu186Asp (Glu190Asp in H3 
numbering) is one of the two human-type specific receptor determinants of HI N 1 influenza 
viruses [207]. Although glycan microarray analysis showed that reversely engineered H5NI 
viruses with this mutation alone are unable to bind to 'human-type' SA-a2,6 Gal, its role in 
efficient replication of H5Nl in MCDK cells should be evaluated particularly in light of the 
current interest of cell culture-based vaccine production [208]. 
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Chapter 6 
A REAL-TIME RT -PCR FOR DETECTION OF CLADE 1 AND 
2 HSNl INFLUENZA A VIRUS USING LOCKED NUCLEIC 
ACID (LNA) TAQMAN PROBES 
143 
ChapTer 6 
6.1 Introduction 
Highly pathogenic avian influenza A (H5N 1) viruses cause sporadic infections in humans, and 
are associated with severe respiratory disease with a mortality of about 60% [5]. Since the re-
emergence of human H5Nl influenza virus infections in January 2003 [71],505 human cases 
have been documented in 15 countries in Asia, Africa, and Europe [5]. Genetic studies have 
revealed that most of the viruses isolated from humans and poultry belong to genotype Z [45, 
46]. The worldwide distribution of this genotype has resulted in the establishment of at least 
two genetically and geographically distinct clades: clade 1 and 2 [209]. Clade 1 H5N 1 viruses 
have been isolated from poultry and humans in Vietnam, Thailand, and Cambodia, and from 
poultry in Laos and Malaysia [54, 210, 211]. Clade 2 viruses have a larger genetic diversity 
and are divided into 5 sub-clades (2.1 to 2.5) [209]. Clade 2.1 viruses have been found only in 
Indonesian poultry and humans [54]. Clade 2.2 viruses have caused poultry outbreaks and 
human infections in the Middle East, Africa, and Europe [5]. Clade 2.3 viruses are further 
divided into four sub-clades (2.3.1 to 2.3.4) [209]. Recently, clade 2.3.4 viruses have become 
predominant in China and have also been reported in Hong Kong, Laos, Malaysia, Thailand, 
and North-Vietnam [59, 198]. In Vietnam, clades 1 and 2.3.4 have co-circulate among poultry 
and have both caused human infections [4,59]. 
The circulation of more than one virus clade poses a challenge for laboratory diagnostics, 
since methods for detection of H5Nl infection usually rely on clade specific amplification of 
the HA gene [212-214]. Although rapid antigen tests, virus isolation, and serological tests can 
be used to diagnose H5NI infection across all clades, these methods have limited use for 
routine diagnostics because of the inability to subtype, the low sensitivity, and the requirement 
of biosafety level 3 laboratory facilities limit their use for routine diagnostics. The accepted 
reference method for routine diagnosis of H5Nl infections is real-time RT-PCR (rRT-PCR) 
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[129]. Compared to conventional RT-PCR, rRT-PCR has a smaller risk of cross-
contamination, higher sensitivity and specificity, and shorter per sample laboratory 
turnaround. Several rRT-PCR assays for H5Nl detection have been described [214-218], but 
few of them have been specifically designed for the detection of both clades [217, 218]. In 
addition, clinical evaluation has not been performed for most of these assays [214, 216-218]. 
Therefore, a well evaluated single assay for detection of both clade 1 and 2 H5N 1 viruses in 
human clinical samples is still needed. 
Locked nucleic acid (LNA) is a new nucleotide analog that was first synthesized in 1998 
[219]. LNA nucleotides contain common nucleobases (A, T, G, and C) in which the ribose 
ring is 'blocked' by a methylene bridge connecting the 2'-0 atom and the 4'-C atom (figure 
6.1) which reduces the conformational flexibility of the ribose and increases the local 
organization of the phosphate backbone [219, 220]. LNAs are linked by the same phosphate 
backbone found in DNA or RNA (figure 6.1) that allow them to easily incorporate into the 
sequences [219, 220]. It has been shown that LNAs improve affinity for complementary DNA 
and RNA [220]. Incorporation of a single LNA residue increases the melting temperature of 
the sequence from 0.6 to 9.6 °c as compared to the same sequence without LNA residue 
[220]. LNA oligonucleotides have cellular delivery and physiological stability and are 
therefore very useful for biological studies especially those that focus on gene silencing and 
gene expression [221-225]. LNA oligonucleotides have also been evaluated as RNA-binding 
drugs for treament of cancer and metabolic diseases [226, 227]. In recent years, LNAs have 
been extensively used as molecular probes for direct isolation of messenger RNAs, in situ 
detection of micro-RNAs, and detection of single point mutations [136]. LNAs have also been 
used as probes in real-time PCR enabling a more flexible probe design and improving probe 
binding and amplification efficiency [136, 228, 229, 230]. This chapter aims to use LNA as a 
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Taqman probe to develop a real-time RT-PCR assay that allows direct detection of clade 1 and 
2 H5Nl viruses in clinical specimens. 
OR 
Base 
Locked nucleic acid 
(LNA) 
Figure 6.1 Locked nucleic acids and their linkage. Figure reproduced from Braasch et al.. 
6.2 Results 
6.2.1 Real-time RT-PCR with original TaqMan probe 
6.2.1.1 Primer and probe design 
Nucleotide sequences of full length H5 HA genes of H5N1 virus (N=312) were retrieved 
from Influenza Virus Resource available at 
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http://www.ncbi.nlm.nih.gov/genomesIFLUlDatabase/multiple.cgi [131] and were 
subsequently aligned using BioEdit version 7.0.1 (Ibis Biosciences). Investigation of 
sequence alignment revealed 9 highly conserved regions of 25 to 45 nucleotides in length 
that can serve as targets of primers and probes (table 6.1). The first four conserved regions 
are located very near each other (1 to 4 nucleotide distance) and expand a region > 130 
nucleotides in length (nt 47-180). These four conserved regions were chosen as target for 
primer and probe design using Primer Express version 2.0 (Applied Biosystems) as 
described in chapter 2. The only exception in the design of primers and probes for this study 
was the melting temperature of TaqMan probe that was set equal to the melting temperature 
of primers to allow more options for primer finding. The sequences of primers and probes 
generated by the software and used in this chapter are shown in table 2.7 in chapter 2. 
Table 6.1 Conserved regions in HA gene ofHPAI H5Nl viruses 
No Conserved sequence HA gene position· 
I GTGATCAGATTTGCATTGGTTACCATGCAAACAACTC 47 - 83 
2 ACAGAGCAGGTTGACACAATAATGGAAAAGAA 85 - 116 
3 ACTGTTACACATGCCCAAGACATACTGGAAA 121- 151 
4 GACACACAACGGGAAGCTCTGCGATCTA 153 - 180 
5 GATTGTAGTGTAGCTGGATGGCTCCTCGG 208 - 236 
6 CCGGAATGGTCTTACATAGTGGAGAAGGCCA 268 - 298 
7 TGAGCAGAATAAACCATTTTGAGAAAATTCAGATCATCCCCAAAA 362 - 406 
8 AGGGGTGAGCTCAGCATGTCCATAC 435 - 459 
9 AATGTGGTATGGCTTATCAAAAAGAACA 484 - 511 
Note: * Positioning is based on the 1 st nucleotide of the starting codon 
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6.2.1.2 Real-time RT -PCR 
Realtime RT-PCR using the designed primers and probes demonstrated favourable sensitivity, 
detecting up to 10 copies of the control plasmid per reaction (figure 6.2). However, the 
endpoint fluorescence was low - approximately 0.1 fluorescent unit at the end of the reaction 
(cycle 45) when using 120 nM of TaqMan probe. This low fluorescent signal suggests 
insufficient amount of probe used or inefficient probe binding and is a challenge for 
intepretation of results. To improve this, instead of increasing probe concentration or 
modifying the probe with minor groove binders, I modified the probe with LNA residues. 
Evaluation and use ofLNA probe are shown in the following section. 
;; 0.05 
-
-I.'-
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10 20 30 40 
ICydel 
Figure 6.2 Fluorescent graph showing results of realtime RT -PCR using single 
stranded control plasmids. The assay was carried out on these plasmid concentrations 105 
101 (from left to right) in triplicate however only one series of plasmid concentration are 
shown. 
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6.2.2 Realtime RT-PCR using LNA probe 
6.2.2.1 Modification of normal probe into LNA probe 
Five LNA residues were incorporated into the original probe. Residues modified with LNA 
are all adenin nucleotides (chapter 2, table 2.7) that did not cause in silico self-complementary 
. secondary structures (tested by LNA tools available at http://lnatools.comlhybridization) or 
form primer-dimers. Incorporation of LNA residues resulted in an increase in melting 
temperature of the probe (average 1°C per modification) (chapter 2, table 2.7). 
The binding efficiency of the LNA modified probe was evaluated by comparing its endpoint 
fluorescence against the original probe. Figure 6.3 illustrates that the LNA modified probe has 
a higher endpoint fluorescent signal compared to original probe. In reactions using the same 
concentration of probe and template, the mean Ct value of reactions using LNA probe was 
2.93 (the mean of 15 replicates) cycles earlier than reactions using the normal probe and this 
difference is significant (T test, P=O.OOOl). These data suggest that the binding of the LNA 
probe is more efficient than normal probe. 
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Figure 6.3 Fluorescent signals of FAM emitted by original (0) and LNA (L) TaqMan 
probes. Each color curve indicates a single rRT-PCR reaction containing 120 oM of either 
probes. A. S, and C: reactions using 4000, 400, and 40 PFU of the virus 
AlVietnam/CL11S1200S, respectively. 
6.2.2.2 Analytical sensitivity and specificity 
The analytical sensitivity of the LNA Taqman rRT-PCR for the detection of the HA gene of 
HSN1 was determined on three occasions using serial 10-fold dilutions of a representatitive 
clade 1 virus (AJVietnamfCL11S/200S). The assay consistently detected the HA gene of the 
virus at a concentration of less than 0.5 PFU per reaction. The analytical sensitivity of the 
assay was also determined using single-stranded quantified DNA (ssDNA) plasmids and the 
detection limit of the assay was 10 copies ofssDNA plasmids per reaction. 
To test for specific detection of influenza A HSN1, tlle assay was used with 12 clade 1, 4 clade 
2.3 and 1 clade 2.1 human H5Nl viruses, and 2 avian clade 1 H5N1 vimses. The 12 human 
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clade 1 viruses were those that have been isolated from patients described in this thesis 
(chapter 3) and are shown in table 5.1 in chapter 5. The four clade 2.3 viruses were isolated 
from 4 patients with influenza A H5Nl admitted to the National Institute of Infectious and 
Tropical Diseases, Ha Noi, Viet Nam in 2007 (appendices 12.5.8-12.5.11). The clade 2.1 virus 
was the AIlndonesial5/2005 that was kindly provided by The National Institute of Infectious 
Diseases, Tokyo, Japan. The two avian clade 1 H5N1 viruses were isolated from sick chickens 
in Vinh Long province in 2006 (appendices 12.5.12-12.5.16). All viruses were successfully 
detected using the assay. 
To test for cross-reactivity, 9 human seasonal viruses and 5 non-H5 avian influenza virues 
were tested. The nine seasonal viruses (HIN1; n=4 and H3N2; n=5) used in this analysis were 
isolated from clinical specimens obtained from patients with influenza symptoms presenting to 
Dong Thap Provincial Hospital in 2006. The five avian viruses (H4N6; n=3, H6Nl; n=l, and 
H8N3; n=l) were isolated from ducks in Dong Thap and Long An provinces in 2006. The 
subtpye ofthese avian and human viruses were confirmed by RT-PCR as described by Wright 
et aI., [3] and Lee et aI., [143] and sequencing (append ice 12.5.6 and 12.5.7). The result 
showed that there was no cross-reactivity with these viruses, indicating specificity for 
influenza A viruses of subtype H5. 
6.2.2.3 Evaluation of sensitivity and specificity using clinical specimens 
The sensitivity of the assay was clinically evaluated in 58 human specimens with clade 1 
(n=10), clade 2.1 (n=25), or clade 2.3 (n=23) H5Nl viruses. The ten clade 1 clinical 
specimens were diagnostic specimens obtained from 10 out of 16 patients described in chapter 
3 (Patients 2-7. 9-13). The twenty five clade 2.1 clinical specimens were diagnostic specimens 
that were obtained from 25 patients in Indonesia in 2006-07. These specimens were sent to 
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The National Institute of Health Research and Development in Jarkata, Indonesia for diagnosis 
of influenza A H5Nl infection. H5Nl viruses in these specimens were confimred using the 
FDA-approved CDC assay [231]. Since only clade 2.1 viruses have been reported in humans 
in Indonesia [54], these clinical specimens most likely contained clade 2.1 viruses. The 23 
clade 2.3 clinical specimens were diagnostic and follow-up specimens obtained from 4 
patients admitted to the National Institute of Infectious and Tropical Diseases, Hanoi, Vietnam 
in 2007 and from which clade 2.3 viruses were isolated and used in the above section (section 
6.2.2.2). My rRT-PCR assay using LNA TaqMan probe detected H5 virus in 56 of these 
samples indicating a 97% sensitivity. The sensitivity was 100% for clade I and clade 2.3, and 
92% for clade 2.1 (table 6.2). 
Table 6.2 H5Nl clinical samples and rRT -PCR results 
Samples / NS TS TA Plas PF Stool Total rRT-
virus clade PCR 
positive 
Clade 1 2 7 1 0 0 0 10 10 
Clade 2.1 7 17 1 0 0 0 25 23 
Clade 2.3 5 7 6 2 2 1 23 23 
Total 14 31 8 2 2 1 58 56 
rRT-PCR 13 30 8 2 2 1 56 
positive 
Note: NS = Nasal swab: TS = Throat swab: T A = Tracheal aspirate; Plas = Plasma; PF = 
Pleural fluid. 
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The specificity of the assay in clinical specimens was assessed by analyzing influenza A HI or 
H3 positive samples (n = 19) and influenza negative (n = 29) respiratory samples. These 
clinical specimens were obtained during 2004-07 from patients with influenza like illness 
presented to Hospital for Tropical Diseases. The 19 samples with influenza A HI N 1 and 
H3N2 were confirmed using a RT-PCR assays described by Wright et al [3] and the CDC 
[231]. The 29 influenza A negative samples were those that were negative in FluA specific 
real-time RT-PCR assay (as described in chapter 2) and/or FluA_CDC assay [231]. The result 
showed that all of these samples were negative in the LNA H5 assay indicating 100% 
specificity . 
6.2.2.4 Sensitivity of LNA assay against CDC assay in detecting clade 2.3 viruses 
The CDC assay for detection of influenza A H5Nl consists of a generic influenza A specific 
(FluA_CDC) and two H5 specific assays: asH5a and asH5b. These assays have been aproved 
by the USA FDA [231] for use in diagnosis of human clinical specimens. Since 2006, CDC 
assays have been used as universal diagnostic assays for influenza H5N 1 infection in 
laboratories of the South East Asia Infectious Diseases Clinical Research Network [181]. 
During seting up the LNA assay, I have compared the sensitivity of the LNA assay against the 
CDC assays in diagnosis of 23 clinical specimens with clade 2.3 H5N 1 viruses. These clinical 
specimens are the clade 2.3 specimens used in the above section (section 6.2.2.3). Table 6.3 
shows that the Ct value of the LNA H5 assay is significantly lower than the Ct value of the 
FluA_CDC, asH5a and asH5b, and the detection rate of the LNA assay is significantly higher 
compared to both the CDC H5 assays. 
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Table 6.3 Sensitivity of LNA_H5 assay vs CDC assay in 23 clinical specimens with clade 
2.3 H5Nl viruses 
Test FluA CDC asH5a asH5b LNA H5 
Positive (%) 23 (100) 9* (39) 14 (61) 23 (100) 
P value (Fisher 
1 <0.001 0.0015 
exect test) 
Median of Ct value 34.7 38.85 37.25 29.85 
P value (Mann-
0.007 0.005 0.0017 
Witney U test) 
Note: * indicates that these specimens were positive in the asH5b assay 
6.3 Discussion 
Recent evidence of co-circulation of clade 1 and clade 2 H5N 1 viruses in South East Asia has 
highlighted the need for RT-PCR assays that allow detection of both genetic clades. In this 
chapter, I have developed a single step rRT-PCR assay using an LNA TaqMan probe for 
direct detection in clinical samples of H5 genes from both clades of H5Nl viruses. This assay 
was shown to be sensitive, specific, and rapid (approximately 3.5 hours after RNA extraction). 
The primers and probe used in this study were designed to target a highly conserved region in 
the HA gene of H5N 1 viruses. Despite that, to ensure amplification of both clade 1 and 2 
RNA, one and two degenerated bases were incorporated into the forward and reverse primers, 
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respectively. Incorporation of degenerated bases into primers (and probes) was frequently 
observed in recent published assays for influenza A H5N 1 detection [231, 232] 
The assay using the original probe was shown to be sensitive, detecting 10 ssDNA plasmids 
per reaction. However, because of its inadequate binding, modification with LNA residues 
was performed. The residues modified with LNA were chosen according to LNA design 
guidelines published by You. Y et aI., [233] and LNA provider available at 
http://www.exiqon.com/oligo-tools.WhenusingLNAmodifiedprobe.anincrease in binding 
efficiency was observed but without increasing sensitivity. The assay using LNA probe could 
also detect 10 ssDNA plasmids and was capable to detect less than 0.5 PFU of H5NI viruses 
per reaction. Data from this chapter suggest that incorporation of LNA residues may be a good 
option to improve the binding efficiency of TaqMan probes, particulartly when the probe has a 
low melting temperatur~. Indeed, it has been shown that incorporation of LNA residues is a 
practical way to improve probe-binding efficiency [234]. 
The LNA assay was shown to be specific for the detection of influenza A of subtype H5. The 
H5 gene of clades I, 2.1, and 2.3 was amplified from both virus isolates and human clinical 
specimens. Cross-reaction with virus isolates from other influenza A subtypes was not 
observed, and no positive results were obtained when analyzing 48 clinical samples from 
patients with either seasonal influenza or non-influenza respiratory illness. 
Clinical evaluation was performed on 58 stored clinical specimens from 39 patients infected 
with either clade 1, 2.1 or 2.3 viruses and showed high concordance when compared to initial 
diagnostic RT-PCR and/or cell culture results. To my knowledge, the number ofH5 positive 
clinical specimens used in this study is larger than in any other previously published assays 
[215]. Nevertheless, my LNA assay failed to detect virus in a nasal swab and a throat swab. 
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This may be due to RNA degradation during long-term storage and multiple freeze-thaw 
cycles. 
The LNA assay was shown to be more sensitive than the FDA aproved CDC assay in 
detecting clade 2.3 viruses in 23 clinical specimens. In these specimens, while my LNA assay 
could detect the presence of the HA gene of H5N 1 virus in all (23/23 specimens), the asH5b 
could only detect 14/23 and asH5a 9/23. This difference is significant indicating that the LNA 
assay is more sensitive than the H5 specific CDC assays. The indicator of this sensitivity 
could be Ct value of reaction that was significantly lower in the LNA assay compared to that 
of the CDC H5 assays. It should be noted that all specimens positive in the asH5a were also 
positive in the asH5b suggesting that the use of CDC assay may result in misdiagnosis of a 
substantial proportion of specimens. For this reason, the LNA assay has been chosen as a 
supplementary assay (in addition to the FDA CDC assay) for diagnosis of influenza A H5N 1 
infection in laboratories within the South East Asia Infectious diseases Clinical Research 
Network [235]. 
The clade 2.2 H5N 1 viruses have shown a widespread global distribution. Therefore including 
viruses and clinical specimens of this sub-clade in assay validation is important. However, this 
LNA assay has not been evaluated in clade 2.2 because viruses and specimens were not 
available to us. Nevertheless, in silico analyses indicates that this assay should be capable in 
detecting viruses of this sub-clade. 
In conclusion, in this chapter I have developed a highly sensitive and specific rRT-PCR assay 
using LNA TaqMan probe for the detection ofH5Nl influenza A virus of both clades 1 and 2 
directly in clinical specimens. Using this assay, reliable diagnostic results can be obtained in a 
few hours, thus would be important for timely clinical management and outbreak control. 
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7.1 Problems surrounding H5Nl influenza 
Since the re-emergence ofH5NI influenza outbreaks in poultry and humans in 2003, the virus 
has spread to a large part of the world and has continued to cause sporadic human infections 
with high morbidity and fatality [5]. Although current world-wide attention is focused to the 
newly emerged influenza A HINI virus that has rapidly spread globally [236], avian influenza 
A H5NI is still a cause of concern because of its ability to give rise to a pandemic strain, 
either through human adaptation or reassortment with circulating human viruses and 
particularly with the pandemic HI N 1 virus. The latter has been shown to cause outbreaks in 
humans, pigs and turkeys providing several hosts for potential co-infection with H5N I 
viruses. Current data on HSNI disease still suggest that if an avian influenza pandemic occurs, 
the outcome would most likely be very grim. Defensive strategies for this event include the 
stockpiling of antiviral drugs and mass-production of vaccines. 
Antiviral drugs would be the first line of defense for such an influenza pandemic. However, 
because of limited options, treatment for HSNI disease relies largely on the NA inhibitor 
oseltamivir carboxylate. This drug is effective against all influenza A subtypes and is 
recommended for stockpiling and use during outbreaks and pandemics 
[http://wwwsearowhointiLinkFiles/Avian_Flu_Stockpile _ Oseltamivirpdf, accessed on May 
22, 2009]. However, to be used effectively, besides early identification of cases and timely 
administration of the drug, a better understanding of the clinical characteristics of H5N 1 
disease and the viral and human responses to treatment are required to determine the optimal 
treatment strategy. Furthermore, the use of this drug alone for H5N 1 influenza treatment may 
result in the emergence of resistant variants causing treatment failure [11] and the risk of 
subsequent spread of resistant viruses [178]. Therefore, while waiting for the availability of 
new antiviral drugs which are under clinical development [237, 238] or new administration 
158 
ChapTer 7 
routes for zanamivir [79, 239] - the drug that oseltamivir resistant virus remains susceptible 
to-, combination treatment with other existing antiviral drugs is an important alternative option 
for treatment of severe influenza and is currently under investigation for severe seasonal 
influenza (Menno de Jong, personal communication). 
Vaccines are the most important weapon for pandemic prevention [9]. Human H5Nl influenza 
vaccines are currently being developed and evaluated in Europe, USA, Japan, Australia, 
China, and others [236]. In Europe, 4 vaccines have been licensed. Those are the Prepandrix 
(adjuvanted vaccine) of GlaxoSmithKline, Daronrix (inactivated vaccine) of 
GlaxoSmithKline, Focetria (subunit vaccine) of Novartis, and Celvapan (inactivated ce11-
cultured vaccine) of Baxter [236]. However, due to their high genetic diversity, these vaccines 
seem not to offer sufficient protection for all circulating H5NI lineages [236]. Therefore, the 
successful use of H5N 1 vaccines always requires an understanding of the genetic and, if 
possible, the antigenic properties of circulating H5N 1 viruses in different regions of the world 
that would be helpful in selection of appropriate vaccine. Thus, monitoring for the molecular 
changes of H5N I viruses from humans and poultry remains of great importance. 
7.2 Findings in this thesis 
Studies in this thesis (chapter 3) revealed that most patients have typical symptoms of severe 
respiratory disease, compatible with severe influenza at presentation. Abnormalities observed 
on chest radiographs included extensive bilateral infiltration, lobar collapse, focal 
consolidation, and air bronchograms. The prominent laboratory factors were marked 
lymphopenia along with neuropenia and thrombocytopenia; increased levels serum 
transaminases. Although rare, patients with H5Nl disease may present with atypical 
symptoms (e.g., gastrointestinal and CNS infections) that may result in misdiagnosis. The 
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finding of this case together with those found in Thailand [93] indicate that accurate clinical 
diagnosis of all H5N 1 infections is challenging and thus, during influenza H5N 1 outbreaks in 
poultry, suspected cases should not only be involved patients with symptoms of respiratory 
infection but also those with unexplained gastrointestinal and CNS infections. 
Data from Chapter 4, together with other larger case studies [79], showed that oseltamivir may 
be benefit to patients with H5NI infection, but this chapter also describes the emergence of 
oseltamivir resistance in two patients under standard dose treatment with ensuing failure and 
fatal outcome. The confirmation of resistant viruses in these patients highlights the need for 
alternative treatment options to prevent resistance emergence and to improve outcome. 
Chapter 5 showed that all H5N I virus strains in this study belonged to clade I, genotype Z 
H5NI viruses. Some of them had mutations in the HAl gene that potentially involved in the 
recognition of 'human-type' receptors and almost all of them had changes in the PB2 gene 
associated with improved replication in and transmission between mammals. Although the 
data in this chapter may not be relevant for appropriate vaccine selection, findings from this 
study are relevant in the sense that they show evidence of rapid adaptation during replication 
in humans and highlight the need for close monitoring of such changes during human 
infection as part of pandemic preparedness. In addition, our findings show that changes in the 
main antigenic protein (HA) occur in different ways in different patients. Moreover, if an 
H5NI virus would acquire pandemic properties through human adaptation, it is not unlikely 
that the sequence of genetic changes leading to successful human to human transmission may 
also partially affect antigenicity and thus vaccine efficacy. Finally, our observations indicate 
that sequences from cultured viruses should be interpreted with caution as 'adaptive' changes 
may also be selected for in tissue culture. Ideally, monitoring for adaptive changes should be 
done in sequences from direct clinical specimens. 
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Chapter 6 describes a diagnostic assay which may be useful for timely and accurate diagnosis 
of human H5N 1 infection in regions where different genetic clades cocirculate. Since 
individual disease management and pandemic preparedness depends on adequate diagnostic 
capacity, reliable and rapid diagnostics are of greatest importance. 
7.3 Future areas of interest 
7.3.1 Evolution of H5Nl viruses 
Since late 2005, human H5NI infection has not been detected in southern Vietnam until April 
2009 when H5NI virus was confirmed in a 3 year-old child in Dong Thap province [240]. 
This long absence of human infections may have been partially a result of nationwide poultry 
vaccination, poultry rearing and selling regulations, and aggressive public education started in 
mid-2005 [147]. Despite all that, avian influenza A H5Nl virus was still circulating in 
domestic birds, possibly in an unvaccinated sUbpopulation [203], posing a continuous risk of 
sporadic human infection [240]. The current concern is that avian influenza A HSNI viruses 
can recombine with other influenza subtypes circulating in humans, particularly the recently 
emerged 2009 pandemic influenza virus A (H 1 N 1) that is causing world-wide infections, to 
form a new strain with combined high pathogenicity ofH5Nl and successful human to human 
transmission of 2009 HI N 1. Therefore, if further human HSN 1 cases are found, we will 
continue to closely monitor the characteristics and molecular evolution of the virus by 
isolation of the virus in MCDK cells and whole genome sequencing of clinical specimens and 
isolates. 
Beside human HSNI viruses, we believe that the evolution of H5Nl virus in poultry should 
also be closely monitored to understand the level of evolution and the circulating lineages. For 
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those reasons, we will conduct a retrospective study to monitor the evolution of H5Nl 
influenza viruses in poultry in southern Vietnam since 2005 to date. In this study, 
approximately 100 H5N 1 virus strains which were isolated and stored by the local animal 
health services during 2005-2009 will be sequenced. Sequence data from these strains will be 
analyzed for their ev~lution, their antigenic variations, and identification of host-specific 
markers and mutations possibly involved in recognizing human-type receptors, virulent 
determinant markers etc. After this study, we will continue our collaboration with the animal 
health services to keep monitoring the evolution of avian influenza A H5Nl viruses and if 
possible we will expand our collaboration to study other avian influenza A subtypes (e.g., 
H3N8, H4N6, H6Nl, H9N2 etc.,) that are circulating in poultry and their evolution. 
7.3.2 Mutations conferring human-type receptor recognition 
Data in this thesis provide evidence for possible occurrence of adaptive mutations in the HA 
gene of H5N 1 influenza virus during infection supporting the notion that continuing 
transmission ofH5Nl virus from poultry to humans may provide a greater opportunity for the 
virus to adapt to humans resulting in a pandemic strain [190]. At least two mutations (A134V 
and I151FIL) in the HA gene could be involved in recognizing human-type SA «2,6 receptors. 
Previously, Auewarakul P et al. has shown that the A134V mutation does influence SA «2,6 
receptor binding in the presence of Leu129Vai [190]. However, our virus with this mutation 
did not have L129V, but instead several other mutations (A83V, D94V, A133S, and 1188T) 
therefore it remains interesting whether the A134V mutation also influences SA «2,6 receptor 
binding in the presence of other mutations. In addition, the role of I151FIL in SA «2,6 
receptor binding has yet to be established. I have planned to study the role of these two and 
other emerging mutations in the recognition of SA «2,6 receptor using glycan arrays in 
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collaboration with Dr Ten Feizi at the Glycosciences lab, Imperial College, London and Dr 
Mikhail Matrosovich at the Institute of Virology, Philipps University, Gennany. 
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APPENDICES 
1. Appendix 1 
Publisbed clinical data 
Patient in this thesis Relevant to published cases Note 
Patient 1 Patient 1 in reference [77] Clinical data from 
Patient 2 Patient 2 in reference [77] these 16 cases have 
Patient 3 Patient 3 in reference [77] been pooled to those 
Patient 4 Patient 4 in reference [77] from the North in 
Patient 5 
Patient 5 in reference [77] and order to investigate 
Patient 5 in reference [62]. prognostic factors 
Patient 6 in reference [77] and associated with fatal 
Patient 6 
Patient 9 in reference [62] outcome m 
Patient 7 in reference [77] and reference [74]. 
Patient 7 
Patient 10 in reference [62] Virological data 
Patient 8 Patient 8 in reference [77] produced from all 
Patient 9 Patient 6 in reference [62] patients have been 
Patient 10 Patient 7 in reference [62] published in 
Patient 11 Patient 8 in reference [62] reference [36]. 
Patient 12 
Not published as case study or 
case series. 
Patient 13 
Not published as case study or 
case series. 
Patient 14 
Not published as case study or 
case series. 
Patient 15 
Not published as case study or 
case series. 
Patient 16 Patient 2 in reference [76] 
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2. Appendix 2 
TR UNG Qu6c 
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.. -~. 
Sinh Dinh (1 case) 
Lam Dong (3 cases) 
::i-....:....--44~~:F----- Tay Ninh (1 case) 
~L----- Ho Chi Minh (2 cases) 
:.~S~@~=====;==== Dong Thap (3 cases) 
r· lien Giang (1 case) 
.' a:< ...... 
An Giang (1 case) 
Vinh Long (1 case) 
Tra Vinh (2 cases) 
Soc Trang (1 case) 
Map of Vietnam showing the geographical location of the 16 enroled cases 
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3. Appendix 3 
Serial chest radiographs obtained from Patient 1. Panel A B, C, and 0 are chest 
radiographs obtained on day 1, 3, 4 and 7 since treatment started respectively showing small 
focal (Panel A), minimal progression of the infiltrate (panel B), focal infiltration (Panel C), 
and extensive infiltration in the right lung with extension to the left lung. Suppl mental 
oxygen was given on day 4 of treatment and intubation and ventilation were performed on day 
6. 
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4. Appendix 4 
Serial hest radiograph obtained on admission and during hospital stay from 
Patient 5, 10, and 12 (Panel A, B, and C ) respectively, showing widespread consolidation 
and interstitial shadowing. The progression of pneumonia in Patient 10 is shown in the 
chest radiograph in panels D, E, and F, that were obtained on days 5t\ 7th, and 10th of 
illness, respectively. 
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5. App ndi 5 
B 
rial ch t radiograpb obtained from Patient 16. Panels A, B, and C are radiographs 
obtain don ebruary 12 15 and 16, re pectively. Patient 16 was the only patient with a 
nonna1 ch st radiograph n admission (Panel A). There were also no abnormalities in his 
chest radiograph taken on day 5 of illness (3 days after hospitalization) (Panel B). 
Howe er, ache t radiograph obtained on day six of illness revealed bilateral infiltration 
(Pan I C). The patient died the day after. 
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6. Appendix 6 
86 
6 
88 
O.OJ 
Genotypes X0-3, 
W,andG 
Genotypes A, B, 
C, D, E, Y, Z+ 
and Z(PB2) 
ML phylogenetic relationship tree of the PB2 gene of the 13 virus strains (in blue). 
Number above (or bellow) the branches indicates neighbor joining bootstrap value. Tree was 
rooted to NEquine/Prague/ l/56(H7N7). 
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7. Appendix 7 
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A, B, Y, 
W,G, V, 
Z+, and Z 
(PD1) 
ML phylogenetic relationship tree of the PDI gene of the 13 virus strains (in blue). 
Number above (or bellow) the branches indicates neighbor joining bootstrap value. Tree was 
rooted to A1Equine/Prague/l /56(H7N7). 
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8. Appendix 8 
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Genotypes 
B, C, D, E, 
G,Y,W,Z+ 
and Z(PA) 
ML phylogenetic relationship tree ofthe PA gene ofthe 13 virus strains (in blue). Number 
above the branches indicates neighbor joining bootstrap value. Tree was rooted to 
AI Ann! Arbor/6/60(H2N2). 
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9. Appendix 9 
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Genotypes 
Z, Z+, Y, 
V, and G 
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11. Appendix 11 
GenBank accession number of deposited viral gene sequences 
Name 
Accession numbers ofviral2ene sequences 
HA NA M NP NS PA PBI PB2 
AI Vietnam/CLO I12004(H5N I) OQ497719 OQ493068 OQ492980 00493156 OQ493244 OQ493332 OQ4934 1 8 OQ492894 
A Nietnam/CL02/2004(H5N 1) OQ497720 OQ493069 OQ492981 OQ493 157 00493245 - OQ493419 OQ492895 
ANietnam/CL 1712004(H5N 1) OQ497721 00493070 OQ492982 OQ493 158 OQ493246 00493333 OQ493420 
-
ANietnamlCL20/2004(H5N 1) OQ497722 OQ493071 OQ492983 OQ493 159 OQ493247 OQ493334 OQ493421 -
ANietnamlCL2612004(H5N I) OQ497723 OQ250160 OQ492984 OQ493 160 OQ493248 OQ493335 OQ493422 OQ492896 
ANietnamlCL36/2004(H5N 1) OQ497724 OQ493073 OQ492985 OQ493 161 OQ493249 OQ493336 OQ493423 OQ492897 
ANietnamlPVE 16T 12004(H5N I) OQ535724 OQ535726 OQ535725 OQ535727 OQ535728 OQ535729 OQ535730 OQ535731 
ANietnamlCL 1 00/2004(H5N 1 ) 0Q497725 OQ493074 OQ492986 OQ493 162 OQ493250 OQ493337 OQ493424 OQ492898 
ANietnamlCL 1 05/2005(H5N I) OQ497726 OQ493075 OQ492987 OQ493 163 OQ493251 OQ493338 OQ493425 OQ492899 
ANietnamlCL 115/2005(H5N I) DQ497727 OQ493076 OQ492988 OQ493 164 OQ493252 OQ493339 OQ493426 OQ492900 
, 
ANietnam/CL 119/2005(H5N 1) 0Q497728 OQ493077 OQ492989 00493165 OQ493253 OQ493340 OQ493427 OQ492901 
ANietnam/CL2009/2005(H5N 1) OQ497729 OQ493078 OQ492990 OQ493 166 00493254 OQ493341 OQ493428 OQ492902 
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12. Appendix 12 - Unpublished sequences 
12.1 Direct HAl sequence from admission throat swab of Patient 10 
GATCAGATTTGCATTGGTTACCACGCAAACAACTCGACAGAGCAGGTTGACACAATAATGGAA 
AAGAACGTTACTGTTACACATGCCCAAGACATACTGGAAAAGACACACAACGGGAAGCTCTGC 
GATCTAGATGGAGTGAAGCCTCTAATTTTGAGAGATTGTAGTGTAGCTGGATGGCTCCTCGGA 
AACCCAATGTGTGACGAATTCATCAATGTGCCGGAATGGTCTTACATAGTGGAGAAGGCCAAT 
CCAGTCAATGACCTCTGCTACCCAGGGAATTTCAATGACTATGAAGAATTGAAACACCTATTG 
AGCAGAATAAACCATTTTGAGAAAATTCAGATCATCCCCAAAAGTTCTTGGTCCAGTCATGAA 
GCCTCATTGGGGGTGAGTGCAGCATGTCCATACCAGGGAAAGTCCTCCTTTTTCAGAAATGTG 
GTATGGCTTATCAAAAAGAACAGTACATACCCAACAATAAAGAGGAGCTACAATAATACCAAC 
CAAGAAGATCTTTTGGTAATGTGGGGGATTCACCATCCTAATGATGCGGCAGAGCAGGCAAAG 
CTCTATCAAAACCCAACCACCTATATTTCCGTTGGGACCTCAACACTAAACCAGAGATTGGTA 
CCAAGAATAGCTACTAGATCCAAAGTAAACGGGCAAAGTGGAAGGATGGAGTTCTTCTGGACA 
ATTTTAAAACCGAATGATGCAATCAACTTCGAGAGTAATGGAAATTTCATTGCTCCAGAATAT 
GCATACAAAATTGTCAAGAAAGGGGACTCAACAATTATGAAAAGTGAATTGGAATATGGTAAC 
TGCAACACCAAGTGTCAAACTCCAATGGGGGCGATAAACTCTAGTATGCCATTCCACAATATA 
CACCCTCTCACCATCGGGGAATGCCCCAAATATGTGAAATCAAACAGATTAGTCCTTGCGACT 
GGGCTCAGAAATAGCCCTCAAAGAGAGAGAAGAAGAAAAAAGAGGGGATTATTTGGAGCCATA 
GCAGGTTTTATAGAGGGAGGATGGCAGGGAATGGTAGATGGT 
12.2 HA sequences 
12.2.1 VNMlCL2009-28/2005 
GATCAGATTTGCATTGGTTACCACGCAAACAACTCGACAGAGCAGGTTGACACAATAATGGAA 
AAGAACGTTACTGTTACACATGCCCAAGACATACTGGAAA-
GACACACAACGGGAAGCTCTGCGATCTAGATGGAGTGAAGCCTCTAATTTTGAGAGATTGTAG 
TGTAGCTGGATGGCTCCTCGGAAACCCAATGTGTGACGAATTCATCAATGTGCCGGAATGGTC 
TTACATAGTGGAGAAGGCCAATCCAGTCAATGACCTCTGCTACCCAGGGAATTTCAATGACTA 
TGAAGAATTGAAACACCTATTGAGCAGAATAAACCATTTTGAGAAAATTCAGATCATCCCCAA 
AAGTTCTTGGTCCAGTCATGAAGCCTCATTGGGGGTGAGTGCAGCATGTCCATACCAGGGAAA 
GTCCTCCTTTTTCAGAAATGTGGTATGGCTTATCAAAAAGAACAGTACATACCCAACAATAAA 
GAGGAGCTACAATAATACCAACCAAGAAGATCTTTTGGTAATGTGGGGGATTCACCATCCTAA 
TGATGCGGCAGAGCAGGCAAAGCTCTATCAAAACCCAACCACCTATATTTCCGTTGGGACCTC 
AACACTAAACCAGAGATTGGTACCAAGAATAGCTACTAGATCCAAAGTAAACGGGCAAAGTGG 
AAGGATGGAGTTCTTCTGGACAATTTTAAAACCGAATGATGCAATCAACTTCGAGAGTAATGG 
AAATTTCATTGCTCCAGAATATGCATACAAAATTGTCAAGAAAGGGGACTCAACAATTATGAA 
AAGTGAATTGGAATATGGTAACTGCAACACCAAGTGTCAAACTCCAATGGGGGCGATAAACTC 
TAGTATGCCATTCCACAATATACACCCTCTCACCATCGGGGAATGCCCCAAATATGTGAAATC 
AAACAGATTAGTCCTTGCGACTGGGCTCAGAAATAGCCCTCAAAGAGAGAGAAGAAGAAAAAA 
GAGGGGATTATTTGGAGCCATAGCAGGTTTTATAGAGGGAGGATGGCAGGGAATGGTAGATGG 
TTGGTATGGGTACCACCATAGCAATGAGCAGGGGAGTGGGTACGCTGCAGACAAAGAATCCAC 
TCAAAAGGCAATAGATGGAGTCACCAATAAGGTCAACTCGATCATTGACAAAATGAACACTCA 
GTTTGAGGCCGTTGGAAGGGAATTTAACAACTTAGAAAGGAGAATAGAGAATTTAAACAAGAA 
GATGGAAGACGGGTTCCTAGATGTCTGGACTTATAATGCTGAACTTCTGGTTCTCATGGAAAA 
TGAGAGAACTCTAGACTTCCATGACTCAAATGTCAAGAACCTTTACGACAAGGTCCGACTACA 
191 
GCTTAGGGATAATGCAAAGGAGCTGGGTAACGGTTGTTTCGAGTTCTATCATAAATGTGATAA 
TGAATGTATGGAAAGTGTAAGAAACGGAACGTATGACTACCCGCAGTATTCAGAAGAAGCAAG 
ATTAAAAAGAGAGGAAATAAATGGAGTAAAATTGGAATCAATAGGAATTTACCAAATACTGTC 
AATTTATTCTACAGTGGCGAGTTCCCTAGCACTGGCAATCATGGTAGCTGGTCTATCCTTATG 
GATG 
12.2.2 VNMlCL 1 07-13/2005 
GATCAGATTTGCATTGGTTACCATGCAAACAACTCGACAGAGCAGGTTGACACAATAATGGAA 
AAGAACGTTACTGTTACACATGCCCAAGACATACTGGAAA-
GACACACAACGGGAAGCTCTGCGATCTAGATGGAGTGAAGCCTCTGATTTTGAGAGATTGTAG 
TGTAGCTGGATGGCTCCTCGGAAACCCAATGTGTGACGAATTCATCAATGTGCCGGAATGGTC 
TTACATAGTGGAGAAGGCCAATCCAGTCAATGACCTCTGTTACCCAGGGAATTTCAATGACTA 
TGAAGAATTGAAACACCTATTGAGCAGAATAAACCATTTTGAGAAAATTCAGATCATCCCCAA 
AAGTTCTTGGTCCAGTCATGAAGCCTCATTAGGGGTGAGTGCAGCATGTCCATACCAGGGAAA 
GTCCTCCTTTTTCAGAAATGTGGTATGGCTTATCAAAAAGAACAGTACATACCCAACAATAAA 
GAGGAGCTACAATAATACCAACCAAGAAGATCTTTTGGTAATGTGGGGGATTCACCATCCTAA 
TGATGCGGCAGAGCAGGCAAAGCTCTATCAAAACCCAACCACCTATATTTCCGTTGGGACCTC 
AACACTAAACCAGAGATTGGTACCAAGAATAGCTACTAGATCCAAAGTAAACGGGCAAAGTGG 
AAGGATGGAGTTCTTCTGGACAATTTTAAAACCGAATGATGCAATCAACTTCGAGAGTAATGG 
AAATTTCATTGCTCCAGAATATGCATACAAAATTGTCAAGAAAGGGGACTCAACAATTATGAA 
AAGTGAATTGGAATATGGTAACTGCAACACCAAGTGTCAAACTCCAATGGGGGCGATAAACTC 
TAGTATGCCATTCCACAATATACACCCTCTCACCATCGGGGAATGCCCCAAATATGTGAAATC 
AAACAGATTAGTCCTTGCGACTGGGCTCAGAAATAGCCCTCAAAGAGAGAGAAGAAGAAAAAA 
GAGGGGATTATTTGGAGCTATAGCAGGTTTTATAGAGGGAGGATGGCAGGGAATGGTAGATGG 
TTGGTATGGGTACCACCATAGCAATGAGCAGGGGAGTGGGTACGCTGCAGACAAAGAATCCAC 
TCAAAAGGCAATAGATGGAGTCACCAATAAGGTCAACTCGATCATTGACAAAATGAACACTCA 
GTTTGAGGCCGTTGGAAGGGAATTTAACAATTTAGAAAGGAGAATAGAGAATTTAAACAAGAA 
GATGGAAGACGGGTTCCTAGATGTCTGGACTTATAATGCTGAACTTCTGGTTCTCATGGAAAA 
TGAGAGAACTCTAGACTTCCATGACTCAAATGTCAAGAACCTTTACGACAAGGTCCGACTACA 
GCTTAGGGATAATGCAAAGGAGCTGGGTAACGGTTGTTTCGAGTTCTATCATAAATGTGATAA 
TGAATGTATGGAAAGTGTAAGAAACGGAACGTATGACTACCCGCAGTATTCAGAAGAAGCAAG 
ATTAAAAAGAGAGGAAATAAATGGAGTAAAATTGGAATCAATAGGAATTTACCAAATACTGTC 
AATTTATTCTACAGTGGCGAGTTCCCTAGCACTGGCAATCATGGTAGCTGGTCTATCCTTATG 
GATGTGCTCCAATGGGTCGTTACAATGCAGAATTGCATTGAAT 
12.2.3 VNMlPEV16B/2004 
ACAATAATGGAAAAGAACGTTACTGTTACACATGCCCAAGACATACTGGAAAAGACACACAAC 
GGGAAGCTCTGCGATCTAGATGGAGTGAAGCCTCTAATTTTGAGAGATTGTAGTGTAGCTGGA 
TGGCTCCTCGGAAACCCAATGTGTGACGAATTCATCAATGTGCCGGAATGGTCTTACATAGTG 
GAGAAGGCCAATCCAGTCAATGACCTCTGTTACCCAGGGGATTTCAATGACTATGAAGAATTG 
AAACACCTATTGAGCAGAATAAACCATTTTGAGAAAATTCAGATCATCCCCAAAAGTTCTTGG 
TCCAGTCATGAAGCCTCATTAGGGGTGAGCTCAGCATGTCCATACCAGGGAAAGTCCTCCTTT 
TTCAGAAATGTGGTATGGCTTATCAAAAAGAACAGTACATACCCAACAATAAAGAGGAGCTAC 
AATAATACCAACCAAGAAGATCTTTTGGTAATGTGGGGGATTCACCATCCTAATGATGCGGCA 
GAGCAGACAAAGCTCTATCAAAACCCAACCACCTATATTTCCGTTGGGACATCAACACTAAAC 
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CAGAGATTGGTACCAAGAATAGCTACTAGATCCAAAGTAAACGGGCAAAGTGGGAGGATGGAG 
TTCTTCTGGACAATTTTAAAACCGAATGATGCAATCAACTTCGAGAGTAATGGAAATTTCATT 
GCTCCAGAATATGCATACAAAATTGTCAAGAAAGGGGACTCAACAATTATGAAAAGTGAATTG 
GAATATGGTAACTGCAACACCAAGTGTCAAACTCCAATGGGGGCGATAAACTCTAGTATGCCA 
TTCCACAATATACACCCTCTCACCATCGGGGAATGCCCCAAATATGTGAAATCAAACAGATTA 
GTCCTTGCGACTGGGCTCAGAAATAGCCCTCAAAGAGAGAGAAGAAGAAAAAAGAGAGGATTA 
TTTGGAGCTATAGCAGGTTTTATAGAGGGAGGATGGCAGGGAATGGTAGATGGTTGGTATGGG 
TACCACCATAGCAATGAGCAGGGGAGTGGGTACGCTGCAGACAAAGAATCCACTCAAAAGGCA 
ATAGATGGAGTCACCAATAAGGTCAACTCGATCATTGACAAAATGAACACTCAGTTTGAGGCC 
GTTGGAAGGGAATTTAACAACTTAGAAAGGAGAATAGAGAATTTAAACAAGAAGATGGAAGAC 
GGGTTCCTAGATGTCTGGACTTATAATGCTGAACTTCTGGTTCTCATGGAAAATGAGAGAACT 
CTAGACTTTCATGACTCAAATGTCAAGAACCTTTACGACAAGGTCCGACTACAGCTTAGAGAT 
AATGCAAAGGAGCTGGGTAACGGTTGTTTCGAGTTCTATCATAAATGTGATAATGAATGTATG 
GAAAGTGTAAGAAACGGAACGTATGACTACCCGCAGTATTCAGAAGAAGCAAGATTAAAAAGA 
GAGGAAATAAGTGGAGTAAAATTGGAATCAATAGGAATTTACCAAATACTGTCAATTTATTCT 
ACAGTGGCGAGTTCC 
12.2.4 VNMlPEV16C/2004 
ACAATAATGGAAAAGAACGTTACTGTTACACATGCCCAAGACATACTGGAAAAGACACACAAC 
GGGAAGCTCTGCGATCTAGATGGAGTGAAGCCTCTAATTTTGAGAGATTGTAGTGTAGCTGGA 
TGGCTCCTCGGAAACCCAATGTGTGACGAATTCATCAATGTGCCGGAATGGTCTTACATAGTG 
GAGAAGGCCAATCCAGTCAATGACCTCTGTTACCCAGGGGATTTCAATGACTATGAAGAATTG 
AAACACCTATTGAGCAGAATAAACCATTTTGAGAAAATTCAGATCATCCCCAAAAGTTCTTGG 
TCCAGTCATGAAGCCTCATTAGGGGTGAGCTCAGCATGTCCATACCAGGGAAAGTCCTCCTTT 
TTCAGAAATGTGGTATGGCTTATCAAAAAGAACAGTACATACCCAACAATAAAGAGGAGCTAC 
AATAATACCAACCAAGAAGATCTTTTGGTAATGTGGGGGATTCACCATCCTAATGATGCGGCA 
GAGCAGACAAAGCTCTATCAAAACCCAACCACCTATATTTCCGTTGGGACATCAACACTAAAC 
CAGAGATTGGTACCAAGAATAGCTACTAGATCCAAAGTAAACGGGCAAAGTGGGAGGATGGAG 
TTCTTCTGGACAATTTTAAAACCGAATGATGCAATCAACTTCGAGAGTAATGGAAATTTCATT 
GCTCCAGAATATGCATACAAAATTGTCAAGAAAGGGGACTCAACAATTATGAAAAGTGAATTG 
GAATATGGTAACTGCAACACCAAGTGTCAAACTCCAATGGGGGCGATAAACTCTAGTATGCCA 
TTCCACAATATACACCCTCTCACCATCGGGGAATGCCCCAAATATGTGAAATCAAACAGATTA 
GTCCTTGCGACTGGGCTCAGAAATAGCCCTCAAAGAGAGAGAAGAAGAAAAAAGAGAGGATTA 
TTTGGAGCTATAGCAGGTTTTATAGAGGGAGGATGGCAGGGAATGGTAGATGGTTGGTATGGG 
TACCACCATAGCAATGAGCAGGGGAGTGGGTACGCTGCAGACAAAGAATCCACTCAAAAGGCA 
ATAGATGGAGTCACCAATAAGGTCAACTCGATCATTGACAAAATGAACACTCAGTTTGAGGCC 
GTTGGAAGGGAATTTAACAACTTAGAAAGGAGAATAGAGAATTTAAACAAGAAGATGGAAGAC 
GGGTTCCTAGATGTCTGGACTTATAATGCTGAACTTCTGGTTCTCATGGAAAATGAGAGAACT 
CTAGACTTTCATGACTCAAATGTCAAGAACCTTTACGACAAGGTCCGACTACAGCTTAGAGAT 
AATGCAAAGGAGCTGGGTAACGGTTGTTTCGAGTTCTATCATAAATGTGATAATGAATGTATG 
GAAAGTGTAAGAAACGGAACGTATGACTACCCGCAGTATTCAGAAGAAGCAAGATTAAAAAGA 
GAGGAAATAAGTGGAGTAAAATTGGAATCAATAGGAATTTACCAAATACTGTCAATTTATTCT 
ACAGTGGCGAGTTCC 
12.2.5 VNMlPEV16RJ2004 
ACAATAATGGAAAAGAACGTTACTGTTACACATGCCCAAGACATACTGGAAAAGACACACAAC 
GGGAAGCTCTGCGATCTAGATGGAGTGAAGCCTCTAATTTTGAGAGATTGTAGTGTAGCTGGA 
193 
TGGCTCCTCGGAAACCCAATGTGTGACGAATTCATCAATGTGCCGGAATGGTCTTACATAGTG 
GAGAAGGCCAATCCAGTCAATGACCTCTGTTACCCAGGGGATTTCAATGACTATGAAGAATTG 
AAACACCTATTGAGCAGAATAAACCATTTTGAGAAAATTCAGATCATCCCCAAAAGTTCTTGG 
TCCAGTCATGAAGCCTCATTAGGGGTGAGCTCAGCATGTCCATACCAGGGAAAGTCCTCCTTT 
TTCAGAAATGTGGTATGGCTTATCAAAAAGAACAGTACATACCCAACAATAAAGAGGAGCTAC 
AATAATACCAACCAAGAAGATCTTTTGGTAATGTGGGGGATTCACCATCCTAATGATGCGGCA 
GAGCAGACAAAGCTCTATCAAAACCCAACCACCTATATTTCCGTTGGGACATCAACACTAAAC 
CAGAGATTGGTACCAAGAATAGCTACTAGATCCAAAGTAAACGGGCAAAGTGGGAGGATGGAG 
TTCTTCTGGACAATTTTAAAACCGAATGATGCAATCAACTTCGAGAGTAATGGAAATTTCATT 
GCTCCAGAATATGCATACAAAATTGTCAAGAAAGGGGACTCAACAATTATGAAAAGTGAATTG 
GAATATGGTAACTGCAACACCAAGTGTCAAACTCCAATGGGGGCGATAAACTCTAGTATGCCA 
TTCCACAATATACACCCTCTCACCATCGGGGAATGCCCCAAATATGTGAAATCAAACAGATTA 
GTCCTTGCGACTGGGCTCAGAAATAGCCCTCAAAGAGAGAGAAGAAGAAAAAAGAGAGGATTA 
TTTGGAGCTATAGCAGGTTTTATAGAGGGAGGATGGCAGGGAATGGTAGATGGTTGGTATGGG 
TACCACCATAGCAATGAGCAGGGGAGTGGGTACGCTGCAGACAAAGAATCCACTCAAAAGGCA 
ATAGATGGAGTCACCAATAAGGTCAACTCGATCATTGACAAAATGAACACTCAGTTTGAGGCC 
GTTGGAAGGGAATTTAACAACTTAGAAAGGAGAATAGAGAATTTAAACAAGAAGATGGAAGAC 
GGGTTCCTAGATGTCTGGACTTATAATGCTGAACTTCTGGTTCTCATGGAAAATGAGAGAACT 
CTAGACTTTCATGACTCAAATGTCAAGAACCTTTACGACAAGGTCCGACTACAGCTTAGAGAT 
AATGCAAAGGAGCTGGGTAACGGTTGTTTCGAGTTCTATCATAAATGTGATAATGAATGTATG 
GAAAGTGTAAGAAACGGAACGTATGACTACCCGCAGTAT TCAGAAGAAGCAAGAT TAAAAAGA 
GAGGAAATAAGTGGAGTAAAATTGGAATCAATAGGAATTTACCAAATACTGTCAATTTATTCT 
ACAGTGGCGAGTTCC 
12.2.6 AlChickenNNMJC13/2006(B5Nl) 
AGAGCAGGTTGACACAATAATGGAAAAGAACGTTACTGTTACACATGCCCAAGACATACTGGA 
AAAGACACATAACGGGAAGCTCTGCGATCTAGATGGAGTGAAGCCTCTGATTTTGAGAGATTG 
TAGTGTAGCTGGATGGCTCCTCGGAAACCCAATGTGTGACGAATTCATCAATGTGCCGGAATG 
GTCTTACATAGTGGAGAAGGCCAATCCAGTCAATGACCTCTGTTATCCAGGGGATTTCAATGA 
CTATGAAGAATTGAAACACCTATTGAGCAGAATAAACCATTTTGAGAAAATTCAGATCATCCC 
CAAAAGTTCTTGGTCCAGTCATGAAGCCTCATTGGGGGTGAGCGCAGCATGTCCATACCAGGG 
AAAGTCCTCCTTTTTCAGGAATGTGGTATGGCTTATCAAAAAGAACAGTACATACCCAACAAT 
AAAGAGGAGCTACAATAATACCAACCAAGAAGATCTTTTGGTAATGTGGGGGATCCACCATCC 
TAATGATGCGGCAGAGCAGACAAAGCTCTATCAAAACCCAACCACCTATATTTCCGTTGGGAC 
ATCAACACTAAACCAGAGATTGGTACCAAGAATAGCTACTAGATCCAAAGTAAACGGGCAAAG 
TGGGAGGATGGAGTTCTTCTGGACAATTTTAAAACCGAATGATGCAATCAACTTCGAGAGTAA 
TGGAAATTTCATTGCTCCAGAATATGCATACAAAATTGTCAAGAAAGGGGACTCAACAATTAT 
GAAAAGTGAATTGGAATATGGTAATTGCAACACCAAGTGTCAAACTCCAATGGGGGCGATAAA 
CTCTAGTATGCCATTCCACAATATACATCCTCTCACCATCGGGGAATGCCCCAAATATGTGAA 
ATCAAACAGATTAGTCCTTGCGACTGGGCTCAGAAATAGCCCTCAAAGAGAGAGAAGAAGAAA 
AAAGAGAGGATTATTTGGAGCTATAGCAGGTTTTATAGAGGGAGGATGGCAGGGAATGGTAGA 
TGGTTGGTATGGGTACCATCATAGCAATGAGCAGGGGAGTGGGTACGCTGCAGACAAAGAATC 
CACTCAAAAGGCTATAGATGGAGTCACCAATAAGGTCAACTCGATCATTGACAAAATGAACAC 
TCAGTTTGAGGCCGTTGGAAGGGAATTTAACAACTTAGAAAGGAGAATAGAGAATTTAAACAA 
GAAGATGGAAGACGGGTTCCTAGATGTCTGGACTTATAATGCTGAACTTCTGGTTCTCATGGA 
AAATGAGAGAACTCTAGACTTCCATGACTCAAATGTCAAGAACCTTTACGACAAGGTCCGACT 
ACAGCTTAGGGATAATGCAAAGGAGCTGGGTAACGGTTGTTTCGAGTTCTATCACAAATGTGA 
TAATGAATGTATGGAAAGTGTGAGAAACGGGACGTATGACTACCCGCAGTATTCAGAAGAAGC 
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AAGATTAAAAAGAGAGGAAATAAGTGGAGTAAAATTGGAATCAATAGGAATTTACCAAATACT 
GTCAATTTATTCTACAGTGGCGTAGT 
12.2.7 AlCbickenNNMlC22/2006 (HSN1) 
ATGGAGAAAATAGTGCTTCTTTTTGCGATAGTCAGTCTTGTTAAAAGTGATCAGATTTGCATT 
GGTTACCATGCAAACAACTCGACAGAGCAGGTTGACACAATAATGGAAAAGAACGTTACTGTT 
ACACATGCCCAAGACATACTGGAAAAGACACATAACGGGAAGCTCTGCGATCTAGATGGAGTG 
AAGCCTCTGATTTTGAGAGATTGTAGTGTAGCTGGATGGCTCCTCGGAAACCCAATGTGTGAC 
GAATTCATCAATGTGCCGGAATGGTCTTACATAGTGGAGAAGGCCAATCCAGTCAATGACCTC 
TGTTATCCAGGGGATTTCAATGACTATGAAGAATTGAAACACCTATTGAGCAGAATAAACCAT 
TTTGAGAAAATTCAGATCATCCCCAAAAGTTCTTGGTCCAGTCATGAAGCCTCATTGGGGGTG 
AGCGCAGCATGTCCATACCAGGGAAAGTCCTCCTTTTTCAGGAATGTGGTATGGCTTATCAAA 
AAGAACAGTACATACCCAACAATAAAGAGGAGCTACAATAATACCAACCAAGAAGATCTTTTG 
GTAATGTGGGGGATCCACCATCCTAATGATGCGGCAGAGCAGACAAAGCTCTATCAAAACCCA 
ACCACCTATATTTCCGTTGGGACATCAACACTAAACCAGAGATTGGTACCAAGAATAGCTACT 
AGATCCAAAGTAAACGGGCAAAGTGGGAGGATGGAGTTCTTCTGGACAATTTTAAAACCGAAT 
GATGCAATCAACTTCGAGAGTAATGGAAATTTCATTGCTCCAGAATATGCATACAAAATTGTC 
AAGAAAGGGGACTCAACAATTATGAAAAGTGAATTGGAATATGGTAATTGCAACACCAAGTGT 
CAAACTCCAATGGGGGCGATAAACTCTAGTATGCCATTCCACAATATACATCCTCTCACCATC 
GGGGAATGCCCCAAATATGTGAAATCAAACAGATTAGTCCTTGCGACTGGGCTCAGAAATAGC 
CCTCAAAGAGAGAGAAGAAGAAAAAAGAGAGGATTATTTGGAGCTATAGCAGGTTTTATAGAG 
GGAGGATGGCAGGGAATGGTAGATGGTTGGTATGGGTACCATCATAGCAATGAGCAGGGGAGT 
GGGTACGCTGCAGACAAAGAATCCACTCAAAAGGCTATAGATGGAGTCACCAATAAGGTCAAC 
TCGATCATTGACAAAATGAACACTCAGTTTGAGGCCGTTGGAAGGGAATTTAACAACTTAGAA 
AGGAGAATAGAGAATTTAAACAAGAAGATGGAAGACGGGTTCCTAGATGTCTGGACTTATAAT 
GCTGAACTTCTGGTTCTCATGGAAAATGAGAGAACTCTAGACTTCCATGACTCAAATGTCAAG 
AACCTTTACGACAAGGTCCGACTACAGCTTAGGGATAATGCAAAGGAGCTGGGTAACGGTTGT 
TTCGAGTTCTATCACAAATGTGATAATGAATGTATGGAAAGTGTGAGAAACGGGACGTATGAC 
TACCCGCAGTATTCAGAAGAAGCAAGATTAAAAAGAGAGGAAATAAGTGGAGTAAAATTGGAA 
TCAATAGGAATTTACCAAATACTGTCAATTTATTCTACAGTGGCGAGTTCCCTAGCACTGGCA 
ATCATGGTAGCTGGTCTATCCTTATGGATGTGCTCCAATGGGTCGTTACAATGCAAAATTTGC 
ATTTAAATTTGTGAGTTCAGATTGTAGTTAAAACACAA 
12.2.8 ANNMI1S/2007(HSN1) 
ATGGAGAAAATAGTGCTTCTTCTTGCAATAATCAGCCTTGTTAAAAGTGATCAGATTTGCATT 
GGTTACCATGCAAACAACTCGACAGAGCAGGTTGACACAATAATGGAAAAGAACGTTACTGTT 
ACACATGCTCAAGATATACTGGAAAAGACACACAACGGGAAGCTCTGCGATCTAGATGGAGTG 
AAGCCTCTGATTTTAAGAGATTGTAGTGTAGCTGGATGGCTCCTCGGAAACCCAATGTGTGAT 
GAATTCATCAATGTGCCGGAATGGTCTTACATAGTGGAGAAGGCCAACCCAGCCAATGACCTC 
TGTTACCCAGGGAATTTCAACGACTATGAAGAACTGAAACACCTATTGAGCAGGATAAACCAT 
TTTGAGAAAATTCAGATCATCCCCAAAAGTTCTTGGTCCGATCATGAAGCCTCATCAGGGGTG 
AGCTCAGCATGTCCATACCAGGGAGTGCCCTCCTTTTTCAGAAATGTGGTATGGCTTATCAAA 
AAGAACAATACATACCCAACAATAAAGAGAAGCTACAATAATACCAACCAGGAAGATCTTTTG 
ATACTGTGGGGGATTCATCATTCTAATGATGCAGCAGAGCAGACAAAGCTCTATCAAAACCCA 
ACCACCTATATTTCCGTTGGGACATCAACACTGAACCAGAGATTGGTACCAAAAATAGCTACT 
AGATCCAAAGTAAACGGGCAAAGTGGAAGGATGGATTTCTTCTGGACAATTTTAAAACCGAAT 
GATGCAATCAACTTCGAGAGTAATGGAAATTTCATTGCTCCAGAATATGCATACAAAATTGTC 
AAGAAAGGGGACTCGGCAATTATGAAAAGTGAGGTGGAGTATGGTAACTGCAACACCAAGTGT 
CAAACTCCAATAGGGGCGATAAACTCTAGTATGCCATTCCACAACATACACCCTCTCACCATC 
195 
GGGGAATGCCCCAAATATGTGAAATCAAACAAATTAGTCCTTGCGACTGGGCTCAGAAATAGT 
CCTCTAAGAGAAAGAAGAAGAAAAAGAGGACTATTTGGAGCTATAGCAGGTTTTATAGAGGG 
12.2.9 AlVNMJ28/2007(H5NI) 
ATGGAGAAAATAGTGCTTCTTCTTGCAATAATCAGCCTTGTTAAAAGTGATCAGATTTGCATT 
GGTTACCATGCAAACAACTCGACAGAGCAGGTTGACACAATAATGGAAAAGAACGTTACTGTT 
ACACATGCTCAAGATATACTGGAAAAGACACACAACGGGAAGCTCTGCGATCTAGATGGAGTG 
AAGCCTCTGATTTTAAGAGATTGTAGTGTAGCTGGATGGCTCCTCGGAAACCCAATGTGTGAT 
GAATTCATCAATGTGCCGGAATGGTCTTACATAGTGGAGAAGGCCAACCCAGCCAATGACCTC 
TGTTACCCAGGGAATTTCAACGACTATGAAGAACTGAAACACCTATTGAGCAGGATAAACCAT 
TTTGAGAAAATTCAGATCATCCCCAAAAGTTCTTGGTCCGATCATGAAGCCTCATCAGGGGTG 
AGCTCAGCATGTCCATACCAGGGAGTGCCCTCCTTTTTCAGAAATGTGGTATGGCTTATCAAA 
AAGAACAATACATACCCAACAATAAAGAGAAGCTACAATAATACCAACCAGGAAGATCTTTTG 
ATACTGTGGGGGATTCATCATTCTAATGATGCAGCAGAGCAGACAAAGCTCTATCAAAACCCA 
ACCACCTATATTTCCGTTGGGACATCAACACTGAACCAGAGATTGGTACCAAAAATAGCTACT 
AGATCCAAAGTAAACGGGCAAAGTGGAAGGATGGATTTCTTCTGGACAATTTTAAAACCGAAT 
GATGCAATCAACTTCGAGAGTAATGGAAATTTCATTGCTCCAGAATATGCATACAAAATTGTC 
AAGAAAGGGGACTCGGCAATTATGAAAAGTGAGGTGGAGTATGGTAACTGCAACACCAAGTGT 
CAAACTCCAATAGGGGCGATAAACTCTAGTATGCCATTCCACAACATACACCCTCTCACCATC 
GGGGAATGCCCCAAATATGTGAAATCAAACAAATTAGTCCTTGCGACTGGGCTCAGAAATAGT 
CCTCTAAGAGAAAGAAGAAGAAAAAGAGGACTATTTGGAGCTATAGCAGGTTTTATAGAGGGA 
GGAATGGCA 
12.2.10 A1VNM188/2007(H5NI) 
ATGGAGAAAATAGTGCTTCTTCTTGCAATAATCAGCCTTGTTAAAAGTGATCAGATTTGCATT 
GGTTACCATGCAAACAACTCGACAGAGCAGGTTGACACAATAATGGAAAAGAACGTTACTGTT 
ACACATGCTCAAGATATACTGGAAAAGACACACAACGGGAAGCTCTGCGATCTAGATGGAGTG 
AAGCCTCTGATTTTAAGAGATTGTAGTGTAGCTGGATGGCTCCTCGGAAACCCAATGTGTGAT 
GAATTCATCAATGTGCCGGAATGGTCTTACATAGTGGAGAAGGCCAACCCAGCCAATGACCTC 
TGTTACCCAGGAAATTTCAACGACTATGAAGAACTGAAACACCTATTGAGCAGGATAAACCAT 
TTTGAGAAAATTCAGATCATCCCCAAAAGTTCTTGGTCCGATCATGAAGCCTCATCAGGGGTG 
AGCTCAGCATGTCCATACCAGGGAGTGCCCTCCTTTTTCAGAAATGTGGTATGGCTTATCAAA 
AAGAACAATACATACCCAACAATAAAGAGAAGCTACAATAATACCAACCAGGAAGATCTTTTG 
ATACTGTGGGGGATTCATCATTCTAATGATGCAGCAGAGCAGACAAAGCTCTATCAAAACCCA 
ACCACCTATATTTCCGTTGGGACATCAACACTGAACCAGAGATTGGTACCAAAAATAGCTACT 
AGATCCAAAGTAAACGGGCAAAGCGGAAGGATGGATTTCTTCTGGACAATTTTAAAACCGAAT 
GATGCAATCAACTTCGAGAGTAATGGAAATTTCATTGCTCCAGAATATGCATACAAAATTGTC 
AAGAAAGGGGACTCGGCAATTATGAAAAGTGAGGTGGAGTATGGTAACTGCAACACCAAGTGT 
CAAACTCCAATAGGGGCGATAAACTCTAGTATGCCATTCCACAACATACACCCTCTCACCATC 
GGGGAATGCCCCAAATATGTGAAATCAAACAAATTAGTCCTTGCGACTGGACTCAGAAATAGT 
CCTCTAAGAGAAAGAAGAAGAAAAAGAGGACTATTTGGAGCTATAGCAGGTTTTATAGA 
12.2.11 ANNMlI23/2007(HSN1) 
GTGATCAGATTTGCATTGGTTACCATGCAAACAACTCGACAGAGCAGGTTGACACAATAATGG 
AAAAGAACGTTACTGTTACACATGCTCAAGATATACTGGAAAAGACACACAACGGGAAGCTCT 
GCGATCTAGATGGAGTGAAGCCTCTGATTTTAAGAGATTGTAGTGTAGCTGGATGGCTCCTCG 
GAAACCCAATGTGTGATGAATTCATCAATGTGCCGGAATGGTCTTACATAGTGGAGAAGGCCA 
ACCCAGCCAATGACCTCTGTTACCCAGGGAATTTCAACGACTATGAAGAACTGAAACACCTAT 
TGAGCAGGATAAACCATTTTGAGAAAATTCAGATCATCCCCAAAAGTTCTTGGTCCGATCATG 
AAGCCTCATCAGGGGTGAGCTCAGCATGTCCATACCAGGGAGTGCCCTCCTTTTTCAGAAATG 
196 
TGGTATGGCTTATCAAAAAGAACAATACATACCCAACAATAAAGAGAAGCTACAATAATACCA 
ACCAGGAAGATCTTTTGATACTGTGGGGGATTCATCATTCTAATGATGCAGCAGAGCAGACAA 
AGCTCTATCAAAACCCAACCACCTATATTTCCGTTGGGACATCAACACTGAACCAGAGATTGG 
TACCAAAAATAGCTACTAGATCCAAAGTAAACGGGCAAAGTGGAAGGATGGATTTCTTCTGGA 
CAATTTTAAAACCGAATGATGCAATCAACTTCGAGAGTAATGGAAATTTCATTGCTCCAGAAT 
ATGCATACAAAATTGTCAAGAAAGGGGACTCGGCAATTATGAAAAGTGAGGTGGAGTATGGTA 
ACTGCAACACCAAGTGTCAAACTCCAATAGGGGCGATAAACTCTAGTATGCCATTCCACAACA 
TACACCCTCTCACCATCGGGGAATGCCCCAAATATGTGAAATCAAACAAATTAGTCCTTGCGA 
CTGGGCTCAGAAATAGTCCTCTAAGAGAAAGAAGAAGAAAAAGAGGACTAT 
12.2.12A1DuckILA404/2006(H4N6) 
CATGCTATCAATTGTGATCTTGTTTCTGCTCGTAGCAGAAAATTCCTCCCAAAACTACACAGG 
AAATCCTGTGATATGCATGGGACATCATGCTGTTGCCAATGGGACCATGGTGAAGACCCTAAC 
CGATGACCAAATAGAAGTGGTCACTGCACAAGAATTGGTAGAATCGCAGAACCTTCCAGAATT 
GTGCCCAAGTCCCCTAAGGCTAATTGATGGCCAGACTTGTGACATCATTAATGCAGCCTTAGG 
GAGCCCAGGATGTGATCACTTGAATGGTGCAGAATGGGACGTATTCATAGAAAGACCCAATGC 
AATAGACACCTGTTACCCGTTTGATGTGCCAGATTACCAAAGCCTGAGAAGCATACTTGCTAA 
CAATGGGAAGTTCGAATTCATTGCCGAAGATTTCCAATGGACCACAGTGAAACAAAATGGGAA 
ATCTGGAGCCTGCAAGAGAGCGAATGTGAATGATTTCTTTAACAGGCTAAATTGGCTGGTGAA 
GTCAGATGGAAATGCATATCCTCTGCAGAACTTGACAAAAGTAAATAACGGTGATTATGCAAG 
GCTTTACATTTGGGGAGTTCATCACCCTTCGACAGATACAGAGCAAACTAATCTATATAAAAA 
TAACCCTGGAAGAGTCACTGTTTCTACTAAAACTACTCAAACAAGTGTAGTCCCCAACATTGG 
TAGTCGACCCTGGGTGAGAGGACAGAGCGGCAGAATAAGTTTCTACTGGACTATTGTAGAGCC 
TGGAGACTTAATAGTTTTCAACACAATAGGGAATCTAATAGCCCCAAGAGGGCATTACAAGCT 
AAACAACCTGAAAAAGAGCACAATTTTGAACACCGCGGTTCCCATAGGTTCATGTGTCAGCAA 
GTGCCACACGGACAAAGGCTCCCTCTCCACGACAAAGCCTTTCCAGAATATCTCAAGAATAGC 
AATTGGAGACTGCCCCAAGTATGTCAAACAAGGCTCTTTAAAACTTGCAACAGGAATGAGGAA 
CATTCCTGAAAAGGCATCGAGAGGGCTCTTTGGAGCAATAGCCGGGTTCATAGAAAATGGCTG 
GCAAGGCCTGATTGATGGTTGGTACGGGTTCAGACATCAGAATGCAGAAGGAACAGGAACAGC 
AGCAGACCTCAAGTCCACTCTGGCAGCCATTGATCAGATCAATGGGAAGCTAAATCGTCTTAT 
CGAGAAAACAAATGAGAAATAT CATCAAATCGAAAAGGAAT TCGAACAGGTTGAAGGAAGGAT 
TCAAGACCTGGAGAAATATGTTGAGGATACAAAGATTGATTTGTGGTCATATAATGCAGAACT 
ATTGGTTGCACTGGAAAATCAGCACACCATAGATGTAACTGACTCGGAAATGAACAAACTTTT 
TGAGAGAGTGAGACGCCAACTCAGAGAAAATGCTGAGGACAAAGGGAATGGATGTTTCGAAAT 
ATTCCACAAGTGTGATAATAGTTGCATTGAGAGCATTCGAAATGGAACTTATAATCACGACAT 
TTATAGAGATGAGGCAATCAACAATCGATTCCAAATCCAGGGAGTTAAATTGACCCAAGGATA 
CAAGGACATCATTCTTTGGATTTCATTCTCCATATCATGCTTTTTGCTCGTTGCACTACTTTT 
AGCCTTCATTTTGTGGGCTG 
12.1.13A DuckILA409/1006(H4N6) 
ATGCTATCAATTGTGATCTTGTTTCTGCTCGTAGCAGAAAATTCCTCCCAAAACTACACAGGA 
AATCCTGTGATATGCATGGGACATCATGCTGTTGCCAATGGGACCATGGTGAAGACCCTAACC 
GATGACCAAATAGAAGTGGTCACTGCACAAGAATTGGTAGAATCGCAGAACCTTCCAGAATTG 
TGCCCAAGTCCCCTAAGGCTAATTGATGGCCAGACTTGTGACATCATTAATGCAGCCTTAGGG 
AGCCCAGGATGTGATCACTTGAATGGTGCAGAATGGGACGTATTCATAGAAAGACCCAATGCA 
ATAGACACCTGTTACCCGTTTGATGTGCCAGATTACCAAAGCCTGAGAAGCATACTTGCTAAC 
AATGGGAAGTTCGAATTCATTGCCGAAGATTTCCAATGGACCACAGTGAAACAAAATGGGAAA 
TCTGGAGCCTGCAAGAGAGCGAATGTGAATGATTTCTTTAACAGGCTAAATTGGCTGGTGAAG 
TCAGATGGAAATGCATATCCTCTGCAGAACTTGACAAAAGTAAATAACGGTGATTATGCAAGG 
197 
CTTTACATTTGGGGAGTTCATCACCCTTCGACAGATACAGAGCAAACTAATCTATATAAAAAT 
AACCCTGGAAGAGTCACTGTTTCTACTAAAACTACTCAAACAAGTGTAGTCCCCAACATTGGT 
AGTCGACCCTGGGTGAGAGGACAGAGCGGCAGAATAAGTTTCTACTGGACTATTGTAGAGCCT 
GGAGACTTAATAGTTTTCAACACAATAGGGAATCTAATAGCCCCAAGAGGGCATTACAAGCTA 
AACAACCTGAAAAAGAGCACAATTTTGAACACCGCGGTTCCCATAGGTTCATGTGTCAGCAAG 
TGCCACACGGACAAAGGCTCCCTCTCCACGACAAAGCCTTTCCAGAATATCTCAAGAATAGCA 
ATTGGAGACTGCCCCAAGTATGTCAAACAAGGCTCTTTAAAACTTGCAACAGGAATGAGGAAC 
ATTCCTGAAAAGGCATCGAGAGGGCTCTTTGGAGCAATAGCCGGGTTCATAGAAAATGGCTGG 
CAAGGCCTGATTGATGGTTGGTACGGGTTCAGACATCAGAATGCAGAAGGAACAGGAACAGCA 
ACAGATCTCAAGTCCACTCAGGCAGCCATTGATCAGATCAATGGGAAGCTAAATCGTCTTATC 
GAGAAAACAAATGAGAAATATCATCAAATCGAAAAGGAATTCGAACAGGTTGAAGGAAGGATT 
CAAAACCTAGAAGTGGTCCTTGAGGATACAAAGATTGATTTATGGTCATATAAAGCAGAACTA 
TTGGTTGCACTGGAAAATCAGCACACCATAGATGTAACTGACTCGGAAATGAACAAACTTTTT 
GAGAGAGTGAGACGCCAACTCAGAGAAAATGCTGAGGACAAAGGGAATGGATGTTTCGAAATA 
TTCCACAAGTGTGATAATAGTTGCATTGAGAGCATTCGAAATGGAACTTATAATCACGACATT 
TATAGAGATGAGGCAATCAACAATCGATTCCAAATCCAGGGAGTTAAATTGACCCAAGGATAC 
AAGGACATCATTCTTTGGATTTCATTCTCCATATCATGCTTTTTGCTCGTTGCCTTACTTTTA 
GCCTTCATTTTGTGGGC 
12.2. 14A1DuckILA42712006(H4N6) 
TATCAATTGTGATCTTGTTTCTGCTCGTAGCAGAAAATTCCTCCCAAAACTACACAGGAAATC 
CTGTGATATGCATGGGACATCATGCTGTTGCCAATGGGACCATGGTGAAGACCCTAACCGATG 
ACCAAATAGAAGTGGTCACTGCACAAGAATTGGTAGAATCGCAGAACCTTCCAGAATTGTGCC 
CAAGTCCCCTAAGGCTAATTGATGGCCAGACTTGTGACATCATTAATGCAGCCTTAGGGAGCC 
CAGGATGTGATCACTTGAATGGTGCAGAATGGGACGTATTCATAGAAAGACCCAATGCAATAG 
ACACCTGTTACCCGTTTGATGTGCCAGATTACCAAAGCCTGAGAAGCATACTTGCTAACAATG 
GGAAGTTCGAATTCATTGCCGAAGATTTCCAATGGACCACAGTGAAACAAAATGGGAAATCTG 
GAGCCTGCAAGAGAGCGAATGTGAATGATTTCTTTAACAGGCTAAATTGGCTGGTGAAGTCAG 
ATGGAAATGCATATCCTCTGCAGAACTTGACAAAAGTAAATAACGGTGATTATGCAAGGCTTT 
ACATTTGGGGAGTTCATCACCCTTCGACAGATACAGAGCAAACTAATCTATATAAAAATAACC 
CTGGAAGAGTCACTGTTTCTACTAAAACTACTCAAACAAGTGTAGTCCCCAACATTGGTAGTC 
GACCCTGGGTGAGAGGACAGAGCGGCAGAATAAGTTTCTACTGGACTATTGTAGAGCCTGGAG 
ACTTAATAGTTTTCAACACAATAGGGAATCTAATAGCCCCAAGAGGGCATTACAAGCTAAACA 
ACCTGAAAAAGAGCACAATTTTGAACACCGCGGTTCCCATAGGTTCATGTGTCAGCAAGTGCC 
ACACGGACAAAGGCTCCCTCTCCACGACAAAGCCTTTCCAGAATATCTCCCGAATAGCAATTG 
GAGACTGCCCCAAGTATGTCAAACAAGGCTCTTTAAAACTTGCAACAGGAATGAGGAACATTC 
CTGAAAAGGCATCGAGAGGGCTCTTTGGAGCAATAGCCGGGTTCATAGAAAATGGCTGGCAAG 
GCCTGATTGATGGTTGGTACGGGTTCAGACATCAGAATGCAGAAGGAACAGGAACAGCAGCAG 
ACCTCAAGTCCACTCAGGCAGCCATTGATCAGATCAATGGGAAGCTAAATCGTCTTATCGAGA 
AAACAAATGAGAAATATCATCAAATCGAAAAGGAATTCGAACAGGTTGAAGGAAGGATTCAAG 
ACCTGGAGAAATATGTTGAGGATACAAAGATTGATTTGTGGTCATATAATGCAGAACTATTGG 
TTGCACTGGAAAATCAGCACACCATAGATGTAACTGACTCGGAAATGAACAAACTTTTTGAGA 
GAGTGAGACGCCAACTCAGAGAAAATGCTGAGGACAAAGGGAATGGATGTTTCGAAATATTCC 
ACAAGTGTGATAATAGTTGCATTGAGAGCATTCGAAATGGAACTTATAATCACGACATTTATA 
GAGATGAGGCAATCAACAATCGATTCCAAATCCAGGGAGTTAAATTGACCCAAGGATACAAGG 
ACATCATTCTTTGGATTTCATTCTCCATATCATGCTTTTTGCTCGTTGCACTACTTTTAGCCT 
TCATTTTGTGGGCTG 
198 
12.2.15A1DuckIDT 416/2006(H3N8) 
CAGCAAAAGCAGGGGATACTTTCATTAACCATGAAGGCCATTATTGCTTTAAGCTGCATTTTC 
TGTCTGGCTTTCAGTCAGGACCTTCCAGGGAATGACAACAATACAGCAACACTGTGTTTGGGA 
CATCATGCAGTACAGAATGGGACACTAGTGAAGACAATCACAGATGATCAGATTGAGGTGACT 
AATGCTACCGAATTGGTCCAAAGCTCTTCAACAGGGAAAATATGCAACAATCCTCACAAGATT 
CTTGATGGAAGGGATTGCACACTAGTAGATGCCCTGTTAGGGGATCCTCACTGTGATGTCTTT 
CAAGATGAAACATGGGACCTTTTTGTGGAACGAAGCAATGCTTTCAGCAATTGTTACCCATAT 
GATGTACCAGATTACGCATCCCTTCGATCCCTGATTGCATCATCAGGCACATTAGAGTTCATT 
ACAGAGGGTTTCACTTGGACCGGAGTGACTCAGAATGGAGGGAGCGGTGCTTGCAAAAGGGGA 
CCTGCTAATGGCTTCTTCAGTAGATTGAATTGGCTGACTAAATCAGGAAGTGCATACCCAGTG 
CTTAACGTGACTATGCCAAACAATGACAACTTTGACAAGCTGTACATCTGGGGAGTTCACCAT 
CCAAGTACAAATAGAGAACAAACTGACCTGTATGTCCAAGCATCAGGAAGAGTAACAGTTTCT 
ACCAGAAAAAGCCAACAGACCATAATCCCGAATATTGGATCTAGACCCTGGGTAAGGGGTCAG 
TCTGGCAGAATAAGCATCTATTGGACAATAGTCAAACCTGGGGATGTTCTGGTAATCAATAGT 
AATGGAAACCTAATAGCCCCTCGAGGTTATTTCAAGATGCGCATTGGGAAAAGCTCAATAATG 
AAATCAGATGCACCTATTGACACCTGCATTTCTGAATGCATCACTCCAAATGGGAGCATTCCC 
AATGACAAGCCCTTTCAAAATGTAAACAAGATAACATATGGAGCATGTCCCAAATATGTGAAG 
CAAAACACCCTGAAGTTGGCAACAGGRATGCGRAATATGCCTGAGAAACAAACCAGGGGCCTA 
TTCGGTGCAATAGCAGGTTTTATAGAAAATGGATGGGAAGGAATGATAGATGGTTGGTATGGA 
TTCCGGCATCAAAATTCTGAAGGCACAGGACAAGCAGCAGATCTAAAAAGCACTCAAGCGGCC 
ATTGACCAAATCAATGGGAAACTGAACAGAGTAATTGAAAAGACAAATGAAAAGTTCCACCAA 
ATAGAAAAGGAATTCTCCGAAGTAGAAGGGAGGATCCAGGACCTTGAGAAGTACGTTGAAGAC 
ACAAAGATAGATCTCTGGTCTTACAATGCAGAGCTTCTTGTTGCCCTGGAAAATCAGCACACA 
ATTGATTTGACTGATTCAGAAATGAACAAGCTGTTTGAAAAGACCAGGAGACAATTGAGGGAA 
AATGCTGAAGATATGGGCAATGGTTGTTTCAAAATATACCACAAATGTGACAATGCTTGCATA 
GAATCAATTAGAAACGGGACTTATGACCACGATATATATCGAGATGAGGCATTGAACAATCGG 
TTCCAGATCAAGGGTGTGGAGCTGAAATCTGGATATAAGGACTGGATCCTGTGGA 
12.2. 16A1DuckIDT51612006(H6Nl) 
CAGGAGCGAAAGCAGGGGAAAATGATTGCAATCATTGTAATAGCAATACTGGCTTCAGCCGGA 
AAATCAGACAAAATCTGTATTGGGTATCATGCCAACAACTCGACAACACAAGTAGATACAATA 
CTTGAGAAGAATATCACCGTCACACACTCAGTTGAATTGCTGGAAAATCAGAAGGAAGAAAGA 
TTCTGCAAGATTTTGAACAAGGCCCCTCTAGACTTGAGGGGATGCACCATAGAGGGTTGGATT 
TTAGGAAATCCTCAATGTGACCTACTGCTTGGTGACCAAAGCTGGTCATATATAGTGGAGAGG 
CCCACTGCTCAAAATGGGATTTGCTATCCAGGGGCTTTGAATGAAGTGGAAGAACTGAAGGCA 
CTTATTGGGTCAGGAGAAAGAGTAGAAAGATTTGAGATGTTCCCCAAAAGCACATGGGCAGGA 
GTAGACACGAATAGTGGGGTGACAAAGGCTTGCCCTTATAATAGTGGCTCATCTTTCTATAGA 
AACCTCCTATGGATAATAAAGACCAAGTCAGCAGCATATCCTGTAATTAAAGGAACTTACAAC 
AACACTGGAAATCAGCCAATTCTTTATTTCTGGGGTGTGCACCACCCTCCTGACACCAATGAA 
CAGAATACCTTGTATGGCTCTGGTGATAGATACGTTAGAATGGGAACCGAAAGCATGAATTTT 
GCTAAGGGTCCGGAAATTGCGGCAAGACCTGCTGTGAACGGTCAGAGAGGCAGGATTGATTAT 
TATTGGTCTGTTTTAAAACCAGGGGAAACCCTGAATGTGGAGTCTAATGGAAATTTAATTGCC 
CCTTGGTATGCATACAAATTTGTCAGCACAAATAACAAAGGAGCCGTCTTCAAATCAAATTTG 
CCAATAGAGAACTGTGATGCCACATGCCAGACTGTTGCAGGAGTCCT 
12.3 NA sequences 
12.3.1 VNMlCL2009-281200S 
GAGATTAAAATGAATCCAAATCAGAAGATAATAACCATGTATGGTAACCGGAATAGTTAGCTT 
AATGTTACAAGTTGGGAACATGATCTCAATATGGGTCAGTCATTCAATTAACACAGGGAATCA 
199 
ACACCAAGCTGAACCAATCAGCAATGCTAATTTTCTTACTGAGAAAGCTGTGGCTTCAGTAAA 
ATTAGCGGGCAATTCATCTCTTTGCCCCATTAACGGATGGGCTGTATACAGTAAGGACAACAG 
TATAAGGATCGGTTCCAAGGGGGATGTGTTTGTTATAAGAGAGCCGTTCATCTCCTGCTCCCA 
CTTGGAATGCAGAACTTTCTTTTTGACTCAGGGAGCCTTGCTGAATGACAAACACTCCAATGG 
GACTGTCAAAGACAGAAGCCCTCACAGAACACTAATGAGTTGTCCTGTGGGTGAGGCTCCCTC 
CCCATATAACTCAAGGTTTGAGTCTGTTGCTTGGTCAGCAAGTGCTTGCCATGATGGCACCAG 
TTGGTTGACAATTGGAATTTCTGGCCCAGACAATGGGGCTGTAGCTGTATTGAAATACAATGG 
CATAATAACAGACACTATCAAGAGTTGGAGGAACAACATACTGAGAACTCAAGAGTCTGAATG 
TGCATGTGTAAATGGCTCTTGCTTTACTGTAATGACTGACGGACCAAGTAATGGTCAGGCATC 
ACATAAGATCTTCAAAATGGAAAAAGGGAAAGTGGTTAAATCAGTCGAATTGGATGCTCCTAA 
TTATTACTATGAGGAATGCTCCTGTTATCCTGATGCCGGCGAAATCACATGTGTGTGCAGGGA 
TAATTGGCATGGTTCAAATCGGCCGTGGGTATCTTTCAATCAAAACTTGGAGTATCAAATAGG 
ATATATATGCAGTGGAGTTTTCGGAGACACTCCACGCCCCAATGATGGAACAGGTAGTTGTGG 
TCCGGTGTCCTCTAACGGGGCATATGGGGTAAAAGGGTTTTCATTTAAATACGGCAATGGTGT 
CTGGATCGGGAGAACCAAAAGCACTAATTCCAGGAGCGGCTTTGAAATGATTTGGGATCCAAA 
TGGGTGGACTGAAACGGACAGTAGCTTTTCAGTGAAACAAGATATCGTAGCAATAACTGATTG 
GTCAGGATATAGCGGGAGTTTTGTCCAGCATCCAGAACTGACAGGACTAGATTGCATAAGACC 
TTGTTTCTGGGTTGAGTTAATCAGAGGGCGGCCCAAAGAGAGCACAATTTGGACTAGTGGGAG 
CAGCATATCTTTTTGTGGTGTAAATAGTGACACTGTGGGTTGGTCTTGGCCAGACGGTGCTGA 
GTTGCCATTCACCATTGACAAGTAGTTGTTCCAAAAACTC 
12.3.2 VNMlCLl07-13/2005 
GAGATTAAAATGAATCCAAATCAGAAGATAATAACCATGTATGGTAACTGGAATAGTTAGCTT 
AATGTTACAAGTTGGGAACATGATCTCAATATGGGTCAGTCATTCAATTCACACAGGGAATCA 
ACACCAAGTTGAACCAATCAGCAATGCTAATTTTCTTACTGAGAAAGCTGTGGCTTCAGTAAA 
ATTAGCGGGCAATTCATCTCTTTGCCCCATTAACGGATGGGCTGTATACAGTAAGGACAACAG 
TATAAGGATCGGTTCCAAGGGGGATGTGTTTGTTATAAGAGAGCCGTTCATCTCATGCTCCCA 
CTTGGAATGCAGAACTTTCTTTTTGACTCAGGGAGCCTTGCTGAATGACAAACACTCCAATGG 
GACTGTCAAAGACAGAAGCCCTCACAGAGCACTAATGAGTTGTCCTGTGGGTGAGGCTCCCTC 
CCCATATAACTCAAGGTTTGAGTCTGTTGCTTGGTCAGCAAGTGCTTGCCATGATGGCACCAG 
TTGGTTGACAATTGGAATTTCTGGCCCAGACAATGGGGCTGTAGCTGTATTGAAATACAATGG 
CATAATAACAGACACTATCAAGAGTTGGAGGAACAACATACTGAGAACTCAAGAGTCTGAATG 
TGCATGTGTAAATGGCTCTTGCTTTACTGTAATGACTGACGGACCAAGTAATGGTCAGGCATC 
ACATAAGATCTTCAAAATGGAAAAAGGGAAAGTGGTTAAATCAGTCGAATTGGATGCTCCTAA 
TTATTACTATGAGGAATGCTCCTGTTATCCTGATGCCGGCGAAATCACATGTGTGTGCAGGGA 
TAATTGGCATGGTTCAAATCGGCCGTGGGTATCTTTCAATCAAAACTTGGAGTATCAAATAGG 
ATATATATGCAGTGGAGTTTTCGGAGACACTCCACGCCCCAATGATGGAACAGGTAGTTGTGG 
TCCGGTGTCCTCTAACGGGGCATATGGGGTAAAAGGGTTTTCATTTAAATACGGCAATGGTGT 
CTGGATCGGGAGAACCAAAAGCACTAATTCCAGGAGCGGCTTTGAAATGATTTGGGATCCAAA 
TGGGTGGACTGAAACGGACAGTAGCTTTTCAGTGAAACAAGATATCGTAGCAATAACTGATTG 
GTCAGGATATAGCGGGAGTTTTGTCCAGCATCCAGAACTGACAGGACTAGATTGCATAAGACC 
TTGTTTCTGGGTTGAGTTAATCAGAGGGCGGCCCAAAGAGAGCACAATTTGGACTAGTGGGAG 
CAGCATATCTTTTTGTGGTGTAAATAGTGACACTGTGGGTTGGTCTTGGCCAGACGGTGCTGA 
GTTGCCATTCACCATTGACAAGTAGTTGTTCCAAAAACTCCT 
200 
12.3.3 VNMlPEV16B/2004 
GGTAACTGGAATAGTTAGCTTAATGTTACAAGTTGGGAACATGATCTCAATATGGGTCAGTCA 
TTCAATTCACACAGGGAGTCAACACCAAGCTGAACCAATCAGCAATACTAATTTTCTTACTGA 
GAAAGCTGTGGCTTCAGTAAAATTAGCGGGCAATTCATCTCTTTGCCCCATTAACGGATGGGC 
TGTATACAGTAAGGACAACAGTATAAGGATCGGTTCCAAGGGGGATGTGTTTGTTATAAGAGA 
GCCGTTCATCTCATGCTCCCACTTGGAATGCAGAACTTTCTTTTTGACTCAGGGAGCCTTGCT 
GAATGACAAACACTCCAATGGGACTGTCAAAGACAGAAGCCCTCACAGAACATTAATGAGTTG 
TCCTGTGGGTGAGGCTCCCTCCCCATATAACTCAAGGTTTGAGTCTGTTGCTTGGTCAGCAAG 
TGCTTGCCATGATGGCACCAGTTGGTTGACAATTGGAATTTCTGGCCCAGACAATGGGGCTGT 
GGCTGTATTGAAATACAATGGCATAATAACAGACACTATCAAGAGTTGGAGGAACAACATACT 
GAGAACTCAAGAGTCTGAATGTGCATGTGTAAATGGCTCTTGCTTTACTGTAATGACTGACGG 
ACCAAGTAATGGTCAGGCATCACATAAGATCTTCAAAATGGAAAAAGGGAAAGTGGTTAAATC 
AGTCGAATTGGATGCTCCTAATTATCACTATGAGGAATGCTCCTGTTATCCTGATGCCGGCGA 
AATCACATGTGTGTGCAGGGATAATTGGCATGGCTCAAATCGGCCATGGGTATCTTTCAATCA 
AAACTTGGAGTATCAAATAGGATATATATGCAGTGGAGTTTTCGGAGACAATCCACGCCCCAA 
TGATGGAACAGGTAGTTGTGGTCCGGTGTCCTCTAACGGGGCATATGGGGTAAAAGGGTTTTC 
ATTTAAATACGGCAATGGTGTCTGGATCGGGAGAACCAAAAGCACTAATTCCAGGAGCGGCTT 
TGAAATGATTTGGGATCCAAATGGGTGGACTGAAACGGACAGTAGCTTTTCAGTGAAACAAGA 
TATCGTAGCAATAACTGATTGGTCAGGATATAGCGGGAGTTTTGTCCAGCATCCAGAACTGAC 
AGGACTAGATTGCATAAGACCTTGTTTCTGGGTTGAGTTGATCAGAGGGCGGCCCAAAGAGAG 
CACAATTTGGACTAGTGGGAGCAGCATATCTTTTTGTGGTGTAAATAGTGACACTGTGGGTTG 
GTCTTGGCCAGACGGTGCTGA 
12.3.4 VNMlPEV16C/2004 
GGTAACTGGAATAGTTAGCTTAATGTTACAAGTTGGGAACATGATCTCAATATGGGTCAGTCA 
TTCAATTCACACAGGGAGTCAACACCAAGCTGAACCAATCAGCAATACTAATTTTCTTACTGA 
GAAAGCTGTGGCTTCAGTAAAATTAGCGGGCAATTCATCTCTTTGCCCCATTAACGGATGGGC 
TGTATACAGTAAGGACAACAGTATAAGGATCGGTTCCAAGGGGGATGTGTTTGTTATAAGAGA 
GCCGTTCATCTCATGCTCCCACTTGGAATGCAGAACTTTCTTTTTGACTCAGGGAGCCTTGCT 
GAATGACAAACACTCCAATGGGACTGTCAAAGACAGAAGCCCTCACAGAACATTAATGAGTTG 
TCCTGTGGGTGAGGCTCCCTCCCCATATAACTCAAGGTTTGAGTCTGTTGCTTGGTCAGCAAG 
TGCTTGCCATGATGGCACCAGTTGGTTGACAATTGGAATTTCTGGCCCAGACAATGGGGCTGT 
GGCTGTATTGAAATACAATGGCATAATAACAGACACTATCAAGAGTTGGAGGAACAACATACT 
GAGAACTCAAGAGTCTGAATGTGCATGTGTAAATGGCTCTTGCTTTACTGTAATGACTGACGG 
ACCAAGTAATGGTCAGGCATCACATAAGATCTTCAAAATGGAAAAAGGGAAAGTGGTTAAATC 
AGTCGAATTGGATGCTCCTAATTATCACTATGAGGAATGCTCCTGTTATCCTGATGCCGGCGA 
AATCACATGTGTGTGCAGGGATAATTGGCATGGCTCAAATCGGCCATGGGTATCTTTCAATCA 
AAACTTGGAGTATCAAATAGGATATATATGCAGTGGAGTTTTCGGAGACAATCCACGCCCCAA 
TGATGGAACAGGTAGTTGTGGTCCGGTGTCCTCTAACGGGGCATATGGGGTAAAAGGGTTTTC 
ATTTAAATACGGCAATGGTGTCTGGATCGGGAGAACCAAAAGCACTAATTCCAGGAGCGGCTT 
TGAAATGATTTGGGATCCAAATGGGTGGACTGAAACGGACAGTAGCTTTTCAGTGAAACAAGA 
TATCGTAGCAATAACTGATTGGTCAGGATATAGCGGGAGTTTTGTCCAGCATCCAGAACTGAC 
AGGACTAGATTGCATAAGACCTTGTTTCTGGGTTGAGTTGATCAGAGGGCGGCCCAAAGAGAG 
CACAATTTGGACTAGTGGGAGCAGCATATCTTTTTGTGGTGTAAATAGTGACACTGTGGGTTG 
GTCTTGGCCAGACGGTGCTGA 
201 
12.3.5 VNMlPEV16R12004 
GGTAACTGGAATAGTTAGCTTAATGTTACAAGTTGGGAACATGATCTCAATATGGGTCAGTCA 
TTCAATTCACACAGGGAGTCAACACCAAGCTGAACCAATCAGCAATACTAATTTTCTTACTGA 
GAAAGCTGTGGCTTCAGTAAAATTAGCGGGCAATTCATCTCTTTGCCCCATTAACGGATGGGC 
TGTATACAGTAAGGACAACAGTATAAGGATCGGTTCCAAGGGGGATGTGTTTGTTATAAGAGA 
GCCGTTCATCTCATGCTCCCACTTGGAATGCAGAACTTTCTTTTTGACTCAGGGAGCCTTGCT 
GAATGACAAACACTCCAATGGGACTGTCAAAGACAGAAGCCCTCACAGAACATTAATGAGTTG 
TCCTGTGGGTGAGGCTCCCTCCCCATATAACTCAAGGTTTGAGTCTGTTGCTTGGTCAGCAAG 
TGCTTGCCATGATGGCACCAGTTGGTTGACAATTGGAATTTCTGGCCCAGACAATGGGGCTGT 
GGCTGTATTGAAATACAATGGCATAATAACAGACACTATCAAGAGTTGGAGGAACAACATACT 
GAGAACTCAAGAGTCTGAATGTGCATGTGTAAATGGCTCTTGCTTTACTGTAATGACTGACGG 
ACCAAGTAATGGTCAGGCATCACATAAGATCTTCAAAATGGAAAAAGGGAAAGTGGTTAAATC 
AGTCGAATTGGATGCTCCTAATTATCACTATGAGGAATGCTCCTGTTATCCTGATGCCGGCGA 
AATCACATGTGTGTGCAGGGATAATTGGCATGGCTCAAATCGGCCATGGGTATCTTTCAATCA 
AAACTTGGAGTATCAAATAGGATATATATGCAGTGGAGTTTTCGGAGACAATCCACGCCCCAA 
TGATGGAACAGGTAGTTGTGGTCCGGTGTCCTCTAACGGGGCATATGGGGTAAAAGGGTTTTC 
ATTTAAATACGGCAATGGTGTCTGGATCGGGAGAACCAAAAGCACTAATTCCAGGAGCGGCTT 
TGAAATGATTTGGGATCCAAATGGGTGGACTGAAACGGACAGTAGCTTTTCAGTGAAACAAGA 
TATCGTAGCAATAACTGATTGGTCAGGATATAGCGGGAGTTTTGTCCAGCATCCAGAACTGAC 
AGGACTAGATTGCATAAGACCTTGTTTCTGGGTTGAGTTGATCAGAGGGCGGCCCAAAGAGAG 
CACAATTTGGACTAGTGGGAGCAGCATATCTTTTTGTGGTGTAAATAGTGACACTGTGGGTTG 
GTCTTGGCCAGACGGTGCTGA 
12.4 PB2 sequences 
12.4.1 VNMlCL2009-2812005 
AGTGCATTTCATTATCCAAAGGTTTACAAAACATACTTTGAGAAGGTTGAAAGGTTAAAACAT 
GGAACCTTCGGTCCCGTCCATTTCCGAAACCAAGTTAAAATACGCCGCCGAGTGGATATAAAT 
CCTGGCCATGCAGATCTCAGTGCTAAAGAAGCACAAGATGTCATCATGGAAGTCGTTTTCCCA 
AATGAAGTGGGAGCTAGAATATTGACATCAGAGTCGCAATTGACAATAACGAAAGAGAAGAAA 
GAAGAGCTCCAAGATTGTAAGATTGCTCCCTTAATGGTTGCATACATGTTGGAAAGGGAACTG 
GTCCGCAAAACCAGATTCCTACCGGTAGCAGGCGGAACAAGCAGTGTGTACATTGAGGTATTG 
CATTTGACTCAAGGGACCTGCTGGGAACAGATGTACACTCCAGGCGGAGAAGTGAGAAATGAC 
GATGTTGACCAGAGTTTGATCATCGCTGCCAGAAACATTGTTAGGAGGGCAACGGTATCAGCG 
GATCCACTGGCATCGCTGCTGGAGATGTGTCACAGCACACAAATTGGTGGGATAAGGATGGTG 
GACATCCTTAGGCAAAATCCAACTGAGGAACAAGCTGTGGATATATGCAAAGCAGCAATGGGT 
CTGAGGATCAGTTCTTCCTTTAGCTTTGGAGGCTTCACTTTCAAAAGAACAAGTGGATCATCC 
GTCAAGAAGGAAGAGGAAGTACTTACAGGCAACCTCCAAACATTGAAAATAAAAGTACATGAG 
GGGTATGAGGAATTCACAATGGTTGGGCGGAGGGCAACAGCTATCCTGAGGAAAGCAACTAGA 
AGGCTGATTCAGTTGATAGTAAGTGGAAGAGACGAACAATCAATCGCTGAGGCAATCATTGTA 
GCAATGGTGTTCTCACAGGAGGATTGCATGATAAAGGCAGTCCGAGGCGATCTGAATTTCGTA 
AACAGAGCAAACCAAAGATTAAACACCATGCATCAACTCCTGAGACATTTTCAAAAGGATGCA 
AAAGTGTTATTTCAGAATTGGGGAATTGAACCCATTGATAATGTCATGGGGATGATCGGAATA 
TTACCTGACATGACTCCCAGCACAGAAATGTCACTGAGAGGAGTAAGAGTTAGTAAAATGGGA 
GTGGATGAATATTCCAGCACTGAGAGAGTAGTTGTAAGTATTGACCGTTTCTTAAGGGTTCGA 
GATCAGCGGGGGAACGTACTCTTATCTCCCGAAGAGGTCAGCGAAACCCAGGGAACAGAGAAA 
TTGACAATAACATATTCATCATCAATGATGTGGGAAATCAACGGTCCTGAGTCAGTGCTTGTT 
AACACCTATCAGTGGATCATCAGAAACTGGGAGACTGTGAAGATTCAATGGTCTCAAGACCCC 
202 
ACGATGCTGTACAATAAGATGGAGTTTGAACCGTTCCAATCCTTGGTACCCAAAGCTGCCAGA 
GGTCAATACAGTGGATTTGTGAGAACATTATTCCAACAAATGCGTGACGTACTGGGGACATTT 
GATACTGTCCAGATAATAAAGCTGCTACCATTTGCAGCAGCCCCACCGAAGCAGAGCAGAATG 
CAGTTTTCTTCTCTAACTGTGAATGTGAGAGGCTCAGGAATGAGAATACTCGTAAGGGGCAAT 
TCCCCTGTGTTCAACTACAATAAGGCAACCAAAAGGCTTACCGTTCTTGGAAAGGACGCAGGT 
GCATTAACAGAGGATCCAGATGAGGGGACAGCCGGAGTGGAATCTGCAGTACTGAGGGGATTC 
TTAATTCTAGGCAAGGAGGACAAAAGGTATGGACCAGCATTGAGCATCAATGAACTGAGCAAT 
CTTGCGAAGGGGGAGAAAGCTAATGTGCTGATAGGGCAAGGAGACGTGGTGTTGGTAATGAAA 
CGAAAACGGGACTCTAGCATACTTACTGACAGCCAGACAGCGACCAAAAGAATTCGGATGGCC 
ATCAATTAGTGTCGAATT 
12.4.2 VNMlCLl07·13/2005 
ACGAGATCTTACGAGATCTAATGTCACAGTCCCGCACTCGCGAGATACTAACAAAAACCACTG 
TGGACCATATGGCCATAATCAAGAAATACACATCAGGAAGACAAGAGAAGAACCCTGCTCTCA 
GAATGAAATGGATGATGGCAATGAAATACCCAATCACAGCGGACAAGAGAATAATAGAGATGA 
TTCCTGAAAGGAATGAACAAGGGCAGACGCTCTGGAGCAAGACAAATGATGCTGGATCGGACA 
GGGTGATGGTGTCTCCCCTAGCTGTAACTTGGTGGAATAGGAATGGGCCGGCAACAAGTGCAG 
TTCATTATCCAAAGGTTTACAAAACATACTTTGAGAAGGTTGAAAGGTTAAAACATGGAACCT 
TCGGTCCCGTCCATTTCCGAAACCAAGTTAAAATACGCCGCCGAGTGGATATAAATCCTGGCC 
ATGCAGATCTCAGTGCTAAAGAAGCACAAGATGTCATCATGGAAGTCGTTTTCCCAAATGAAG 
TGGGAGCTAGAATATTGACATCAGAGTCGCAATTGACAATAACGAAAGAGAAGAAAGAAGAGC 
TCCAAGATTGTAAGATTGCTCCCTTAATGGTTGCATACATGTTGGAAAGGGAACTGGTCCGCA 
AAACCAGATTCCTACCGGTAGCAGGCGGAACAAGCAGTGTGTACATTGAGGTATTGCATTTGA 
CTCAAGGGACCTGCTGGGAACAGATGTACACTCCAGGCGGAGAAGTGAGAAATGACGATGTTG 
ACCAGAGTTTGATCATCGCTGCCAGAAACATTGTTAGGAGAGCAACGGTATCAGCGGATCCAC 
TGGCATCGCTGCTGGAGATGTGTCACAGCACACAAATTGGTGGGATAAGGATGGTGGACATCC 
TTAGGCAAAATCCAACTGAGGAACAAGCTGTGGATATATGCAAAGCAGCAATGGGTCTGAGGA 
TCAGTTCTTCCTTTAGCTTTGGAGGCTTCACTTTCAAAAGAACAAGTGGATCATCCGTCAAGA 
AGGAAGAGGAAGTACTTACAGGCAACCTCCAAACATTGAAAATAAAAGTACATGAGGGGTATG 
AGGAATTCACAATGGTTGGGCGGAGGGCAACAGCTATCCTGAGGAAAGCAACTAGAAGGCTGA 
TTCAGTTGATAGTAAGTGGAAGAGACGAACAATCAATCGCTGAGGCAATCATTGTAGCAATGG 
TGTTCTCACAGGAGGATTGCATGATAAAGGCAGTCCGAGGCGATCTGAATTTCGTAAACAGAG 
CAAACCAAAGATTAAACACCATGCATCAACTCCTGAGACATTTTCAAAAGGATGCAAAAGTGT 
TATTTCAGAATTGGGGAATTGAACCCATTGATAATGTCATGGGGATGATCGGAATATTACCTG 
ACATGACTCCCAGCACAGAAATGTCACTGAGAGGAGTAAGAGTTAGTAAAATGGGAGTGGATG 
AATATTCCAGCACTGAGAGAGTAGTTGTAAGTATTGACCGTTTCTTAAGGGTTCGAGATCAGC 
GGGGGAACGTACTCTTATCTCCCGAAGAGGTCAGCGAAACCCAGGGAACAGAGAAATTGACAA 
TAACATATTCATCATCAATGATGTGGGAAATCAACGGTCCTGAGTCAGTGCTTGTTAACACCT 
ATCAGTGGATCATCAGAAACTGGGAGACTGTGAAGATTCAATGGTCTCAAGACCCCACGATGC 
TGTACAATAAGATGGAGTTTGAACCGTTCCAATCCTTGGTACCCAAAGCTGCCAGAGGTCAAT 
ACAGTGGATTTGTGAGAACATTATTCCAACAAATGCGTGACGTACTGGGGACATTTGATACTG 
TCCAGATAATAAAGCTGCTACCATTTGCAGCAGCCCCACCGAAGCAGAGCAGAATGCAGTTTT 
CTTCTCTAACTGTGAATGTGAGAGGCTCAGGAATGAGAATACTCGTAAGGGGCAATTCCCCTG 
TGTTCAACTACAATAAGGCAACCAAAAGGCTTACCGTTCTTGGAAAGGACGCAGGTGCATTAA 
CAGAGGATCCAGATGAGGGGACAGCCGGAGTGGAATCTGCAGTACTGAGGGGATTCTTAATTC 
TAGGCAAGGAGGACAAAAGGTATGGACCAGCATTGAGCATCAATGAACTGAGCAATCTTGCGA 
AGGGGGAGAAAGCTAATGTGCTGATAGGGCAAGGAGACGTGGTGTTGGTAATGAAACGAAAAC 
203 
GGGACTCTAGCATACTTACTGACAGCCAGACAGCGACCAAAAGAATTCGGATGGCCATCAATT 
AGTGTCGAATTGTTTAAAAA 
12.4.3 VNMlPEV16B/2004 
TCGCGAGATACTAACAAAAACCACTGTGGACCATATGGCCATAATCAAGAAATACACATCAGG 
AAGACAAGAGAAGAACCCTGCTCTCAGAATGAAATGGATGATGGCAATGAAATATCCAATCAC 
AGCGGACAAGAGAATAATAGAGATGATTCCTGAAAGGAATGAACAAGGGCAGACGCTCTGGAG 
CAAGACAAATGATGCTGGATCGGACAGGGTGATGGTGTCTCCCCTAGCTGTAACTTGGTGGAA 
TAGGAATGGGCCGGCAACAAGTGCAGTTCATTATCCAAAGGTTTACAAAACATACTTTGAGAA 
GGTTGAAAGGTTAAAACATGGAACCTTCGGTCCCGTCCATTTCCGAAACCAAGTTAAAATACG 
CCGCCGAGTGGATATAAATCCTGGCCATGCAGATCTCAGTGCTAAAGAAGCACAAGATGTCAT 
CATGGAGGTCGTTTTCCCAAATGAAGTGGGAGCTAGAATATTGACATCAGAGTCGCAATTGAC 
AATAACGAAAGAGAAGAAAGAAGAGCTCCAAGATTGTAAGATTGCTCCCTTAATGGTTGCATA 
CATGTTGGAAAGGGAACTGGTCCGCAAAACCAGATTCCTACCGGTAGCAGGCGGAACAAGCAG 
TGTGTACATTGAGGTATTGCATTTGACTCAAGGGACCTGCTGGGAACAGATGTACACTCCAGG 
CGGAGAAGTGAGAAATGACGATGTTGACCAGAGTTTGATCATCGCTGCCAGAAACATTGTTAG 
GAGAGCAACGGTATCAGCGGATCCACTGGCATCACTGCTGGAGATGTGTCACAGCACACAAAT 
TGGTGGGATAAGGATGGTGGACATCCTTAGGCAAAATCCAACTGAGGAACAAGCTGTGGATAT 
ATGCAAAGCAGCAATGGGTCTGAGGATCAGTTCTTCCTTTAGCTTTGGAGGCTTCACTTTCAA 
AAGAACAAGTGGATCATCCGTCAAGAAGGAAGAGGAAGTGCTTACAGGCAACCTCCAAACATT 
GAAAATAAGAGTACATGAGGGGTATGAGGAATTCACAATGGTTGGGCGGAGGGCAACAGCTAT 
CCTGAGGAAAGCAACTAGAAGGCTGATTCAGTTGATAGTAAGTGGAAGAGACGAACAATCAAT 
CGCTGAGGCAATCATTGTAGCAATGGTGTTCTCACAGGAGGATTGCATGATAAAGGCAGTCCG 
AGGCGATCTGAATTTCGTAAACAGAGCAAACCAAAGATTAAACACCATGCATCAACTCCTGAG 
ACATTTTCAAAAGGATGCAAAAGTGTTATTTCAGAATTGGGGAATTGAACCCATTGATAATGT 
CATGGGGATGATCGGAATATTACCTGACATGACTCCCAGCACAGAAATGTCACTGAGAGGAGT 
AAGAGTTAGTAAAATGGGAGTGGATGAATATTCCAGCACTGAGAGAGTAGTTGTAAGTATTGA 
CCGTTTCTTAAGGGTTCGAGATCAGCGGGGGAACGTACTCTTATCTCCCGAAGAGGTCAGCGA 
AACCCAGGGAACAGAGAAATTGACAATAACATATTCATCATCAATGATGTGGGAAATCAACGG 
TCCTGAGTCAGTGCTTGTTAACACCTATCAGTGGATCATCAGAAACTGGGAGACTGTGAAGAT 
TCAATGGTCTCAAGACCCCACGATGCTGTACAATAAGATGGAGTTTGAACCGTTCCAATCCTT 
GGTACCCAAAGCTGCCAGAGGTCAATACAGTGGATTTGTGAGAACATTATTCCAACAAATGCG 
TGACGTACTGGGGACATTTGATACTGTCCAGATAATAAAGCTGCTACCATTTGCAGCAGCCCC 
ACCGAAGCAGAGCAGAATGCAGTTTTCTTCTCTAACTGTGAATGTGAGAGGCTCAGGAATGAG 
AATACTCGTAAGGGGCAATTCCCCTGTGTTCAACTACAATAAGGCAACCAAAAGGCTTACCGT 
TCTTGGAAAGGACGCAGGTGCATTAACAGAGGATCCAGATGAGGGGACAGCCGGAGTGGAATC 
TGCAGTACTGAGGGGATTCTTAATTCTAGGCAAGGAGGACAAAAGGTATGGACCAGCATTGAG 
CATCAATGAACTGAGCAATCTTGCGAAGGGGGAGAAAGCTAATGTGCTGATAGGGCAAGGAGA 
CGTGGTGTTGGTAATGAAACGAAAACGGGACTCTAGCATACTTACTGACAGCCAGACAGCGAC 
CAAAAGAATTCGGATGGCCATCAATTAG 
12.4.4 VNMlPEV16C/2004 
TCGCGAGATACTAACAAAAACCACTGTGGACCATATGGCCATAATCAAGAAATACACATCAGG 
AAGACAAGAGAAGAACCCTGCTCTCAGAATGAAATGGATGATGGCAATGAAATATCCAATCAC 
AGCGGACAAGAGAATAATAGAGATGATTCCTGAAAGGAATGAACAAGGGCAGACGCTCTGGAG 
204 
CAAGACAAATGATGCTGGATCGGACAGGGTGATGGTGTCTCCCCTAGCTGTAACTTGGTGGAA 
TAGGAATGGGCCGGCAACAAGTGCAGTTCATTATCCAAAGGTTTACAAAACATACTTTGAGAA 
GGTTGAAAGGTTAAAACATGGAACCTTCGGTCCCGTCCATTTCCGAAACCAAGTTAAAATACG 
CCGCCGAGTGGATATAAATCCTGGCCATGCAGATCTCAGTGCTAAAGAAGCACAAGATGTCAT 
CATGGAGGTCGTTTTCCCAAATGAAGTGGGAGCTAGAATATTGACATCAGAGTCGCAATTGAC 
AATAACGAAAGAGAAGAAAGAAGAGCTCCAAGATTGTAAGATTGCTCCCTTAATGGTTGCATA 
CATGTTGGAAAGGGAACTGGTCCGCAAAACCAGATTCCTACCGGTAGCAGGCGGAACAAGCAG 
TGTGTACATTGAGGTATTGCATTTGACTCAAGGGACCTGCTGGGAACAGATGTACACTCCAGG 
CGGAGAAGTGAGAAATGACGATGTTGACCAGAGTTTGATCATCGCTGCCAGAAACATTGTTAG 
GAGAGCAACGGTATCAGCGGATCCACTGGCATCACTGCTGGAGATGTGTCACAGCACACAAAT 
TGGTGGGATAAGGATGGTGGACATCCTTAGGCAAAATCCAACTGAGGAACAAGCTGTGGATAT 
ATGCAAAGCAGCAATGGGTCTGAGGATCAGTTCTTCCTTTAGCTTTGGAGGCTTCACTTTCAA 
AAGAACAAGTGGATCATCCGTCAAGAAGGAAGAGGAAGTGCTTACAGGCAACCTCCAAACATT 
GAAAATAAGAGTACATGAGGGGTATGAGGAATTCACAATGGTTGGGCGGAGGGCAACAGCTAT 
CCTGAGGAAAGCAACTAGAAGGCTGATTCAGTTGATAGTAAGTGGAAGAGACGAACAATCAAT 
CGCTGAGGCAATCATTGTAGCAATGGTGTTCTCACAGGAGGATTGCATGATAAAGGCAGTCCG 
AGGCGATCTGAATTTCGTAAACAGAGCAAACCAAAGATTAAACACCATGCATCAACTCCTGAG 
ACATTTTCAAAAGGATGCAAAAGTGTTATTTCAGAATTGGGGAATTGAACCCATTGATAATGT 
CATGGGGATGATCGGAATATTACCTGACATGACTCCCAGCACAGAAATGTCACTGAGAGGAGT 
AAGAGTTAGTAAAATGGGAGTGGATGAATATTCCAGCACTGAGAGAGTAGTTGTAAGTATTGA 
CCGTTTCTTAAGGGTTCGAGATCAGCGGGGGAACGTACTCTTATCTCCCGAAGAGGTCAGCGA 
AACCCAGGGAACAGAGAAATTGACAATAACATATTCATCATCAATGATGTGGGAAATCAACGG 
TCCTGAGTCAGTGCTTGTTAACACCTATCAGTGGATCATCAGAAACTGGGAGACTGTGAAGAT 
TCAATGGTCTCAAGACCCCACGATGCTGTACAATAAGATGGAGTTTGAACCGTTCCAATCCTT 
GGTACCCAAAGCTGCCAGAGGTCAATACAGTGGATTTGTGAGAACATTATTCCAACAAATGCG 
TGACGTACTGGGGACATTTGATACTGTCCAGATAATAAAGCTGCTACCATTTGCAGCAGCCCC 
ACCGAAGCAGAGCAGAATGCAGTTTTCTTCTCTAACTGTGAATGTGAGAGGCTCAGGAATGAG 
AATACTCGTAAGGGGCAATTCCCCTGTGTTCAACTACAATAAGGCAACCAAAAGGCTTACCGT 
TCTTGGAAAGGACGCAGGTGCATTAACAGAGGATCCAGATGAGGGGACAGCCGGAGTGGAATC 
TGCAGTACTGAGGGGATTCTTAATTCTAGGCAAGGAGGACAAAAGGTATGGACCAGCATTGAG 
CATCAATGAACTGAGCAATCTTGCGAAGGGGGAGAAAGCTAATGTGCTGATAGGGCAAGGAGA 
CGTGGTGTTGGTAATGAAACGAAAACGGGACTCTAGCATACTTACTGACAGCCAGACAGCGAC 
CAAAAGAATTCGGATGGCCATCAATTAG 
12.4.5 VNMlPEV16RJ2004 
TCGCGAGATACTAACAAAAACCACTGTGGACCATATGGCCATAATCAAGAAATACACATCAGG 
AAGACAAGAGAAGAACCCTGCTCTCAGAATGAAATGGATGATGGCAATGAAATATCCAATCAC 
AGCGGACAAGAGAATAATAGAGATGATTCCTGAAAGGAATGAACAAGGGCAGACGCTCTGGAG 
CAAGACAAATGATGCTGGATCGGACAGGGTGATGGTGTCTCCCCTAGCTGTAACTTGGTGGAA 
TAGGAATGGGCCGGCAACAAGTGCAGTTCATTATCCAAAGGTTTACAAAACATACTTTGAGAA 
GGTTGAAAGGTTAAAACATGGAACCTTCGGTCCCGTCCATTTCCGAAACCAAGTTAAAATACG 
CCGCCGAGTGGATATAAATCCTGGCCATGCAGATCTCAGTGCTAAAGAAGCACAAGATGTCAT 
CATGGAGGTCGTTTTCCCAAATGAAGTGGGAGCTAGAATATTGACATCAGAGTCGCAATTGAC 
AATAACGAAAGAGAAGAAAGAAGAGCTCCAAGATTGTAAGATTGCTCCCTTAATGGTTGCATA 
CATGTTGGAAAGGGAACTGGTCCGCAAAACCAGATTCCTACCGGTAGCAGGCGGAACAAGCAG 
TGTGTACATTGAGGTATTGCATTTGACTCAAGGGACCTGCTGGGAACAGATGTACACTCCAGG 
CGGAGAAGTGAGAAATGACGATGTTGACCAGAGTTTGATCATCGCTGCCAGAAACATTGTTAG 
GAGAGCAACGGTATCAGCGGATCCACTGGCATCACTGCTGGAGATGTGTCACAGCACACAAAT 
205 
TGGTGGGATAAGGATGGTGGACATCCTTAGGCAAAATCCAACTGAGGAACAAGCTGTGGATAT 
ATGCAAAGCAGCAATGGGTCTGAGGATCAGTTCTTCCTTTAGCTTTGGAGGCTTCACTTTCAA 
AAGAACAAGTGGATCATCCGTCAAGAAGGAAGAGGAAGTGCTTACAGGCAACCTCCAAACATT 
GAAAATAAGAGTACATGAGGGGTATGAGGAATTCACAATGGTTGGGCGGAGGGCAACAGCTAT 
CCTGAGGAAAGCAACTAGAAGGCTGATTCAGTTGATAGTAAGTGGAAGAGACGAACAATCAAT 
CGCTGAGGCAATCATTGTAGCAATGGTGTTCTCACAGGAGGATTGCATGATAAAGGCAGTCCG 
AGGCGATCTGAATTTCGTAAACAGAGCAAACCAAAGATTAAACACCATGCATCAACTCCTGAG 
ACATTTTCAAAAGGATGCAAAAGTGTTATTTCAGAATTGGGGAATTGAACCCATTGATAATGT 
CATGGGGATGATCGGAATATTACCTGACATGACTCCCAGCACAGAAATGTCACTGAGAGGAGT 
AAGAGTTAGTAAAATGGGAGTGGATGAATATTCCAGCACTGAGAGAGTAGTTGTAAGTATTGA 
CCGTTTCTTAAGGGTTCGAGATCAGCGGGGGAACGTACTCTTATCTCCCGAAGAGGTCAGCGA 
AACCCAGGGAACAGAGAAATTGACAATAACATATTCATCATCAATGATGTGGGAAATCAACGG 
TCCTGAGTCAGTGCTTGTTAACACCTATCAGTGGATCATCAGAAACTGGGAGACTGTGAAGAT 
TCAATGGTCTCAAGACCCCACGATGCTGTACAATAAGATGGAGTTTGAACCGTTCCAATCCTT 
GGTACCCAAAGCTGCCAGAGGTCAATACAGTGGATTTGTGAGAACATTATTCCAACAAATGCG 
TGACGTACTGGGGACATTTGATACTGTCCAGATAATAAAGCTGCTACCATTTGCAGCAGCCCC 
ACCGAAGCAGAGCAGAATGCAGTTTTCTTCTCTAACTGTGAATGTGAGAGGCTCAGGAATGAG 
AATACTCGTAAGGGGCAATTCCCCTGTGTTCAACTACAATAAGGCAACCAAAAGGCTTACCGT 
TCTTGGAAAGGACGCAGGTGCATTAACAGAGGATCCAGATGAGGGGACAGCCGGAGTGGAATC 
TGCAGTACTGAGGGGATTCTTAATTCTAGGCAAGGAGGACAAAAGGTATGGACCAGCATTGAG 
CATCAATGAACTGAGCAATCTTGCGAAGGGGGAGAAAGCTAATGTGCTGATAGGGCAAGGAGA 
CGTGGTGTTGGTAATGAAACGAAAACGGGACTCTAGCATACTTACTGACAGCCAGACAGCGAC 
CAAAAGAATTCGGATGGCCATCAATTAG 
12.5 PB1 sequences 
12.5.1 VNMlPEV16B/2004 
ATGGATGTCAATCCGACTTTACTTTTCTTGAAAGTACCAGTGCAAAATGCTATAAGTACCACA 
TTCCCTTATACTGGAGACCCTCCATACAGCCATGGAACAGGGACAGGATACACCATGGACACA 
GTCAACAGAACACACCAATATTCAGAAAAGGGGAAGTGGACAACAAACACAGAGACTGGAGCA 
CCCCAACTCAACCCGATTGATGGACCACTACCTGAGGATAATGAGCCCAGTGGGTATGCACAA 
ACAGATTGTGTATTGGAAGCAATGGCTTTCCTTGAAGAATCCCACCCAGGGATCTTTGAAAAC 
TCGTGTCTTGAAACGATGGAAATTGTTCAACAAACAAGAGTGGATAAACTGACCCAAGGTCGC 
CAGACCTATGACTGGACATTGAATAGAAACCAACCGGCTGCAACTGCTTTGGCCAACACTATA 
GAAATCTTCAGATCGAACGGTCTAACAGCCAATGAATCGGGACGGCTAATAGATTTCCTCAAG 
GATGTGATGGAATCAATGGATAAGGAAGAAATGGAGATAACAACACATTTCCAGAGAAAGAGA 
AGGGTGAGGGACAACATGACCAAGAAAATGGTCACACAAAGAACAATAGGGAAGAAAAAACAA 
AGGCTGAACAAAAAGAGCTACCTGATAAGAGCACTGACACTGAACACAATGACAAAAGATGCA 
GAAAGAGGCAAATTGAAGAGGCGAGCGATTGCAACACCCGGAATGCAAATCAGAGGATTCGTC 
TACTTTGTTGAAACACTAGCGAGGAGTATCTGTGAGAAACTTGAGCAATCTGGACTCCCAGTC 
GGAGGGAATGAGAAGAAGGCTAAATTGGCAAACGTCGTGAGGAAGATGATGACTAACTCACAA 
GATACTGAACTCTCCTTTACAATTACTGGAGACAATACCAAATGGAATGAGAATCAGAATCCT 
AGGATGTTTCTGGCAATGATAACGTACATCACAAGGAACCAGCCAGAATGGTTTCGGAATGTC 
TTAAGCATTGCTCCTATAATGTTCTCAAACAAAATGGCGAGACTAGGAAAAGGATACATGTTC 
GAAAGTAAGAGCATGAAGTTACGAACACAAATACCAGCAGAAATGCTTGCAAACATTGATCTT 
AAATACTTCAATGAATTAACGAAAAAGAAAATTGAGAAAATAAGGCCTCTATTAATAGATGGT 
ACAGCCTCATTGAGCCCTGGAATGATGATGGGCATGTTCAACATGCTGAGTACAGTCCT~GGA 
GTTTCAATCCTGAATCTTGGACAGAAAAGGTACACCAAAACCACATATTGGTGGGACGGACTC 
206 
CAATCCTCTGATGATTTCGCTCTCATCGTAAATGCACCGAATCATGAGGGAATACAAGCAGGA 
GTGGATAGGTTTTATAGGACTTGTAAACTAGTTGGAATCAATATGAGCAAGAAGAAGTCTTAC 
ATAAATCGGACAGGGACATTTGAATTCACGAGCTTTTTCTACCGCTATGGATTTGTAGCCAAT 
TTCAGTATGGAGCTGCCCAGTTTTGGAGTGTCTGGAATTAATGAATCGGCCGACATGAGCATT 
GGTGTTACAGTGATAAAAAACAATATGATAAACAACGACCTTGGGCCAGCAACAGCTCAGATG 
GCTCTTCAGTTATTCATCAAGGACTACAGATACACATACCGATGCCACAGAGGGGATACGCAA 
ATCCAAACAAGGAGATCATTCGAGCTGAAGAAGCTGTGGGAGCAAACCCGTTCAAAGGCAGGA 
CTGTTGGTTTCAGATGGAGGACCAAATCTATACAATATCCGAAATCTCCATATTCCTGAAGTC 
TGCTTAAAATGGGAATTGATGGATGAAGATTACCAGGGCAGACTGTGTAATCCTCTGAATCCA 
TTCGTCAGCCATAAGGAAATTGAATCTGTCAACAATGCTGTAGTAATGCCAGCTCAT 
12.5.2 VNMlPEV16C/2004 
ATGGATGTCAATCCGACTTTACTTTTCTTGAAAGTACCAGTGCAAAATGCTATAAGTACCACA 
TTCCCTTATACTGGAGACCCTCCATACAGCCATGGAACAGGGACAGGATACACCATGGACACA 
GTCAACAGAACACACCAATATTCAGAAAAGGGGAAGTGGACAACAAACACAGAGACTGGAGCA 
CCCCAACTCAACCCGATTGATGGACCACTACCTGAGGATAATGAGCCCAGTGGGTATGCACAA 
ACAGATTGTGTATTGGAAGCAATGGCTTTCCTTGAAGAATCCCACCCAGGGATCTTTGAAAAC 
TCGTGTCTTGAAACGATGGAAATTGTTCAACAAACAAGAGTGGATAAACTGACCCAAGGTCGC 
CAGACCTATGACTGGACATTGAATAGAAACCAACCGGCTGCAACTGCTTTGGCCAACACTATA 
GAAATCTTCAGATCGAACGGTCTAACAGCCAATGAATCGGGACGGCTAATAGATTTCCTCAAG 
GATGTGATGGAATCAATGGATAAGGAAGAAATGGAGATAACAACACATTTCCAGAGAAAGAGA 
AGGGTGAGGGACAACATGACCAAGAAAATGGTCACACAAAGAACAATAGGGAAGAAAAAACAA 
AGGCTGAACAAAAAGAGCTACCTGATAAGAGCACTGACACTGAACACAATGACAAAAGATGCA 
GAAAGAGGCAAATTGAAGAGGCGAGCGATTGCAACACCCGGAATGCAAATCAGAGGATTCGTC 
TACTTTGTTGAAACACTAGCGAGGAGTATCTGTGAGAAACTTGAGCAATCTGGACTCCCAGTC 
GGAGGGAATGAGAAGAAGGCTAAATTGGCAAACGTCGTGAGGAAGATGATGACTAACTCACAA 
GATACTGAACTCTCCTTTACAATTACTGGAGACAATACCAAATGGAATGAGAATCAGAATCCT 
AGGATGTTTCTGGCAATGATAACGTACATCACAAGGAACCAGCCAGAATGGTTTCGGAATGTC 
TTAAGCATTGCTCCTATAATGTTCTCAAACAAAATGGCGAGACTAGGAAAAGGATACATGTTC 
GAAAGTAAGAGCATGAAGTTACGAACACAAATACCAGCAGAAATGCTTGCAAACATTGATCTT 
AAATACTTCAATGAATTAACGAAAAAGAAAATTGAGAAAATAAGGCCTCTATTAATAGATGGT 
ACAGCCTCATTGAGCCCTGGAATGATGATGGGCATGTTCAACATGCTGAGTACAGTCCTAGGA 
GTTTCAATCCTGAATCTTGGACAGAAAAGGTACACCAAAACCACATATTGGTGGGACGGACTC 
CAATCCTCTGATGATTTCGCTCTCATCGTAAATGCACCGAATCATGAGGGAATACAAGCAGGA 
GTGGATAGGTTTTATAGGACTTGTAAACTAGTTGGAATCAATATGAGCAAGAAGAAGTCTTAC 
ATAAATCGGACAGGGACATTTGAATTCACGAGCTTTTTCTACCGCTATGGATTTGTAGCCAAT 
TTCAGTATGGAGCTGCCCAGTTTTGGAGTGTCTGGAATTAATGAATCGGCCGACATGAGCATT 
GGTGTTACAGTGATAAAAAACAATATGATAAACAACGACCTTGGGCCAGCAACAGCTCAGATG 
GCTCTTCAGTTATTCATCAAGGACTACAGATACACATACCGATGCCACAGAGGGGATACGCAA 
ATCCAAACAAGGAGATCATTCGAGCTGAAGAAGCTGTGGGAGCAAACCCGTTCAAAGGCAGGA 
CTGTTGGTTTCAGATGGAGGACCAAATCTATACAATATCCGAAATCTCCATATTCCTGAAGTC 
TGCTTAAAATGGGAATTGATGGATGAAGATTACCAGGGCAGACTGTGTAATCCTCTGAATCCA 
TTCGTCAGCCATAAGGAAATTGAATCTGTCAACAATGCTGTAGTAATGCCAGCTCAT 
12.5.3 VNMIPEV16RJ2004 
ATGGATGTCAATCCGACTTTACTTTTCTTGAAAGTACCAGTGCAAAATGCTATAAGTACCACA 
TTCCCTTATACTGGAGACCCTCCATACAGCCATGGAACAGGGACAGGATACACCATGGACACA 
207 
GTCAACAGAACACACCAATATTCAGAAAAGGGGAAGTGGACAACAAACACAGAGACTGGAGCA 
CCCCAACTCAACCCGATTGATGGACCACTACCTGAGGATAATGAGCCCAGTGGGTATGCACAA 
ACAGATTGTGTATTGGAAGCAATGGCTTTCCTTGAAGAATCCCACCCAGGGATCTTTGAAAAC 
TCGTGTCTTGAAACGATGGAAATTGTTCAACAAACAAGAGTGGATAAACTGACCCAAGGTCGC 
CAGACCTATGACTGGACATTGAATAGAAACCAACCGGCTGCAACTGCTTTGGCCAACACTATA 
GAAATCTTCAGATCGAACGGTCTAACAGCCAATGAATCGGGACGGCTAATAGATTTCCTCAAG 
GATGTGATGGAATCAATGGATAAGGAAGAAATGGAGATAACAACACATTTCCAGAGAAAGAGA 
AGGGTGAGGGACAACATGACCAAGAAAATGGTCACACAAAGAACAATAGGGAAGAAAAAACAA 
AGGCTGAACAAAAAGAGCTACCTGATAAGAGCACTGACACTGAACACAATGACAAAAGATGCA 
GAAAGAGGCAAATTGAAGAGGCGAGCGATTGCAACACCCGGAATGCAAATCAGAGGATTCGTC 
TACTTTGTTGAAACACTAGCGAGGAGTATCTGTGAGAAACTTGAGCAATCTGGACTCCCAGTC 
GGAGGGAATGAGAAGAAGGCTAAATTGGCAAACGTCGTGAGGAAGATGATGACTAACTCACAA 
GATACTGAACTCTCCTTTACAATTACTGGAGACAATACCAAATGGAATGAGAATCAGAATCCT 
AGGATGTTTCTGGCAATGATAACGTACATCACAAGGAACCAGCCAGAATGGTTTCGGAATGTC 
TTAAGCATTGCTCCTATAATGTTCTCAAACAAAATGGCGAGACTAGGAAAAGGATACATGTTC 
GAAAGTAAGAGCATGAAGTTACGAACACAAATACCAGCAGAAATGCTTGCAAACATTGATCTT 
AAATACTTCAATGAATTAACGAAAAAGAAAATTGAGAAAATAAGGCCTCTATTAATAGATGGT 
ACAGCCTCATTGAGCCCTGGAATGATGATGGGCATGTTCAACATGCTGAGTACAGTCCTAGGA 
GTTTCAATCCTGAATCTTGGACAGAAAAGGTACACCAAAACCACATATTGGTGGGACGGACTC 
CAATCCTCTGATGATTTCGCTCTCATCGTAAATGCACCGAATCATGAGGGAATACAAGCAGGA 
GTGGATAGGTTTTATAGGACTTGTAAACTAGTTGGAATCAATATGAGCAAGAAGAAGTCTTAC 
ATAAATCGGACAGGGACATTTGAATTCACGAGCTTTTTCTACCGCTATGGATTTGTAGCCAAT 
TTCAGTATGGAGCTGCCCAGTTTTGGAGTGTCTGGAATTAATGAATCGGCCGACATGAGCATT 
GGTGTTACAGTGATAAAAAACAATATGATAAACAACGACCTTGGGCCAGCAACAGCTCAGATG 
GCTCTTCAGTTATTCATCAAGGACTACAGATACACATACCGATGCCACAGAGGGGATACGCAA 
ATCCAAACAAGGAGATCATTCGAGCTGAAGAAGCTGTGGGAGCAAACCCGTTCAAAGGCAGGA 
CTGTTGGTTTCAGATGGAGGACCAAATCTATACAATATCCGAAATCTCCATATTCCTGAAGTC 
TGCTTAAAATGGGAATTGATGGATGAAGATTACCAGGGCAGACTGTGTAATCCTCTGAATCCA 
TTCGTCAGCCATAAGGAAATTGAATCTGTCAACAATGCTGTAGTAATGCCAGCTCAT 
12.6 PA sequences 
12.6.1 VNMlPEV16B/2004 
ATGCTTCAATCCAATGATTGTCGAGCTTGCAGAAAAGGCAATGAAAGAATATGGGGAAGATCC 
GAAAATCGAAACGAACAAGTTTGCTGCAATATGCACACACTTGGAGGTCTGTTTCATGTATTC 
GGATTTTCACTTTATTGATGAACGGAGTGAATCAATAATTGTAGAATCTGGAGATCCGAATGC 
ATTATTGAAACACCGATTTGAAATAATTGAAGGAAGAGACCGAACGATGGCCTGGACTGTGGT 
GAATAGTATCTGCAACACCACAGGAGTTGAGAAACCTAAATTTCTCCCAGATTTGTATGACTA 
CAAAGAGAACCGATTCATCGAAATTGGAGTGACACGGAGGGAAGTTCATACATACTATCTGGA 
GAAAGCCAACAAGATAAAATCCGAGAAGACACATATTCACATATTCTCATTCACAGGGGAGGA 
AATGGCCACCAAAGCGGACTACACCCTTGATGAAGAGAGCAGGGCAAGAATTAAAACCAGGCT 
GTTCACCATAAGGCAGGAAATGGCCAGTAGGGGTCTATGGGATTCCTTTCGTCAATCCGAGAG 
AGGCGAAGAGACAATTGAAGAAAAATTTGAAATCACTGGAACCATGCGCAGACTTGCAGACCA 
AAGTCTCCCACCGAACTTCTCCAGCCTTGAAAACTTTAGAGCCTATGTGGATGGATTCGAACC 
GAACGGCTGCATTGAGGGCAAGCTTTCTCAAATGTCAAAAGAAGTGAATGCTAGAATTGAGCC 
ATTTTTGAAGACAACGCCACGCCCTCTCAGACTACCTGATGGGCCTCCTTGCTCTCAGCGGTC 
GAAGTTCTTGCTGATGGATGCCCTTAAATTAAGCATCGAAGACCCGAGTCATGAGGGGGAGGG 
GATACCACTATACGATGCAATCAAATGCATGAAGACATTTTTCGGCTGGAAAGAACCCAACAT 
208 
CGTGAAACCACATGAAAAAGGTATAAACCCCAATTACCTCCTGGCTTGGAAGCAAGTGCTGGC 
AGAAC TCCAAGATAT TGAAAATGAGGAGAAAATCCCAAAAACAAAGAACATGAAAAAAACAAG 
CCAGTTGAAGTGGGCACTCGGTGAGAACATGGCACCAGAGAAAGTAGACTTTGAGGACTGCAA 
AGATGTTAGCGATCTAAGACAGTATGACAGTGATGAACCAGAGTCTAGATCACTAGCAAGCTG 
GATTCAGAGTGAATTCAACAAGGCATGTGAATTGACAGATTCGAGTTGGATTGAACTTGATGA 
GATAGGAGAAGACGTAGCTCCAATTGAGCACATTGCAAGTATGAGAAGGAACTATTTTACAGC 
GGAAGTATCCCATTGCAGGGCCACTGAATACATAATGAAGGGGGTGTACATAAACACAGCCCT 
GTTGAATGCATCCTGTGCAGCCATGGATGACTTTCAACTGATTCCAATGATAAGCAAATGCAG 
AACCAAAGAAGGAAGACGGAAAACTAATCTGTATGGATTCATTATAAAAGGGAGATCCCACTT 
GAGGAATGATACCGATGTGGTAAATTTTGTGAGTATGGAATTCTCTCTTACTGATCCGAGGCT 
GGAGCCACACAAGTGGGAAAAGTACTGTGTCCTCGAGATAGGAGACATGCTCCTCCGGACTGC 
AGTAGGCCAAGTTTCAAGGCCCATGTTCCTGTATGTAAGAACCAATGGAACCTCCAAGATCAA 
AATGAAATGGGGCATGGAAATGAGGCGATGCCTTCTTCAATCCCTTCAACAAATTGAAAGCAT 
GATTGAAGCCGAGTCTTCTGTCAAAGAGAAGGACATGACCAAAGAATTCTTTGAAAACAAATC 
AGAAACATGGCCGATTGGAGAGTCCCCCAAGGGAGTGGAGGAAG.GCTCCATCGGAAAGGTGTG 
CAGAACCTTGCTGGCGAAGTCTGTGTTCAACAGTTTATATGCATCTCCACAACTCGAGGGGTT 
TTCAGCTGAATCAAGAAAATTGCTTCTCATTGCTCAGGCACTTAGGGACAACCTGGAACCTGG 
GACCTTCGATCTTGGAGGGCTATATGAAGCAATTGAGGAGTGCCTGATTAACGATCCCTGGGT 
TTTGCTTAATGCGTCTTGGTTCAACTCCTTCCTCGCACATGCACTGAAATAGTTGTGGCAATG 
CTACTATTTGCTATCCATACTGTC 
12.6.2 VNMlPEV16C/2004 
ATGCTTCAATCCAATGATTGTCGAGCTTGCAGAAAAGGCAATGAAAGAATATGGGGAAGATCC 
GAAAATCGAAACGAACAAGTTTGCTGCAATATGCACACACTTGGAGGTCTGTTTCATGTATTC 
GGATTTTCACTTTATTGATGAACGGAGTGAATCAATAATTGTAGAATCTGGAGATCCGAATGC 
ATTATTGAAACACCGATTTGAAATAATTGAAGGAAGAGACCGAACGATGGCCTGGACTGTGGT 
GAATAGTATCTGCAACACCACAGGAGTTGAGAAACCTAAATTTCTCCCAGATTTGTATGACTA 
CAAAGAGAACCGATTCATCGAAATTGGAGTGACACGGAGGGAAGTTCATACATACTATCTGGA 
GAAAGCCAACAAGATAAAATCCGAGAAGACACATATTCACATATTCTCATTCACAGGGGAGGA 
AATGGCCACCAAAGCGGACTACACCCTTGATGAAGAGAGCAGGGCAAGAATTAAAACCAGGCT 
GTTCACCATAAGGCAGGAAATGGCCAGTAGGGGTCTATGGGATTCCTTTCGTCAATCCGAGAG 
AGGCGAAGAGACAATTGAAGAAAAATTTGAAATCACTGGAACCATGCGCAGACTTGCAGACCA 
AAGTCTCCCACCGAACTTCTCCAGCCTTGAAAACTTTAGAGCCTATGTGGATGGATTCGAACC 
GAACGGCTGCATTGAGGGCAAGCTTTCTCAAATGTCAAAAGAAGTGAATGCTAGAATTGAGCC 
ATTTTTGAAGACAACGCCACGCCCTCTCAGACTACCTGATGGGCCTCCTTGCTCTCAGCGGTC 
GAAGTTCTTGCTGATGGATGCCCTTAAATTAAGCATCGAAGACCCGAGTCATGAGGGGGAGGG 
GATACCACTATACGATGCAATCAAATGCATGAAGACATTTTTCGGCTGGAAAGAACCCAACAT 
CGTGAAACCACATGAAAAAGGTATAAACCCCAATTACCTCCTGGCTTGGAAGCAAGTGCTGGC 
AGAACTCCAAGATATTGAAAATGAGGAGAAAATCCCAAAAACAAAGAACATGAAAAAAACAAG 
CCAGTTGAAGTGGGCACTCGGTGAGAACATGGCACCAGAGAAAGTAGACTTTGAGGACTGCAA 
AGATGTTAGCGATCTAAGACAGTATGACAGTGATGAACCAGAGTCTAGATCACTAGCAAGCTG 
GATTCAGAGTGAATTCAACAAGGCATGTGAATTGACAGATTCGAGTTGGATTGAACTTGATGA 
GATAGGAGAAGACGTAGCTCCAATTGAGCACATTGCAAGTATGAGAAGGAACTATTTTACAGC 
GGAAGTATCCCATTGCAGGGCCACTGAATACATAATGAAGGGGGTGTACATAAACACAGCCCT 
GTTGAATGCATCCTGTGCAGCCATGGATGACTTTCAACTGATTCCAATGATAAGCAAATGCAG 
AACCAAAGAAGGAAGACGGAAAACTAATCTGTATGGATTCATTATAAAAGGGAGATCCCACTT 
GAGGAATGATACCGATGTGGTAAATTTTGTGAGTATGGAATTCTCTCTTACTGATCCGAGGCT 
GGAGCCACACAAGTGGGAAAAGTACTGTGTCCTCGAGATAGGAGACATGCTCCTCCGGACTGC 
209 
AGTAGGCCAAGTTTCAAGGCCCATGTTCCTGTATGTAAGAACCAATGGAACCTCCAAGATCAA 
AATGAAATGGGGCATGGAAATGAGGCGATGCCTTCTTCAATCCCTTCAACAAATTGAAAGCAT 
GATTGAAGCCGAGTCTTCTGTCAAAGAGAAGGACATGACCAAAGAATTCTTTGAAAACAAATC 
AGAAACATGGCCGATTGGAGAGTCCCCCAAGGGAGTGGAGGAAGGCTCCATCGGAAAGGTGTG 
CAGAACCTTGCTGGCGAAGTCTGTGTTCAACAGTTTATATGCATCTCCACAACTCGAGGGGTT 
TTCAGCTGAATCAAGAAAATTGCTTCTCATTGCTCAGGCACTTAGGGACAACCTGGAACCTGG 
GACCTTCGATCTTGGAGGGCTATATGAAGCAATTGAGGAGTGCCTGATTAACGATCCCTGGGT 
TTTGCTTAATGCGTCTTGGTTCAACTCCTTCCTCGCACATGCACTGAAATAGTTGTGGCAATG 
CTACTATTTGCTATCCATACTGTC 
12.6.3 VNMlPEVI6R12004 
ATGCTTCAATCCAATGATTGTCGAGCTTGCAGAAAAGGCAATGAAAGAATATGGGGAAGATCC 
GAAAATCGAAACGAACAAGTTTGCTGCAATATGCACACACTTGGAGGTCTGTTTCATGTATTC 
GGATTTTCACTTTATTGATGAACGGAGTGAATCAATAATTGTAGAATCTGGAGATCCGAATGC 
ATTATTGAAACACCGATTTGAAATAATTGAAGGAAGAGACCGAACGATGGCCTGGACTGTGGT 
GAATAGTATCTGCAACACCACAGGAGTTGAGAAACCTAAATTTCTCCCAGATTTGTATGACTA 
CAAAGAGAACCGATTCATCGAAATTGGAGTGACACGGAGGGAAGTTCATACATACTATCTGGA 
GAAAGCCAACAAGATAAAATCCGAGAAGACACATATTCACATATTCTCATTCACAGGGGAGGA 
AATGGCCACCAAAGCGGACTACACCCTTGATGAAGAGAGCAGGGCAAGAATTAAAACCAGGCT 
GTTCACCATAAGGCAGGAAATGGCCAGTAGGGGTCTATGGGATTCCTTTCGTCAATCCGAGAG 
AGGCGAAGAGACAATTGAAGAAAAATTTGAAATCACTGGAACCATGCGCAGACTTGCAGACCA 
AAGTCTCCCACCGAACTTCTCCAGCCTTGAAAACTTTAGAGCCTATGTGGATGGATTCGAACC 
GAACGGCTGCATTGAGGGCAAGCTTTCTCAAATGTCAAAAGAAGTGAATGCTAGAATTGAGCC 
ATTTTTGAAGACAACGCCACGCCCTCTCAGACTACCTGATGGGCCTCCTTGCTCTCAGCGGTC 
GAAGTTCTTGCTGATGGATGCCCTTAAATTAAGCATCGAAGACCCGAGTCATGAGGGGGAGGG 
GATACCACTATACGATGCAATCAAATGCATGAAGACATTTTTCGGCTGGAAAGAACCCAACAT 
CGTGAAACCACATGAAAAAGGTATAAACCCCAATTACCTCCTGGCTTGGAAGCAAGTGCTGGC 
AGAACTCCAAGATATTGAAAATGAGGAGAAAATCCCAAAAACAAAGAACATGAAAAAAACAAG 
CCAGTTGAAGTGGGCACTCGGTGAGAACATGGCACCAGAGAAAGTAGACTTTGAGGACTGCAA 
AGATGTTAGCGATCTAAGACAGTATGACAGTGATGAACCAGAGTCTAGATCACTAGCAAGCTG 
GATTCAGAGTGAATTCAACAAGGCATGTGAATTGACAGATTCGAGTTGGATTGAACTTGATGA 
GATAGGAGAAGACGTAGCTCCAATTGAGCACATTGCAAGTATGAGAAGGAACTATTTTACAGC 
GGAAGTATCCCATTGCAGGGCCACTGAATACATAATGAAGGGGGTGTACATAAACACAGCCCT 
GTTGAATGCATCCTGTGCAGCCATGGATGACTTTCAACTGATTCCAATGATAAGCAAATGCAG 
AACCAAAGAAGGAAGACGGAAAACTAATCTGTATGGATTCATTATAAAAGGGAGATCCCACTT 
GAGGAATGATACCGATGTGGTAAATTTTGTGAGTATGGAATTCTCTCTTACTGATCCGAGGCT 
GGAGCCACACAAGTGGGAAAAGTACTGTGTCCTCGAGATAGGAGACATGCTCCTCCGGACTGC 
AGTAGGCCAAGTTTCAAGGCCCATGTTCCTGTATGTAAGAACCAATGGAACCTCCAAGATCAA 
AATGAAATGGGGCATGGAAATGAGGCGATGCCTTCTTCAATCCCTTCAACAAATTGAAAGCAT 
GATTGAAGCCGAGTCTTCTGTCAAAGAGAAGGACATGACCAAAGAATTCTTTGAAAACAAATC 
AGAAACATGGCCGATTGGAGAGTCCCCCAAGGGAGTGGAGGAAGGCTCCATCGGAAAGGTGTG 
CAGAACCTTGCTGGCGAAGTCTGTGTTCAACAGTTTATATGCATCTCCACAACTCGAGGGGTT 
TTCAGCTGAATCAAGAAAATTGCTTCTCATTGCTCAGGCACTTAGGGACAACCTGGAACCTGG 
GACCTTCGATCTTGGAGGGCTATATGAAGCAATTGAGGAGTGCCTGATTAACGATCCCTGGGT 
TTTGCTTAATGCGTCTTGGTTCAACTCCTTCCTCGCACATGCACTGAAATAGTTGTGGCAATG 
CTACTATTTGCTATCCATACTGTC 
210 
12.7 NP sequences 
12.7.1 VNMlCLI07-13/2005 
ACCGAGTGACATCAACATCATGGCGCGATCTTATGAACAGATGGAAACTGGTGGGGAACGCCA 
GAATGCTACTGAGATCAGGGCATCTGTTGGAAGAATGGTTAGTGGCATTGGGAGGTTCTACAT 
ACAGATGTGCACAGAACTCAAACTCAGTGACTATGAAGGGAGGCTGATCCAGAACAGCATAAC 
AATAGAGAGAATGGTACTCTCTGCATTTGATGAAAGAAGGAACAGATACCTGGAAGAACACCC 
CAGTGCGGGAAAGGACCCGAAGAAGACTGGAGGTCCAATTTATCGGAGGAGAGACGGAAAGTG 
GGTGAGAGAGCTAATTCTGTACGACAAAGAGGAGATCAGGAGGATTTGGCGTCAAGCGAACAA 
TGGAGAGGACGCAACTGCTGGTCTTACCCACCTGATGATATGGCATTCCAATCTAAATGATGC 
CACATATCAGAGAACGAGAGCTCTCGTGCGTACTGGAATGGACCCAAGGATGTGCTCTCTGAT 
GCAAGGGTCAACTCTCCCGAGGAGATCTGGAGCTGCTGGTGCAGCAGTAAAGGGGGTAGGGAC 
AATGGTGATGGAGCTGATTCGGATGATAAAACGAGGGATCAACGACCGGAATTTCTGGAGAGG 
CGAAAATGGAAGAAGAACAAGGATTGCATATGAGAGAATGTGCAACATCCTCAAAGGGAAATT 
CCAAACAGCAGCACAAAGAGCAATGATGGATCAAGTGCGAGAGAGCAGAAATCCTGGGAATGC 
TGAAATTGAAGATCTCATTTTTCTGGCACGGTCTGCACTCATCCTGAGAGGATCAGTGGCCCA 
TAAGTCCTGTTTGCCTGCTTGTGTGTACGGACTTGCAGTGGCCAGTGGATATGACTTTGAGAG 
AGAAGGGTACTCTCTGGTTGGAATAGATCCTTTCCGCCTGCTTCAAAACAGCCAGGTCTTTAG 
TCTCATTAGACCAAATGAGAATCCAGCACATAAGAGTCAATTAGTGTGGATGGCATGCCACTC 
TGCAGCATTTGAGGACCTTAGAGTCTCAAGTTTCATCAGAGGGACAAGAGTGGTCCCAAGAGG 
ACAGCTATCCACCAGAGGGGTTCAAATTGCTTCAAATGAGAACATGGAGGCAATGGACTCCAA 
CACTCTTGAACTGAGAAGCAGATATTGGGCTATAAGAACCAGAAGCGGAGGAAACACCAACCA 
GCAGAGGGCATCTGCAGGACAGATCAGCGTTCAGCCCACTTTCTCGGTACAGAGAAACCTTCC 
CTTCGAAAGAGCGACCATTATGGCAGCATTTACAGGAAATACTGAGGGCAGAACGTCTGACAT 
GAGAACTGAAATCATAAGAATGATGGAAAGTGCCAGACCAGAAGATGTGTCATTCCAGGGGCG 
GGGAGTCTTCGAGCTCTCGGACGAAAAGGCAACGAACCCGATCGTGCCTTCCTTTGACATGAA 
TAATGAAGGATCTTATTTCTTCGGAGACAATGCA 
12.7.2 VNMJPEV16B/2004 
TCTTATGAACAGATGGAAACTGGTGGGGAACGCCAGAATGCTACTGAGATCAGGGCATCTGTT 
GGAAGAATGGTTAGTGGCATTGGGAGGTTCTACATACAGATGTGCACAGAACTCAAACTCAGT 
GACTATGAAGGGAGGCTGATCCAGAACAGCATAACAATAGAGAGAATGGTACTCTCTGCATTT 
GATGAAAGAAGGAACAGATACCTGGAAGAACACCCCAGTGCGGGAAAGGACCCGAAGAAGACT 
GGAGGTCCAATTTATCGGAGGAGAGACGGGAAATGGGTGAGAGAGCTAATTCTGTACGACAAA 
GAGGAGATCAGGAGGATTTGGCGTCAAGCGAACAATGGAGAGGACGCAACTGCTGGTCTTACC 
CACCTGATGATATGGCATTCCAATCTAAATGATGCCACATATCAGAGAACGAGAGCTCTCGTG 
CGTACTGGAATGGACCCAAGGATGTGCTCTCTGATGCAAGGGTCAACTCTCCCGAGGAGATCT 
GGAGCTGCTGGTGCAGCAGTAAAGGGGGTAGGGACAATGGTGATGGAGCTGATTCGGATGATA 
AAACGAGGGATCAACGACCGGAATTTCTGGAGAGGCGAAAATGGAAGAAGAACAAGGATTGCA 
TATGAGAGAATGTGCAACATCCTCAAAGGGAAATTCCAAACAGCAGCACAAAGAGCAATGATG 
GATCAAGTGCGAGAGAGCAGAAATCCTGGGAATGCTGAAATTGAAGATCTCATTTTTCTGGCA 
CGGTCTGCACTCATCCTGAGAGGATCAGTGGCCCATAAGTCCTGCTTGCCTGCTTGTGTGTAC 
GGACTTGCAGTGGCCAGTGGATATGACTTTGAGAGAGAAGGGTACTCTCTGGTTGGAATAGAT 
CCTTTCCGCCTGCTTCAAAACAGCCAGGTCTTTAGTCTCATTAGACCAAATGAGAATCCAGCA 
CATAAGAGTCAATTAGTGTGGATGGCATGCCACTCTGCAGCATTTGAGGACCTTAGAGTCTCA 
AGTTTCATCAGAGGGACAAGAGTGGTCCCAAGAGGACAGCTATCCACCAGAGGGGTTCAAATT 
GCTTCAAATGAGAACATGGAGGCAATGGACTCCAACACTCTTGAACTGAGAAGCAGATATTGG 
GCTATAAGAACCAGAAGCGGAGGAAACACCAACCAGCAGAGGGCATCTGCAGGACAGATCAGC 
211 
GTTCAGCCCACTTTCTCGGTACAGAGAAACCTTCCCTTCGAAAGAGCGACCATTATGGCAGCA 
TTTACAGGAAATACTGAGGGCAGAACGTCTGACATGAGGACTGAAATCATAAGAATGATGGAA 
AGTGCCAGACCAGAAGATGTGTCATTCCAGGGGCGGGGAGTCTTCGAGCTCTCGGACGAAAAG 
GCAACGAACCCGATCGTGCCTTCCTTTGACATGAATAATGAAGGATCTTATTTCTTCGGAGAC 
AATGCAGAGGA 
12.7.3 VNMlPEV16C/2004 
TCTTATGAACAGATGGAAACTGGTGGGGAACGCCAGAATGCTACTGAGATCAGGGCATCTGTT 
GGAAGAATGGTTAGTGGCATTGGGAGGTTCTACATACAGATGTGCACAGAACTCAAACTCAGT 
GACTATGAAGGGAGGCTGATCCAGAACAGCATAACAATAGAGAGAATGGTACTCTCTGCATTT 
GATGAAAGAAGGAACAGATACCTGGAAGAACACCCCAGTGCGGGAAAGGACCCGAAGAAGACT 
GGAGGTCCAATTTATCGGAGGAGAGACGGGAAATGGGTGAGAGAGCTAATTCTGTACGACAAA 
GAGGAGATCAGGAGGATTTGGCGTCAAGCGAACAATGGAGAGGACGCAACTGCTGGTCTTACC 
CACCTGATGATATGGCATTCCAATCTAAATGATGCCACATATCAGAGAACGAGAGCTCTCGTG 
CGTACTGGAATGGACCCAAGGATGTGCTCTCTGATGCAAGGGTCAACTCTCCCGAGGAGATCT 
GGAGCTGCTGGTGCAGCAGTAAAGGGGGTAGGGACAATGGTGATGGAGCTGATTCGGATGATA 
AAACGAGGGATCAACGACCGGAATTTCTGGAGAGGCGAAAATGGAAGAAGAACAAGGATTGCA 
TATGAGAGAATGTGCAACATCCTCAAAGGGAAATTCCAAACAGCAGCACAAAGAGCAATGATG 
GATCAAGTGCGAGAGAGCAGAAATCCTGGGAATGCTGAAATTGAAGATCTCATTTTTCTGGCA 
CGGTCTGCACTCATCCTGAGAGGATCAGTGGCCCATAAGTCCTGCTTGCCTGCTTGTGTGTAC 
GGACTTGCAGTGGCCAGTGGATATGACTTTGAGAGAGAAGGGTACTCTCTGGTTGGAATAGAT 
CCTTTCCGCCTGCTTCAAAACAGCCAGGTCTTTAGTCTCATTAGACCAAATGAGAATCCAGCA 
CATAAGAGTCAATTAGTGTGGATGGCATGCCACTCTGCAGCATTTGAGGACCTTAGAGTCTCA 
AGTTTCATCAGAGGGACAAGAGTGGTCCCAAGAGGACAGCTATCCACCAGAGGGGTTCAAATT 
GCTTCAAATGAGAACATGGAGGCAATGGACTCCAACACTCTTGAACTGAGAAGCAGATATTGG 
GCTATAAGAACCAGAAGCGGAGGAAACACCAACCAGCAGAGGGCATCTGCAGGACAGATCAGC 
GTTCAGCCCACTTTCTCGGTACAGAGAAACCTTCCCTTCGAAAGAGCGACCATTATGGCAGCA 
TTTACAGGAAATACTGAGGGCAGAACGTCTGACATGAGGACTGAAATCATAAGAATGATGGAA 
AGTGCCAGACCAGAAGATGTGTCATTCCAGGGGCGGGGAGTCTTCGAGCTCTCGGACGAAAAG 
GCAACGAACCCGATCGTGCCTTCCTTTGACATGAATAATGAAGGATCTTATTTCTTCGGAGAC 
AATGCAGAGGA 
12.7.4 VNMlPEV16R12004 
TCTTATGAACAGATGGAAACTGGTGGGGAACGCCAGAATGCTACTGAGATCAGGGCATCTGTT 
GGAAGAATGGTTAGTGGCATTGGGAGGTTCTACATACAGATGTGCACAGAACTCAAACTCAGT 
GACTATGAAGGGAGGCTGATCCAGAACAGCATAACAATAGAGAGAATGGTACTCTCTGCATTT 
GATGAAAGAAGGAACAGATACCTGGAAGAACACCCCAGTGCGGGAAAGGACCCGAAGAAGACT 
GGAGGTCCAATTTATCGGAGGAGAGACGGGAAATGGGTGAGAGAGCTAATTCTGTACGACAAA 
GAGGAGATCAGGAGGATTTGGCGTCAAGCGAACAATGGAGAGGACGCAACTGCTGGTCTTACC 
CACCTGATGATATGGCATTCCAATCTAAATGATGCCACATATCAGAGAACGAGAGCTCTCGTG 
CGTACTGGAATGGACCCAAGGATGTGCTCTCTGATGCAAGGGTCAACTCTCCCGAGGAGATCT 
GGAGCTGCTGGTGCAGCAGTAAAGGGGGTAGGGACAATGGTGATGGAGCTGATTCGGATGATA 
AAACGAGGGATCAACGACCGGAATTTCTGGAGAGGCGAAAATGGAAGAAGAACAAGGATTGCA 
TATGAGAGAATGTGCAACATCCTCAAAGGGAAATTCCAAACAGCAGCACAAAGAGCAATGATG 
GATCAAGTGCGAGAGAGCAGAAATCCTGGGAATGCTGAAATTGAAGATCTCATTTTTCTGGCA 
CGGTCTGCACTCATCCTGAGAGGATCAGTGGCCCATAAGTCCTGCTTGCCTGCTTGTGTGTAC 
GGACTTGCAGTGGCCAGTGGATATGACTTTGAGAGAGAAGGGTACTCTCTGGTTGGAATAGAT 
212 
CCTTTCCGCCTGCTTCAAAACAGCCAGGTCTTTAGTCTCATTAGACCAAATGAGAATCCAGCA 
CATAAGAGTCAATTAGTGTGGATGGCATGCCACTCTGCAGCATTTGAGGACCTTAGAGTCTCA 
AGTTTCATCAGAGGGACAAGAGTGGTCCCAAGAGGACAGCTATCCACCAGAGGGGTTCAAATT 
GCTTCAAATGAGAACATGGAGGCAATGGACTCCAACACTCTTGAACTGAGAAGCAGATATTGG 
GCTATAAGAACCAGAAGCGGAGGAAACACCAACCAGCAGAGGGCATCTGCAGGACAGATCAGC 
GTTCAGCCCACTTTCTCGGTACAGAGAAACCTTCCCTTCGAAAGAGCGACCATTATGGCAGCA 
TTTACAGGAAATACTGAGGGCAGAACGTCTGACATGAGGACTGAAATCATAAGAATGATGGAA 
AGTGCCAGACCAGAAGATGTGTCATTCCAGGGGCGGGGAGTCTTCGAGCTCTCGGACGAAAAG 
GCAACGAACCCGATCGTGCCTTCCTTTGACATGAATAATGAAGGATCTTATTTCTTCGGAGAC 
AATGCAGAGGA 
12.8 MP sequences 
12.8.1 VNMlCL2009-28/2005 
AAAGATGAGTCTTCTAACCGAGGTCGATCATCCCGTCAGGCCCCCTCAAAGCCGAGATCGCGC 
GGAAACTTGAAGATGTCTTTGCAGGAAAGAACACCGATCTCGAGGCTCTCATGGAGTGGCTAA 
AGACAAGACCAATCCTGTCACCTCTGACTAAAGGGATTTTGGGATTTGTATTCACGCTCACCG 
TGCCCAGTGAGCGAGGACTGCAGCGTAGACGCTTTGTCCAGAACGCCCTAAATGGAAATGGAG 
ATCCAAATAATATGGATAGGGCAGTTAAGCTATATAAGAAGCTGAAAAGAGAAATAACATTCC 
ATGGGGCTAAGGAGGTCGCACTCAGCTACTCAACCGGTGCACTTGCCAGTTGCATGGGTCTCA 
TATACAACAGGATGGGAACGGTGACTACGGAAGTGGCTTTTGGCCTAGTGTGTGCCACTTGTG 
AGCAGATTGCAGATTCACAGCATCGGTCTCACAGACAGATGGCAACTATCACCAACCCACTAA 
TCAGACATGAGAACAGAATGGTGCTGGCCAGCACTACAGCTAAGGCTATGGAGCAGATGGCGG 
GATCAAGTGAGCAGGCAGCGGAAGCCATGGAGATCGCTAATCAGGCTAGGCAGATGGTGCAGG 
CAATGAGGACAATTGGGACTCATCCTAACTCTAGTGCTGGTCTGAGAGATAATCTTCTTGAAA 
ATTTGCAGGCCTACCAGAAACGAATGGGAGTGCAGATGCAGCGATTCAAGTGACCCTATTGTT 
GTTGCCGCAAATATCATTGGGATCTTGCACTTGATATTGTGGATTCTTGATCGTCTTTTCTTC 
AAATGCATTTATCGTCGCCTTAAATACGGTTTGAAAAGAGGGCCTGCTATGGCAGGGGTACCT 
GAGTCTATGAGGGAAGAGTACCGGCAGGAACAGCAGAGTGCTGTGGATGTTGACGATGGTCAT 
TTTGTCAACATAGAATTGGAGTAAAAA 
12.8.2 VNMlCL107-1312005 
AAAGATGAGTCTTCTAACCGAGGTCGATCATCCCGTCAGGCCCCCTCAAAGCCGAGATCGCGC 
AGAAACTTGAAGATGTCTTTGCAGGAAAGAACACCGATCTCGAGGCTCTCATGGAGTGGCTAA 
AGACAAGACCAATCCTGTCACCTCTGACTAAAGGGATTTTGGGATTTGTATTCACGCTCACCG 
TGCCCAGTGAGCGAGGACTGCAGCGTAGACGCTTTGTCCAGAACGCCCTAAATGGAAATGGAG 
ATCCAAATAATATGGATAGGGCAGTTAAGCTATATAAGAAGCTGAAAAGAGAAATAACATTCC 
ATGGGGCTAAGGAGGTCGCACTCAGCTACTCAACCGGTGCACTTGCCAGTTGCATGGGTCTCA 
TATACAACAGGATGGGAACGGTGACTACGGAAGTGGCTTTTGGCCTAGTGTGTGCCACTTGTG 
AGCAGATTGCAGATTCACAGCATCGGTCTCACAGACAGATGGCAACTATCACCAACCCACTAA 
TCAGACATGAGAACAGAATGGTGCTGGCCAGCACTACAGCTAAGGCTATGGAGCAGATGGCGG 
GATCAAGTGAGCAGGCAGCGGAAGCCATGGAGATCGCTAATCAGGCTAGGCAGATGGTGCAGG 
CAATGAGGACAATTGGGACTCATCCTAACTCTAGTGCTGGTCTGAGAGATAATCTTCTTGAAA 
ATTTGCAGGCCTACCAGAAACGAATGGGAGTGCAGATGCAGCGATTCAAGTGATCCTATTGTT 
GTTGCCGCAAATATCATTGGGATCTTGCACTTGATATTGTGGATTCTTGATCGTCTTTTCTTC 
AAATGCATTTATCGTCGCCTTAAATACGGTTTGAAAAGAGGGCCTGCTATGGCAGGGGTACCT 
213 
GAGTCTATGAGGGAAGAGTACCGGCAGGAACAGCAGAGTGCTGTGGATGTTGACGATGGTCAT 
TTTGTCAACATAGAATTGGAGTAAAAAT 
12.8.3 VNMlPEV16B/2004 
AGGCCCCCTCAAAGCCGAGATCGCGCAGAAACTTGAAGATGTCTTTGCAGGAAAGAACACCGA 
TCTCGAGGCTCTCATGGAGTGGCTAAAGACAAGACCAATCCTGTCACCTCTGACTAAAGGGAT 
TTTGGGATTTGTATTCACGCTCACCGTGCCCAGTGAGCGAGGACTGCAGCGTAGACGCTTTGT 
CCAGAACGCCCTAAATGGAAATGGAGATCCAAATAATATGGATAGGGCAGTTAAGCTATATAA 
GAAGCTGAAAAGAGAAATAACATTCCATGGGGCTAAGGAGGTCGCACTCAGCTACTCAACCGG 
TGCACTTGCCAGTTGCATGGGTCTCATATACAACAGGATGGGAACGGTGACTACGGAAGTGGC 
TTTTGGCCTAGTGTGTGCCACTTGTGAGCAGATTGCAGATTCACAGCATCGGTCTCACAGACA 
GATGGCAACTATCACCAACCCACTAATCAGACATGAGAACAGAATGGTGCTGGCCAGCACTAC 
AGCTAAGGCTATGGAGCAGATGGCGGGATCAAGTGAGCAGGCAGCGGAAGCCATGGAGATCGC 
TAATCAGGCTAGGCAGATGGTGCAGGCAATGAGGACAATTGGGACTCATCCTAACTCTAGTGC 
TGGTCTGAGAGATAATCTTCTTGAAAATTTGCAGACCTACCAGAAACGAATGGGAGTGCAGAT 
GCAGCGATTCAAGTGATCCTATTGTTGTTGCCGCAAATATCATTGGGATCTTGCACTTGATAT 
TGTGGATTCTTGATCGTCTTTTCTTCAAATGCATTTATCGTCGCCTTAAATACGGTTTGAAAA 
GAGGGCC 
12.8.4 VNMlPEV16C/2004 
AGGCCCCCTCAAAGCCGAGATCGCGCAGAAACTTGAAGATGTCTTTGCAGGAAAGAACACCGA 
TCTCGAGGCTCTCATGGAGTGGCTAAAGACAAGACCAATCCTGTCACCTCTGACTAAAGGGAT 
TTTGGGATTTGTATTCACGCTCACCGTGCCCAGTGAGCGAGGACTGCAGCGTAGACGCTTTGT 
CCAGAACGCCCTAAATGGAAATGGAGATCCAAATAATATGGATAGGGCAGTTAAGCTATATAA 
GAAGCTGAAAAGAGAAATAACATTCCATGGGGCTAAGGAGGTCGCACTCAGCTACTCAACCGG 
TGCACTTGCCAGTTGCATGGGTCTCATATACAACAGGATGGGAACGGTGACTACGGAAGTGGC 
TTTTGGCCTAGTGTGTGCCACTTGTGAGCAGATTGCAGATTCACAGCATCGGTCTCACAGACA 
GATGGCAACTATCACCAACCCACTAATCAGACATGAGAACAGAATGGTGCTGGCCAGCACTAC 
AGCTAAGGCTATGGAGCAGATGGCGGGATCAAGTGAGCAGGCAGCGGAAGCCATGGAGATCGC 
TAATCAGGCTAGGCAGATGGTGCAGGCAATGAGGACAATTGGGACTCATCCTAACTCTAGTGC 
TGGTCTGAGAGATAATCTTCTTGAAAATTTGCAGACCTACCAGAAACGAATGGGAGTGCAGAT 
GCAGCGATTCAAGTGATCCTATTGTTGTTGCCGCAAATATCATTGGGATCTTGCACTTGATAT 
TGTGGATTCTTGATCGTCTTTTCTTCAAATGCATTTATCGTCGCCTTAAATACGGTTTGAAAA 
GAGGGCC 
12.8.5 VNMlPEV16R12004 
AGGCCCCCTCAAAGCCGAGATCGCGCAGAAACTTGAAGATGTCTTTGCAGGAAAGAACACCGA 
TCTCGAGGCTCTCATGGAGTGGCTAAAGACAAGACCAATCCTGTCACCTCTGACTAAAGGGAT 
TTTGGGATTTGTATTCACGCTCACCGTGCCCAGTGAGCGAGGACTGCAGCGTAGACGCTTTGT 
CCAGAACGCCCTAAATGGAAATGGAGATCCAAATAATATGGATAGGGCAGTTAAGCTATATAA 
GAAGCTGAAAAGAGAAATAACATTCCATGGGGCTAAGGAGGTCGCACTCAGCTACTCAACCGG 
TGCACTTGCCAGTTGCATGGGTCTCATATACAACAGGATGGGAACGGTGACTACGGAAGTGGC 
TTTTGGCCTAGTGTGTGCCACTTGTGAGCAGATTGCAGATTCACAGCATCGGTCTCACAGACA 
GATGGCAACTATCACCAACCCACTAATCAGACATGAGAACAGAATGGTGCTGGCCAGCACTAC 
AGCTAAGGCTATGGAGCAGATGGCGGGATCAAGTGAGCAGGCAGCGGAAGCCATGGAGATCGC 
TAATCAGGCTAGGCAGATGGTGCAGGCAATGAGGACAATTGGGACTCATCCTAACTCTAGTGC 
TGGTCTGAGAGATAATCTTCTTGAAAATTTGCAGACCTACCAGAAACGAATGGGAGTGCAGAT 
214 
GCAGCGATTCAAGTGATCCTATTGTTGTTGCCGCAAATATCATTGGGATCTTGCACTTGATAT 
TGTGGATTCTTGATCGTCTTTTCTTCAAATGCATTTATCGTCGCCTTAAATACGGTTTGAAAA 
GAGGGCC 
12.9 NS sequences 
12.9.1 VNMlCL2009-28/2005 
CTGCTTTCTTTGGCATGTCCGCAAACGATTTGCAGACCAAGAACTGGGTGATGCCCCATTCCT 
TGACCGGCTTCGCCGAGATCAGAAGTCCCTAAGAGGAAGAGGCAACACTCTTGGTCTGGACAT 
TGAAACAGCTACTCGCGCAGGAAAGCAGATAGTGGAGCGGATTCTGGAGGAGGAGTCTGATAA 
GGCACTTAAAATGCCGGCTTCATGCTACCTAACTGACATGACTCTCGAAGAAATGTCAAGGGA 
CTGGTTCATGCTCATGCCCAAGCAGAAAGTGGCAGGTTCCCTTTGCATCAAAATGGACCAGGC 
AATAATGGATAAAACCATCATATTGAAAGCAAACTTCAGTGTGACTTTTGACCGGTTGGAAAC 
CCTAATACTACTTAGAGCTTTCACAGAAGGAGGAGCAATCGTGGGAGAAATCTCACCATTACC 
TTCTCTTCCAGGACATACTGGTGAGGATGTCAAAAATGCAATTGGCGTCCTCATCGGAGGACT 
TGAATGGAATGATAACACAGTTCGAGTCACTGAAACTATACAGAGATTCGCTTGGAGAAGCAG 
TGATGAGGATGGGAGACTTCCACTCCCTCCAAATCAGAAACGGAAAATGGCGAGAACAATTGA 
GTCAGAAGTTTGAAGAAATAAGGTGGCTGATTGAAGAATTAAGACATAGATTGAAAATTACAG 
AAAACAGCTTCGAACAAATAACGTTTATGCAAGCCTTACAACTACTGCTTGAAGTGGAGCAAG 
AGATAAGAAC 
12.9.2 VNMlCLI07-13/2005 
ACATAATGGATCCCAACACTGTGTCACTGCTTTCTTTGGCATGTCCGCAAACGATTTGCAGAC 
CAAGAACTGGGTGATGCCCCATTCCTTGACCGGCTTCGCCGAGATCAGAAGTCCCTAAGAGGA 
AGAGGCAACACTCTTGGTCTGGACATCGAAACAGCCACTCGCGCAGGAAAGCAGACAGTGGAG 
CGGATTCTGGAGGAGGAGTCCGATAAGGCACTTAAAATGCCGGCTTCATGCTACCTAACTGAC 
ATGACTCTCGAAGAAATGTCAAGGGACTGGTTCATGCTCATGCCCAAGCAGAAAGTGGCAGGT 
TCCCTTTGCATCAAAATGGACCAGGCAATAATGGATAAAACCATCATATTGAAAGCAAACTTC 
AGTGTGACTTTTGACCGGTTGGAAACCCTAATACTACTTAGAGCTTTCACAGAAGGAGGAGCA 
ATCGTGGGAGAAATCTCACCATTACCTTCTCTTCCAGGACATACTGGTGAGGATGTCAAAAAT 
GCAATTGGCGTCCTCATCGGAGGACTTGAATGGAATGATAACACAGTTCAAGTCACTGAAACT 
ATACAGAGATTCGCTTGGAGAAGCAGTGATGAGGATGGGAGACTTCCACTCCCTCCAAATCAG 
AAACGGAAAATGGCGAGAACAATTGAGTCAGAAGTTTGAAGAAATAAGGTGGCTGATTGAAGA 
ATTAAGACATAGATTGAAAATTACAGAAAACAGCTTCGAACAAATAACGTTTATGCAAGCCTT 
ACAACTACTGCTTGAAGTGGAGCAAGAGATAAGAAC 
12.9.3 VNMlPEV16B/2004 
CAAAAACATAATGGATTCCAACACTGTGTCAAGCTTTCAGGTAGACTGTTTCTTTGGCATGTC 
CGCAAACGATTTGCAGACCAAGAACTGGGTGATGCCCCATTCCTTGACCGGCTTCGCCGAGAT 
CAGAAGTCCCTAAGAGGAAGAGGCAACACTCTTGGTCTGGACATCGAAACAGCTACTCGCGCA 
GGAAAGCAGATAGTGGAGCGGATTCTGGAGGAGGAGTCTGATAAGGCACTTAAAATGCCGGCT 
TCACGCTACCTAACTGACATGACTCTCGAAGAAATGTCAAGGGACTGGTTCATGCTCATGCCC 
AAGCAGAAAGTGGCAGGTTCCCTTTGCATCAAAATGGACCAGGCAATAATGGATAAAACCATC 
ATATTGAAAGCAAACTTCAGTGTGACTTTTGACCGGTTGGAAACCCTAATACTACTTAGAGCT 
215 
TTCACAGAAGGAGGAGCAATCGTGGGAGAAATCTCACCATTACCTTCTCTTCCAGGACATACT 
GGTGAGGATGTCAAAAATGCAATTGGCGTCCTCATCGGAGGACTTGAATGGAATGATAACACA 
GTTCGAGTCACTGAAACTATACAGAGATTCGCTTGGAGAAGCAGTGATGAGGATGGGAGACTT 
CCACTCCCTCCAAATCAGAAACGGAAAATGGCGAGAACAATTGAGTCAGAAGTTTGAAGAAAT 
AAGGTGGCTGATTGAAGAAGTAAGACATAGATTGAAAATTACAGAAAACAGCTTCGAACAGAT 
AACGTTTATGCAAGCCTTACAACTACTGCTTGAAGTGGAGCAAGAGATAAGAACCTTCTCGTT 
TCAGCTTATTTAATGATAAA 
12.9.4 VNMlPEV16C/2004 
CAAAAACATAATGGATTCCAACACTGTGTCAAGCTTTCAGGTAGACTGTTTCTTTGGCATGTC 
CGCAAACGATTTGCAGACCAAGAACTGGGTGATGCCCCATTCCTTGACCGGCTTCGCCGAGAT 
CAGAAGTCCCTAAGAGGAAGAGGCAACACTCTTGGTCTGGACATCGAAACAGCTACTCGCGCA 
GGAAAGCAGATAGTGGAGCGGATTCTGGAGGAGGAGTCTGATAAGGCACTTAAAATGCCGGCT 
TCACGCTACCTAACTGACATGACTCTCGAAGAAATGTCAAGGGACTGGTTCATGCTCATGCCC 
AAGCAGAAAGTGGCAGGTTCCCTTTGCATCAAAATGGACCAGGCAATAATGGATAAAACCATC 
ATATTGAAAGCAAACTTCAGTGTGACTTTTGACCGGTTGGAAACCCTAATACTACTTAGAGCT 
TTCACAGAAGGAGGAGCAATCGTGGGAGAAATCTCACCATTACCTTCTCTTCCAGGACATACT 
GGTGAGGATGTCAAAAATGCAATTGGCGTCCTCATCGGAGGACTTGAATGGAATGATAACACA 
GTTCGAGTCACTGAAACTATACAGAGATTCGCTTGGAGAAGCAGTGATGAGGATGGGAGACTT 
CCACTCCCTCCAAATCAGAAACGGAAAATGGCGAGAACAATTGAGTCAGAAGTTTGAAGAAAT 
AAGGTGGCTGATTGAAGAAGTAAGACATAGATTGAAAATTACAGAAAACAGCTTCGAACAGAT 
AACGTTTATGCAAGCCTTACAACTACTGCTTGAAGTGGAGCAAGAGATAAGAACCTTCTCGTT 
TCAGCTTATTTAATGATAAA 
12.9.5 VNMlPEV16R12004 
CAAAAACATAATGGATTCCAACACTGTGTCAAGCTTTCAGGTAGACTGTTTCTTTGGCATGTC 
CGCAAACGATTTGCAGACCAAGAACTGGGTGATGCCCCATTCCTTGACCGGCTTCGCCGAGAT 
CAGAAGTCCCTAAGAGGAAGAGGCAACACTCTTGGTCTGGACATCGAAACAGCTACTCGCGCA 
GGAAAGCAGATAGTGGAGCGGATTCTGGAGGAGGAGTCTGATAAGGCACTTAAAATGCCGGCT 
TCACGCTACCTAACTGACATGACTCTCGAAGAAATGTCAAGGGACTGGTTCATGCTCATGCCC 
AAGCAGAAAGTGGCAGGTTCCCTTTGCATCAAAATGGACCAGGCAATAATGGATAAAACCATC 
ATATTGAAAGCAAACTTCAGTGTGACTTTTGACCGGTTGGAAACCCTAATACTACTTAGAGCT 
TTCACAGAAGGAGGAGCAATCGTGGGAGAAATCTCACCATTACCTTCTCTTCCAGGACATACT 
GGTGAGGATGTCAAAAATGCAATTGGCGTCCTCATCGGAGGACTTGAATGGAATGATAACACA 
GTTCGAGTCACTGAAACTATACAGAGATTCGCTTGGAGAAGCAGTGATGAGGATGGGAGACTT 
CCACTCCCTCCAAATCAGAAACGGAAAATGGCGAGAACAATTGAGTCAGAAGTTTGAAGAAAT 
AAGGTGGCTGATTGAAGAAGTAAGACATAGATTGAAAATTACAGAAAACAGCTTCGAACAGAT 
AACGTTTATGCAAGCCTTACAACTACTGCTTGAAGTGGAGCAAGAGATAAGAACCTTCTCGTT 
TCAGCTTATTTAATGATAAA 
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